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Abstract
The need for software tools to support decision-m aking relating to biomanufacture is becoming 
increasingly critical in order to accelerate the time-to-market and reduce costs. The main objective o f  
this thesis is the design and implementation o f a decision-support tool that integrates both the business 
and process perspectives o f  biopharmaceutical manufacture to aid the evaluation o f manufacturing 
alternatives. The tool, designated BioPharmKit, was built on the platform o f the simulation package 
Extend Industrial Suite (Imagine That Inc., San Jose, USA ). As an illustration, the tool was used to 
evaluate manufacturing alternatives for the production o f  monoclonal antibodies derived from 
mammalian-based processes. The functionalities o f such a tool to model cost summation, perform 
mass balance calculations, simulate resource handling, and incorporate uncertainties are demonstrated 
via two industrial-related case studies.
The first case study was based upon the assessment o f  pooling strategies in perfusion culture o f  
mammalian cells to deliver a therapeutic protein for commercial use. The analysis in this study 
addressed the trade-offs between investing in a plant with a smaller downstream process (DSP) 
capacity and em ploying more frequent pooling o f the broth for purification or opting for a plant with a 
larger DSP capacity and less frequent pooling o f  broth. The feasibility o f  each manufacturing option 
was evaluated based on the annual throughput, resource utilisation profiles and cost o f goods per gram 
(COG/g). Project appraisal was based on expected output values and the likelihood o f  achieving or 
exceeding critical threshold indicators generated using Monte Carlo simulations. Critical drivers that 
may affect the decision were identified through scenario analyses to improve the robustness o f the 
decision-making process. In the second case study, the decision-support tool developed was 
employed to evaluate the econom ic feasibility o f  fed-batch and perfusion cultures. The trade-offs 
between the relative sim plicity and high titres o f  fed-batch system s and the high productivity but 
greater complexity o f  perfusion processes were analysed. The study aimed to investigate the relative 
economics o f the two operational modes by exam ining key performance metrics such as the COG/g 
and the net present value (NPV). Another major objective o f this study was to compare the relative 
usefulness and limitations o f the decision tree and Monte Carlo simulations, which are typical tools 
used for risk analysis to aid decision-m aking in situations subject to uncertainty. Although the 
decision tree analysis provided a simple approach for decision-m aking based on the expected values 
o f performance metrics, it does not explicitly consider the underlying uncertainty in each contributory 
estimate. The Monte Carlo simulation method was more tim e-consum ing but provided a more 
complete estimation o f  process uncertainties subject to fluctuating product titres and process yields.
The examples illustrate the benefits o f  using the tool to investigate the cost effectiveness o f different 
manufacturing alternatives and may assist the process o f  decision-m aking in the context o f both 
business and process drivers. It is envisaged that such a tool might be em ployed in early process 
development, hence contributing to transparent planning and project management decisions.
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C hapter  i
Scope and Background
1.1. Introduction
The biopharmaceutical industry faces enormous pressures to achieve timely delivery 
of drugs to the market whilst reducing costs. As production technologies for new 
drugs become progressively more complex, seamless process development is critical 
to enhance manufacturing operations in order to streamline timelines and reduce cost 
of goods (Bryom, 2000). Early planning of process development activities, 
recognition of lead times and efficient resource utilisation can help to achieve these 
objectives. As a consequence, the application of computer-aided design tools to 
facilitate process design and development of biochemical processes is of increasing 
interest. However, to date, the technologies to deliver such potential improvement 
are not leading-edge (Norris, 2001). They are utilised and deployed more 
aggressively in process industries such as chemicals, petrochemicals, polymers etc 
but remain considerably underdeveloped for the description of biotechnology 
processes. This thesis explores the possible creation of a software tool to model the 
manufacture of biopharmaceuticals in order to support the decision-making processes 
in the biotechnology industry.
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The aim of this introductory chapter is to provide an overview of the 
biopharmaceutical industry with its key manufacturing concerns, highlight the role of 
process modelling and update its current status in the bioprocessing industry. 
Section 1.2 gives a brief description of the biopharmaceutical drug development 
pathway. The prime problems in the biopharmaceutical drug manufacturing process 
are addressed in Section 1.3. The challenges and benefits of bioprocess simulation as 
well as some state-of-the-art computer packages for simulating biotech- 
manufacturing processes are examined in Section 1.4. The methods used for cost 
analysis and several examples found in published literature are discussed in Section 
1.5. Techniques for performing risk assessment to incorporate process and market- 
related uncertainties are provided in Section 1.6. The objectives of this research are 
highlighted in Section 1.7. Finally, the organisation of the remaining thesis is 
covered in Section 1.8.
1.2. Biopharmaceutical Drug Development
The beginning of the latest era of biotechnology can be traced back to the mid-1970s 
with the development of genetic engineering and hybridoma technology. Over the 
years, advances in both molecular science and technology have enabled scientists to 
clone genes, express the corresponding protein in bacterial, insect or mammalian 
cells and for engineers to purify the resulting product. These biotechnological 
innovations have helped generate a vast number of therapeutic biological products to 
intervene in diseases and have lead to the foundation of the biotechnology industry. 
The biotechnology industry has grown substantially since the first 
biopharmaceuticals were approved in the 1980s (Gosse & Manocchia, 1996) and 
there are currently 371 biotechnology medicines in development by 144 companies 
for nearly 200 diseases (Holmer, 2002). The types of molecules under development 
are mostly recombinant proteins, including growth factors, monoclonal antibodies 
(Mabs), enzymes, fusion proteins and peptides (Walsh 2000; Lias & Fogerty, 2002). 
Other drug candidates, such as antisense therapeutics and viral gene therapy agents 
and vaccines, are also emerging. The major areas of indication are directed at 
treating arthritis, respiratory disorders and cancer (McNamara, 2002).
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Biopharmaceuticals are among some of the most expensive pharmaceutical 
substances. For example, the sales value of antibodies such as Enbrel and Herceptin 
is $4,500/g (Curling, 2000). Since the 1980s, the worldwide sales value of 
biopharmaceuticals had climbed to US$5 billion by 1993 (Walsh, 1998). By 1997, 
the global market value of biopharmaceutical products exceeded the $7 billion mark 
(Walsh & Murphy, 2000). The estimated worldwide market value of some notable 
biopharmaceutical products in 2000 is presented in Table 1.1.
Table 1.1. Estimated annual global sales value of some biopharmaceuticals in 2000a.
Product Indications Y ear first 
ap proved b
Sales 
($ m illion)
Actimmune Chronic granulomatous disease 2000 8
Activase Acute myocardial infarction 1996 206
Avonex Relapsing multiple sclerosis 1996 761
Enbrel Rheumatoid arthritis 1998 652
Epogen Anemia (Chronic renal failure) 1999 1,963
Herceptin Metastatic breast cancer 1998 276
Intron A Hairy cell leukemia 1997 1,360
Neumega Thrombocytopenia 1997 34
Neupogen Neutropenia 1998 1,220
Ontak Cutaneous T-cell lymphoma 1999 13
Proleukin Renal cell carcinoma 1998 113
Pulm ozym e Respiratory infections (cystic fibrosis) 1998 122
Rem icade Rheumatoid arthritis 1998 370
Reopro Anti-blood clotting agent 1997 418
Rituxan Relapsed, refractory non-Hodgkin’s 
lymphom
1997 444
Roferon-A Hairy cell leukemia 1999 159
Synagis Respiratory syncytial virus infections 1998 427
a Adapted from Ginsberg et al. (2002)
b Source: http://www.fda.gov/cder/biologics/biologics_table.htm
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As larger numbers of new biopharmaceuticals progress through the discovery and 
development phases, more are getting through to the approval phase. Given the 
undoubted scientific and commercial prominence of this sector, analysts and the 
biotechnology industry expect the number of approved biopharmaceuticals to grow 
rapidly. The worldwide biotechnology market is expected to reach a value of $100 
billion by 2010 (Focus on Catalysts, 2003).
1.2.1. The Stages of Drug Development
The drug development process is a lengthy, complex and highly risky one that 
involves drug discovery, laboratory testing, animal studies, clinical trials and 
regulatory reviews. Of 5,000-10,000 chemically synthesised molecules screened, 
only one becomes an approved drug (Pharmaceutical Industry Profile, 1999). The 
biopharmaceutical companies take extraordinary measures to ensure that a potential 
drug is safe and effective by subjecting it to a series of tests. A summary of pre- 
clinical and clinical phases during the drug development pathway is provided in 
Table 1.2.
Table 1.2. A summary of the testing stages during drug development.
Stage T est population D uration Intention
Pre-clin ical Laboratory and animal testing 3 years Initial characterisation
C lin ical trials
Phase I 2 0 -8 0  healthy volunteers 1 year Determine safety and dosage
Phase II 100-300  patient volunteers 2 years Look for efficacy and side 
effects
Phase III 1 ,000-5 ,000  patient volunteers 3 years Monitor adverse reactions to 
long-term use
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The goal of pre-clinical animal studies is to characterise any relationship between 
increased doses of the drug and toxic effects in the animals. After completing such 
pre-clinical testing, the developing company submits an investigational new drug 
(IND) application, detailing pre-clinical findings, methods of manufacture and 
proposed protocols for initial clinical trials to the relevant authority, e.g. the Food 
and Drug Administration (FDA) in the USA, for approval to commence clinical 
trials. Once the drug has been characterised, and even before early clinical trials are 
under way, the drug is patented by the developing company in order to receive 
maximum commercial benefit from the discovery (Walsh 1998). Upon completion 
of clinical trials, the company submits a new drug application (NDA) to the 
regulatory authority to allow the drug to be placed in the market. After marketing 
approval is granted, post marketing surveillance is necessary to monitor and assess 
the safety of the drug.
Once on the market, a drug is taken by many more patients as compared to during the 
clinical trials. Adverse drug reactions (ADRs) that occur in fewer than 1 in 3,000- 
5,000 patients are unlikely to be detected in Phase I -  III investigational clinical trials 
and may be unknown at the time a drug is approved (Pharmaceutical Industry 
Profile, 1999). Biopharmaceutical companies must inform regulatory agencies of 
serious and unexpected ADRs within 15 days. Companies must also take voluntary 
corrective steps as appropriate such as withdrawing a drug from the market. While 
the drug development process may seem lengthy and cumbersome, the 
biopharmaceutical companies and regulatory authorities have taken stringent steps to 
ensure safety of all approved medicines.
1.2.2. Time-to-Market
Confronted with competitive pressures of limited finances and tight timelines, 
biotech companies worldwide are racing to bring new biological products to market. 
Once the recombinant DNA expression system for a new drug is defined and a patent 
application submitted, it is essential to complete process development and obtain 
regulatory approval as fast as possible. Such timely approval and marketing of drugs 
is crucial in order to gain substantial market share and secure a good profit margin. 
If the product is not delivered on time to the market, the company may lose share to
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competitive products, which can result in a considerable loss of sales revenue. A 
day’s delay in gaining regulatory approval and product availability could be worth 
approximately $1 million in lost sales (Clemento, 1999). In addition, the product 
lifetimes of biopharmaceuticals are shrinking due to intense competition, which leads 
to reduced earnings in an era with increased product testing, licensing, and operating 
costs (Gerson et al., 1998). It is imperative therefore that the biopharmaceutical 
companies accelerate the time-to-market while reducing the costs of development in 
order to maintain attractive economic returns.
Current estimates for the time-to-market of a biopharmaceutical drug fall in the range 
of 5 to 12 years, with an average of 7 to 8 years (Foo et al., 2001). Most of this time 
is spent in the clinical phases (Marks & Power, 2002). Table 1.3 shows the mean 
phase lengths for biopharmaceuticals over three time periods. The license 
application review period has shortened over the years but longer clinical phases due 
to the need for complex and sophisticated technologies used to characterise and 
manufacture biopharmaceutical products are now extending development times. The 
growing complexity and length of the clinical trials has resulted in increased 
development costs. In turn the estimated average cost to develop a new drug to the 
point of marketing approval was US$802 million in 2000 with the clinical cost 
representing 50% of this total cost (DiMasi et a l, 2003). The biopharmaceutical 
industry is working together with the regulatory authority to shorten time for clinical 
trials so as to speed up public access to effective biopharmaceutical medicines 
(Reichert, 2003).
Table 1.3. Mean total phase lengths for biopharmaceuticals*.
T im e period
T otal num ber o f  
approvals
C linical phase  
(m onths)
A pproval phase  
(m onths)
T otal phase 
(m onths)
1982-1989 14 32.7 24.0 56.7
1990-1994 15 46.5 21.3 67.8
1995-1999 26 58.6 14.7 73.3
* Adapted from Reichert (2000)
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1.3. Biopharmaceutical Drug Manufacturing
The biopharmaceutical manufacturing industry is highly regulated, having to comply 
with stringent rules and procedures. All aspects of a biopharmaceutical manufacture 
must follow the most rigorous standards and principles, outlined in publications that 
document Good Manufacturing Practice (GMP). After the drug has been approved, 
most regulatory agencies require that the drug product be tested for its identity, 
potency, quality, purity and stability before it can be released for use. For this 
purpose, process controls are crucial to ensure that a specific process will 
consistently produce a product, which meets its predetermined specifications, and 
quality attributes at various critical stages of a manufacturing process. Quality 
control (QC), quality assurance (QA) and batch documentation form an integral part 
of GMP. Adequate in-process testing, thorough process validation and analytical 
methodologies are required at various stages during product manufacture to evaluate 
the effectiveness of the manufacturing processes and to demonstrate lot-to-lot 
consistency (Chow, 1997; Geigert, 1997). Every aspect of biopharmaceutical 
manufacture is characterised by extensive documentation in order to prevent 
misrepresentations associated with verbal communication, facilitate the tracking of 
the history of any batch of product and to ensure reproducibility within all aspects of 
biomanufacture (Walsh, 1998). These documents involve standard operating 
procedures (SOPs), specifications for conformation of raw materials, manufacturing 
formulae, processing and packaging instructions.
The production of new drugs, using progressively more complex production 
technologies, the wide range of biopharmaceuticals’ potency and stability, combined 
with sociological factors has triggered the development of stringent regulations in the 
biopharmaceutical industry (Doblhoff-Dier & Bliem, 1999). With an increasing 
number of international and national regulations, companies bringing new drugs to 
market face additional burdens of ensuring and improving quality. These are 
expensive and time-consuming activities. Good regulations are essential to the 
gaining of public acceptance and to diminish the risks involved, such as through the 
contamination of products and the subsequent infection of the patient. Thus, GMP 
quality management should be viewed as a valuable asset during the process of 
gaining regulatory approval. Such a system also helps to identify problems,
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streamline operations by improving communications between organisational 
structures and reduce process failure and downtime.
1.3.1. Manufacturing Capacity
The growth of the biopharmaceutical industry has increased the need for large-scale 
and efficient production of new biochemical entities, and has in turned placed 
mounting pressure on the biomanufacturing industry to cope with this demand. 
Several blockbuster bio-drugs, especially Mabs, currently in the market are designed 
as long-term therapies or require large doses and so they must be manufactured in 
mass quantities and hence require high volumes of biomanufacturing capacity (Lias 
& Fogerty, 2002). For example, protein-based therapeutics utilised approximately 
three-quarters of total industry capacity in the year 2000 (Ginsberg et al., 2002). In 
the year 2001, the biotech industry anticipated shortages in GMP production capacity 
(Garber, 2001; Morrow, 2001). However, more recently, there has been a lot of 
controversy about this issue. Ginsberg et al. (2002) and Sinclair (2003) provided an 
analysis of capacity estimates and reported that there may be sufficient 
biomanufacturing capacity in the market to meet capacity requirements.
Drug shortages have been in the limelight during recent months (Wechsler, 2002), 
generating complaints from pharmacists. Limited access has aroused public health 
authority concerns in examining the factors underlying this troubling situation. The 
FDA identifies numerous factors that contribute to drug shortages with many arising 
from difficulties encountered during manufacturing. Delays in the time-to-market 
are often due to deficiencies in manufacturing divisions rather than to the scientific 
or clinical sections in the biotechnology industry (Fisher & Pascucci, 1996) and this 
is exacerbated by the fact that the design of production techniques for new drugs has 
become more complex. Suppliers of bulk active raw ingredients may run into 
production or packaging problems, leading to production delays. Natural diseases 
may also hinder raw material shipments. Industry consolidation has further 
aggravated drug dearths (Weshsler, 2002).
Manufacturers often complain however that production problems are largely due to 
regulatory compliance policies that plague the availability of drugs and vaccines.
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Overly-strict regulatory compliance practices have forced them to revise their 
production processes, leading to considerable time losses. The demand for GMP 
biopharmaceutical production is becoming apparent, with more products being 
developed and commercialised. Access to GMP production capacity is critical to 
guard against shortfalls in drug development, ensure product availability and prevent 
delays in market launch. The biotech companies are often in a dilemma as to 
whether to develop expertise in-house, build and acquire their own plants or to 
employ outsourced biomanufacturing facilities (Grimster, 2003). Because the drug 
development cycle is compressed, the companies must build a GMP-compliant plant 
in time to meet clinical trials and commercial sales within a relatively narrow time 
frame. Furthermore, building manufacturing capacity represents a significant 
commitment of capital and resources (Lawlis, 2001). Estimated costs for a large- 
scale biologies facility with a plant capacity of 100,000L range from $200 million to 
$4,100 million (Ginsberg et al., 2002). On average, it may take 4-5  years to design, 
build and validate a new biologies manufacturing facility (Molowa et al., 2001).
The effects of financial pressure, increased costs of capital and the delays that 
confront the biopharmaceutical companies favour contracting out manufacturing by 
accessing the appropriate type and scale of contract manufacturing facilities 
(Sherwood, 2003). A company can thereby defer capital costs and take economic 
advantage by relying on contract manufacturing organisations (CMOs) to make their 
products (Nicholson & Latham, 1994; Seaver, 1994). Outsourced manufacturing 
supplies skill and technical expertise for different biological products and production 
methods that the client company may not have, which in turn allows them to 
concentrate on their core competences (Byrom, 2000). Therefore, contract 
manufacturing offers an attractive and cost-effective alternative to in-house 
production. However, this may not be true for all cases. Analysis of the financial 
outcomes of using in-house manufacturing or outsourcing for a portfolio of 
companies revealed that for companies with large and diversified potential products, 
the benefit of contracting out was relatively small (Nicholson & Latham, 1994). This 
might be expected since such a company can depreciate gradually the cost of its own 
plant over a number of projects.
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1.3.2. Scale-up of Production Processes
The success of manufacturing is also underpinned by the necessity to produce 
sufficient quantities of the prospective drug for critical steps such as drug 
characterisation, pre-clinical and clinical testing and commercial introduction 
(Clemento, 1999; Savage, 2000). Figure 1.1 depicts the scale-up procedure during a 
typical drug development process (Welsh, 1998). During the R&D phase, probably 
only a few milligrams are required for initial product characterisation. This could 
increase to several grams for pre-clinical/clinical trials. For full commercialisation 
of the final product, the demand could increase several fold, requiring a quantity 
between hundreds of grams or kilograms. The goal of manufacturing is to meet 
product demand, as well as rendering the product safe. The proposed manufacturing 
processes must therefore conform to the highest safety and quality standards. The 
rise in product demand commands a synchronised change in process capacity (Foo et 
al., 2001). Although the increase may be accommodated by incremental changes in 
manufacturing, significant alterations of processes are not usually viable. Any 
subsequent scale-up or changes to the production protocol could invalidate 
antecedent efforts and entail additional proof to establish process and product 
equivalence. As a result, prior planning for the production during the development 
track must occur even though with significant uncertainty in terms of likely dose and 
operating capacity.
Lab sca le  production Pilot sca le  production P rocess sca le  production
(mg scale) (g scale) (100g - kg scale)
r 1r 1r
(  R&D (  (  cm r a iw a s (  ( commercial product^ )
Figure 1.1. Scale-up of biopharmaceutical production process to generate product 
for initial R&D, clinical trials and commercialisation.
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1.4. Process Modelling
Process simulation is one of the most widely used techniques to imitate and analyse 
the operations of various kinds of real-world processes or systems. The complexities 
of real-world systems do not allow realistic models to be evaluated analytically and 
thus, these systems can be studied by means of simulation (Law & Kelton, 1991). 
Simulation is used to describe the behaviour of a system, ask “what-if’ questions 
about the system and aid in the design of real systems. Simulation models are 
largely classified along three different dimensions as follows (Banks, 1998).
• Static vs Dynamic simulation models
A static model represents a system at a particular time and ignores time-based 
variances. Dynamic modelling is a software representation of the time-based 
behaviour of a system.
• Deterministic vs Stochastic simulation models
Deterministic models do not contain any probabilistic or random variables. Since all 
the inputs are constant, the results of simulating a deterministic model are 
“determined” or set based on the input values. However, many systems typically 
contain some elements of randomness. Incorporating randomness by adding 
distributions into a deterministic model changes it to a stochastic model. Stochastic 
simulations models take into account the effect of variability and provide more 
reliable estimates of system performance.
• Continuous vs Discrete simulation models
In continuous models, values change directly based on changes in time and time 
changes in equal increments. Discrete-event simulation concerns the representation 
of a system in which items change state as events occur in the simulation. The 
simulated time advances from one event to the next and the time between events is 
unlikely to be equal.
Detailed modelling is required to predict the performance of a system accurately. A 
simulation study is not a simple sequential process. As new insights about the 
system of interest are obtained during the study, it is often desirable to revise the
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simulation process (Law & Kelton, 1991). The steps intrinsic to a simulation study 
are illustrated in Figure 1.2.
Documentation & Reporting
Design of Simulation Scenarios
Model Translation
Problem Formulation
Setting of Objectives
Model Conceptualisation
Decision-Making
Simulation Runs & Analysis
Verification/Validation
Data Collection
Figure 1.2. Steps in a simulation study. (Adapted from Banks, 1998)
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1.4.1. Benefits of Process Modelling
In conjunction with the effort for improved process infrastructure, shortened time-to- 
market and optimised profits, the use of process design tools to evaluate the 
feasibility of bioprocess methodologies and procedures is gaining increased 
awareness (Petrides et a l,  1995a). Companies are beginning to recognise the gains 
of applying such tools to reduce process development time by allowing different 
processing sequences and operation specifics to be modelled inexpensively. Such 
tools can be used to screen project ideas and focus on the most promising ones, 
design process protocols and exploit fully the existing facilities to minimize 
production cost. Computer-aided process tools also act as a common language of 
communication among various research and development groups to accomplish the 
scale-up and commercialisation of biological products.
The key to the successful commercialisation of biopharmaceuticals is to have a well- 
formulated system involving integration of process design and development at all 
levels (Petrides et a l,  1989). Process modelling enables virtual experimenting or 
design of possible processes; improve communication between various groups 
involved in process development; design robust recipe protocols; interpret 
experimental results and optimise existing plant capacity (Evans & Field, 1989; 
Petrides, 1994). Simulation can also be used to identify process bottlenecks and 
determine the cause of delays to improve the time required for process development. 
Such bioprocess simulations form a framework for process management, resource 
utilisation, cost analysis, mass balance assessments and prove seemingly useful in the 
examination and selection of process options, characterization and optimisation of 
unit operations, which can lead to speeding of biochemical products to market and at 
optimum profit. The modelling process aids in the design for the manufacturing 
culture and ultimately delivers a robust and efficient system, which permit better 
decision-making events in the context of business and process needs.
1.4.2. Challenges in Bioprocess Simulation
Process simulation has been exploited more commonly in the petroleum and 
chemical industries since it began in the late 1950s. Development of process 
simulation software for the biotechnology industry has only taken place within the
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last 15 years. Due to the complexity of biochemical processes, there is often 
insufficient data to predict accurately unit operation models based on first principles. 
Therefore, a bioprocess simulator must rely on empirical and semi-empirical data 
obtained from experimental and industrial experience. Biopharmaceutical products 
are manufactured by a series of tasks from inoculum grow-up, fermentation and 
eventually the concentration and purification of the product. The software tool must 
be able to model each unit operation with their own specific characteristics to 
simulate processes of interest. The architecture of the simulator must be flexible to 
accommodate and accomplish rigorous level of models. The model should handle 
dynamic allocation of resources, execute cost calculation and perform mass balances. 
The software platform must provide an interface that enables interaction between the 
users and the models.
The ability of simulation software to provide accurately a complete model of all 
phenomena occurring within a biopharmaceutical process is limited (Evans & Field, 
1989; Petrides, 1994; Shanklin et al., 2001) due to the lack of fundamental physical 
property data for biologic systems, as well as the mixing of operational modes 
employed in a process which can prove difficult to simulate accurately. In addition, 
ancillary manufacturing operations such as the preparation of intermediate materials, 
cleaning-in-place (CIP) and sterilising-in-place (SIP) of equipment, scheduling and 
validation issues must be taken into consideration (Farid et al., 2000; Shanklin et al., 
2001). Finally, the administrative management level is often more concerned with 
the clinical schedule and related business aspects while the production area is faced 
with tightening deadlines and meeting demands. To achieve a close integration of 
process and business needs, the software must be able to represent the common 
information shared between them. These factors were re-emphasised in the recent 
study of selection of bioprocess simulators for industrial applications (Shanklin et al.,
2001). All these problems pose a major barrier in the creation of simulation models 
that are capable of reflecting real biopharmaceutical processes.
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1.4.3. Simulators for the Biomanufacturing Industry
Custom planning methods include general-purpose simulators or spreadsheet-based 
evaluators, e.g. Excel, equipped with numerical-solving techniques but these 
methods are often static and limited, leaving a gap between the industrial 
management and process systems. The use of process simulation software in the 
biopharmaceutical industry has only evolved during the last 15 years. A review of 
the literature shows only limited published information on this subject with most of 
the publications on these topics being from the founders discussing their own 
software for general bioprocess simulation usage. Two commercial bioprocess 
simulators namely, BioProcess Simulator (BPS™) (Aspen Technology, Inc., 
Cambridge, Massachusetts) and SuperPro Designer® (Intelligen, Inc., Scotch Plains, 
New Jersey) are used for modelling industrial biotechnology processes. BPS™, 
which is an extension of the established chemical process simulator ASPEN PLUS, 
was the first commercially available simulation tool for the biotech industry. 
However, BPS™ retained several chemical engineering characteristics that rendered 
it difficult to evaluate bioprocesses and the simulation tool was withdrawn in 1998. 
SuperPro Designer® is a subset of BioPro Designer®, which was the second 
commercial bioprocess tool to emerge.
The use of Aspen BPS™ to model bioprocesses was illustrated by evaluating the 
production of porcine growth hormone (pGH) from Escherichia coli (E.coli) 
(Petrides et al., 1989). Laboratory and pilot plant data were captured in building the 
flowsheet model to evaluate process economics and improvement. BioPro Designer 
emerged on the market later (Petrides, 1994). It originated from the Biotechnology 
Process Engineering Center (BPEC) of Massachusetts Institute of Technology 
(MIT). The software was further developed and made commercially available by 
Intelligen, Inc. Until recently, there have been a few publications to provide a 
critical assessment of these software packages. Researchers at University of 
Maryland, Baltimore, USA carried out a comparison study between Aspen BPS™ 
and SuperPro Designer® to evaluate a vaccine manufacturing process under 
development at Merck & Company (Shanklin et al., 2001). These two simulation 
packages could successfully perform specific simulation tasks including executing 
basic material and energy balances; explore equipment change and analyse process
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economics. However, such packages do not support dynamic resource allocation to 
monitor workloads. Furthermore their use is often restricted to built-in models with 
no option for user-defined models or customisation. An economic evaluation of 
Aspen BPS™ and SuperPro Designer® for the large-scale production of tissue 
plasminogen activator (t-PA) from Chinese hamster ovary (CHO) cells was 
demonstrated (Rouf et a l, 2001a). BPS™ is found to be more geared towards 
chemical processes. As the calculation mode is rigorous, it requires more data to 
make appropriate use of the package. SuperPro Designer® is more suitable in the 
absence of detailed data.
Lately, there has been increasing interest in object-oriented based tools for real time 
and dynamic usage. Research at University College London (UCL) identified 
Gensym’s G2 (Gensym Corporation, Cambridge, Massachusetts), a graphical object- 
oriented programming environment, to be capable of developing rapid manufacturing 
prototypes. A tool for modelling strategic decisions in the manufacture of cell- 
culture-derived products was implemented into ReThink, a G2-based tool (Farid et 
al., 2000a). A hypothetical case study was evaluated using the tool, involving 
decision whether to invest in a conventional pilot plant based on stainless steel 
equipment or to opt for a plant utilising disposable equipment. However, certain 
aspects of biopharmaceutical manufacturing were not incorporated explicitly into the 
model such as quality control and documentation activities. Such exclusions might 
distort the genuine projection of results. Although G2 is a Rapid Application 
Development (RAD) graphical-interface tool, the average user of the tool must at 
least possess a certain level of programming knowledge to work with this simulator. 
This could impair the popularity of the tool in the application of bioprocesses.
1.5. Cost Modelling
The biotech sector tends to focus on getting drugs through clinical trials quickly and 
as such, minimal efforts are being placed on the development of process technology 
and manufacturing issues (Pisano & Wheelwright, 1995). However, this is becoming 
increasingly unacceptable as manufacturing costs escalate. Gura (2002) indicated 
that the need for cost reductions remain the key issue in the biopharmaceutical
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industry. Stringent regulations on product quality and reliability require biotech 
companies to invest in more sophisticated production equipment and control systems. 
In addition, the increasing complexity in the design of new compounds commands 
more advanced and costly production technology. To provide realistic estimates of 
the value of their technologies, the biotech companies must take into account the cost 
of producing the product (Stewart et al., 2001). As a result, methods to predict or 
estimate manufacturing costs are increasingly important in biopharmaceutical 
companies. Byrom (2000) highlighted that early cost modelling offers an indication 
of costs at an early stage and identifies process areas likely to give the maximum cost 
benefits.
Manufacturing costs typically consist of the fixed costs such as the capital charges, 
insurance and taxes, and variable costs such as raw materials and utilities. The fixed 
operating costs do not vary with the production rate while the variable costs are 
dependent on the amount of product produced. Chemical and biochemical 
engineering textbooks (e.g. Bailey & Ollis, 1986; Peters & Timmerhaus, 1991; 
Sinnott, 1993) provide the cost estimation breakdown for project evaluation. The 
production costs are estimated from a flowsheet, which gives the capital cost 
estimates and raw material requirements. Capital cost estimation is often based on a 
factorial method. The factorial method is attributed to Lang (1948), where the fixed 
capital investment is obtained by multiplying the total purchase equipment costs by a 
factor, usually termed the “Lang factor”. The remaining costs are derived either as a 
function of utilisation or as percentages of the fixed capital investment or direct 
operating labour.
Economic appraisals of bioprocess alternatives can be found in the literature. 
Examples are provided in applications using the commercially available bioprocess 
tools (e.g. Petrides et a l, 1989; Petrides et al., 1996; Rouf et al., 2000). Datar et al. 
(1993) compared the process economics of the production of recombinant t-PA using 
CHO and E.coli fermentations. Costing models were developed to permit the 
comparative economic analysis to be carried out. The financial parameters used for 
the comparison purposes include the unit production cost, the gross margin, the cost 
of sales and the return on investment (ROI). A recent publication involved the use of 
a financially-based model to evaluate downstream recovery alternatives (Baker &
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Wheelwright, 2004). The costing format presented included operating costs as well 
as the development and implementation costs.
In addition to the production costs, several publications have considered discounted 
cash-flow analysis to determine the profitability of a project. All cash flows in the 
future are discounted at a particular rate back to the present to determine the net 
present value (NPV) of an investment. A positive NPV indicates that the project is 
worth taking forward. Novais et al. (2001) illustrated the use of a NPV analysis to 
provide an economic comparison of a conventional stainless steel plant and a fully 
disposable bioprocessing plant for the commercial production of biopharmaceuticals. 
Other performance indicators that are normally computed together with the NPV are 
the internal rate of return (IRR) and the payback time. Petrides et al. (1995b) 
provided an example of using such economic indexes to analyse the economic 
feasibility for the biosynthetic production of human insulin.
The NPV approach has also been widely employed in other engineering situations 
(e.g. portfolio management) to assess the profitability of investments. Nicholson & 
Latham (1994) used the NPV analysis to examine the financial impact of in-house 
and contract manufacturing. Blau et a l (2000) described the use of Crystal Ball 
(Decisioneering, London, England) to generate distributions of NPV for drug 
portfolio decision-making. Coates (2003) demonstrated the use of the simulation 
software SLAM II (Pritsker Corporation, Indianapolis, USA) to generate 
distributions of NPV of a project and compare alternative investment opportunities 
under uncertainty. The NPV model is a popular method for investment decision. 
However, the limitation of the NPV model is its subjectivity to discount rates; the 
slightest estimation error could lead to a huge error in NPV values (Pandey, 2003).
1.6. Risk Management
The complexity of having risks affects the business environment (Nichols, 1994). 
Biopharmaceutical management is characterised by risks arising from uncertainty in 
the discovery process, continuing unpredictability in the safety profile of a drug until 
late phase clinical trials and ultimately during production. For example, common
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technical uncertainties in manufacturing systems include process yields, processing 
times, equipment failures and the possibility of contamination. Other factors include 
the costs of resources, dosage levels and market demand. Such a high-risk 
environment often necessitates the need to balance strategic management with risk 
analysis to improve the quality of the decision-making process.
There are a number of approaches for handling uncertainty. A convenient method is 
via sensitivity analysis. Sensitivity analysis provides an organised and systematic 
way to look into the effect of changing parameters on the key output measures. The 
key input variables in the process were identified and subjected to ±x% change (i.e. 
best-case and worst-case scenarios) while the impact on the output metrics was 
observed. However, the determination of values that correspond to variations in key 
factors is based upon the best information at the disposal of the analyst. This 
inevitably implies the reliance on ad hoc methods for determining pessimistic, 
optimistic and most likely estimates.
For more complicated scenarios, where the probability distributions of uncertain 
factors are known or may be estimated, Monte Carlo simulation (stochastic 
modelling) can be used to determine the impact of uncertainties on process outputs. 
Monte Carlo simulation generates random behaviours for probabilistic factors when 
applied to a static or dynamic model (Law & Kelton, 1991). Probability description 
of an input variable is a set of random values that specifies the relative frequency 
with which an event occurs or is likely to occur. Distributions represent the data 
observed in real-world situations and help to compensate for information that is often 
overlooked during data collection. Repeating these simulations many times indicates 
a range of possible output values and this facilitates the identification of trends or 
anomalies and helps to determine the expected performance of the system within a 
certain level of confidence. Farid et al. (2001) presented the use of Monte Carlo 
techniques to assess the impact of risks on the performance of a biopharmaceutical 
company manufacturing clinical trial materials. Recent simulation studies at 
Genentech explored the outcomes of adding uncertainties in the planning of 
manufacturing strategies by using the Monte Carlo technique (Brastow & Rice,
2003). The Monte Carlo model was implemented as a Microsoft Excel add-in. The
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model outputs provided probability information about demand distributions and 
improved insight into the impact of uncertainty in alternative capacity decisions.
The decision tree approach is another useful technique for analysing a decision 
situation. Decision trees are powerful and simple means to improve project 
evaluation and planning process. In a decision tree, the expected value of each 
outcome is computed and a decision is made based on these expected values (Taylor, 
1999). The construction of decision trees aids in the understanding of the likely 
events during the execution of a project and facilitates the calculation of revised 
probabilities as the project progresses (Raffia, 1968). The graphical illustration of a 
decision tree proves useful in project selection and management. However, decision 
trees are not ideal for parallel events that could happen (Doctor et al., 2001). In 
addition, the construction of a decision tree is a time-consuming process for each 
project. Sharpe & Keelin (1998) described how SmithKline Beecham constructed 
decision trees to determine the expected NPV of different portfolios to facilitate 
resource-allocation decisions. Such expected NPV methodology combines the use of 
NPV and decision tree analysis by factoring in the probability of distributions of 
future outcomes and improves the decision-making process.
1.7. Objectives of Research
Global competition to compress timescales and tighten financial budgets is driving 
the need to improve manufacturing operations in the biotech sector. Hence fast, 
efficient and effective methods are required to reduce costs whilst simultaneously 
increasing the speed to market. It is often risky to conduct investigational studies on 
a full-scale facility. There is a growing demand for tools with which to investigate 
process strategies in the early development stage of a candidate drug and preferably 
during initial clinical trial phases (Karri et al., 2001). As noted earlier, computer- 
aided design processes had long been embraced in the chemical and petroleum 
industries and are quite advanced in these sectors. However, the use of computer 
simulation for assisting decision-making in the biopharmaceutical industry is a new 
area of endeavour. Some large companies have employed a number of software 
tools, but largely in an isolated and ad hoc way. This thesis explores the possibility
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of developing a bioprocess simulation support tool in a logical and consistent 
framework so as to achieve rapid process modelling for the manufacture of 
biological products.
The modelling framework in this thesis will seek to use the basis set out in previous 
studies (Farid, 2001) carried out at UCL. It is envisaged that implementation work 
will need to focus on translating the original framework in ReThink to a Window- 
based simulation tool and enhancing the tool features so as to facilitate decision­
making in biopharmaceutical manufacture. The ultimate objective will be to design a 
tool for use during the early stage of process development where information is often 
sparse. The tool can be used to formulate process design methodologies, predict 
performance of biochemical operations and facilitate decision-support that relates 
bioprocess decisions to the following strategic issues: costing, resource management 
and risk. The functionalities of the tool will be demonstrated through its application 
to industrially-related case studies. In order to achieve such goals, a set of objectives 
has been identified and discussed below:
• Integrating business and process perspectives
In practice, management is often more concerned with the business aspects of cutting 
costs and can become disconnected from the process issues of tightening deadlines 
and meeting production demands. In reality these two elements remain 
quantitatively unconnected and this often results in development that is inefficient. 
Conventional software tools for bioprocess design have provided limited business- 
related information for decision-making. These factors have driven the need to 
capture both the business and process perspectives of biopharmaceutical 
manufacturing in a bioprocess simulator to facilitate effective decision-making. The 
conceptual framework seeks to integrate the business and process aspects, including 
resource management, mass balance analysis and costing, that each relate to strategic 
bioprocess decision-making.
• Modelling regulatory-compliance activities
Manufacturing decisions are often complicated by the need to comply with the ever- 
increasing demands for regulatory conformation and emphasis on QC/QA. These 
regulatory compliance activities are critical for controlling the consistency, quality
- 3 5 -
Chapter 1. Scope and Background
and safety of biologies. A major challenge faced by biotechnology companies is the 
need for efficient in-process testing and documentation systems in order to deliver 
new drugs to the market quickly (Glaser, 2002). An examination of existing process 
modelling tools for the simulation of biomanufacturing shows that the issue of in- 
process testing/batch documentation is usually not included in any analysis. Farid 
(2001) reported the implications of these support activities on the manufacturing 
environment but no implementation was attempted. This deficiency could vitiate the 
accuracy of any model to provide an actual reflection of the entire manufacturing 
process and distort the accuracy of resource management and manufacturing cost 
estimates incurred. Furthermore including these support activities, which run in 
parallel with production, is of critical importance in the biopharmaceutical industry 
in order to identify lead times and bottlenecks in the manufacturing process. As the 
need for speed to market rises, the application of simulation modelling tools to 
address these problems is becoming increasingly important. These factors provided 
the impetus and motivation for this work, which examines the capacity to reflect 
such regulatory compliance activities in a bioprocess simulator so as to gauge the 
impact of current Good Manufacturing Practices (cGMP) in biopharmaceutical 
plants.
• Incorporating risk analysis
Commercial process simulators use deterministic models but these do not account for 
uncertainties and are unlikely to give reliable measures of actual process 
performance. In reality, production systems typically display some element of 
randomness. Incorporating randomness into a model can help predict the likelihood 
of not achieving a certain demand or of the danger of exceeding a financial budget. 
Not surprisingly there is increasing interest in the ability to model uncertainty in 
manufacturing processes so as to carry out risk assessments and to estimate the 
potential risks associated with probabilistic factors during the course of a 
manufacturing process. The results of such modelling aid understanding of the 
impact of risks on the process output parameters. The research in this thesis sets out 
to incorporate such uncertainties in the decision-support tool in order to reflect the 
inherent variability of process parameters during the operation of a 
biopharmaceutical plant.
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1.8. Organisation of Thesis
This chapter has highlighted the financial and timescale pressures faced during the 
drug development and manufacturing process, which in part reflect the regulations 
surrounding the biotechnology industry, and has discussed the challenges of process 
modelling and available simulators for the biopharmaceutical industry. Cost 
evaluation techniques for biopharmaceutical manufacture and specific examples 
found in published literature are discussed. The importance of incorporating risk 
analysis in processes subject to uncertainty is examined. The objectives of this thesis 
are identified in the preceding section of this chapter.
Chapter 2 provides a general background to antibodies, their applications and market 
potential. The various expression and culture methods employed in the industrial 
manufacture of Mabs are introduced. The analysis given highlights the advantages 
and disadvantages found in such production techniques and enables typical industrial 
concerns to be identified, which provide the foundation for subsequent case studies. 
Generic processes for the commercial production of Mabs expressed in mammalian 
cells, which are later used as the basis for the unit operations within a 
biopharmaceutical plant, are defined. Recent trends in the development of 
commercial antibody production methods are discussed.
In Chapter 3, the suitability of software platforms for the development and 
configuration of the decision-support tool is outlined. The design methodology and 
modelling approach for the decision-support tool, designated as BioPharmKit, are 
proposed. The production of Mabs, based on mammalian cell culture, is used for the 
design, implementation and application of the decision-support tool. The conceptual 
framework is based on a hierarchical structure in a task-oriented manner. The main 
components in the domain of the simulation tool are described. Its key 
characteristics and parameters that relate to both business and process applications 
are discussed.
An overall discussion of the tool and its utility is provided in Chapter 4. The flow of 
information during the simulation run is briefly discussed. The key input and output 
parameters of the tool are identified. A brief discussion of the data collection
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methods and the default input values employed to construct and populate the 
framework is given. The procedures to use the bioprocess tool to assemble and 
simulate an upstream processing operation are outlined.
Chapter 5 presents an application of the decision-support tool to perform mass 
balance calculations, simulate resource handling and model cost estimates to aid the 
evaluation of manufacturing options. A case study is set up to demonstrate the 
functionalities of such a tool to assess pooling strategies in perfusion culture to 
deliver a therapeutic Mab for commercial use. A deterministic analysis is initially 
carried out to determine the base case values. Sensitivity analysis is used to gauge 
the impact of variables on the key output parameters. The Monte Carlo simulation 
technique is applied to evaluate potential risks associated with technical and market- 
related uncertainties. A series of scenarios is considered to investigate their 
implications on key performance metrics. The statistics derived from the simulation 
results are then used to determine the ranking of the manufacturing options.
A second case study is presented in Chapter 6 to examine the production economics 
of fed-batch and perfusion modes of operation. This is achieved by simulating two 
alternative process flowsheets. The relative economics of the two operational modes 
are evaluated based on key operational and financial performance metrics. The 
impact of key influencing factors on the performance measures is investigated via a 
sensitivity analysis. Both the decision tree and Monte Carlo techniques are 
employed to incorporate uncertainties such as the risk of contamination and 
equipment failure. The simulation results from each method are analysed in order to 
compare each of their performance to compute useful statistics.
Chapter 7 provides a summary of the results achieved in this work and suggests 
possible extensions for future work. Papers published by the author through the 
course of this work are attached in Appendix A. Finally, the models used to compute 
the product mass are given in Appendix B.
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C hapter  2
Monoclonal Antibodies
2.1. Introduction
Since the development of the hybridoma technology in the mid 1970s, monoclonal 
antibodies (Mabs) have become an extraordinarily important resource for medical 
research and are now used extensively as therapeutics, diagnostic reagents and 
imaging agents. The considerable engineering effort to design and produce 
antibody-based proteins with high specificity is leading to an increase in both the 
range and the number of applications in which Mabs can be used successfully. With 
such developments in the understanding of the nature and function of antibody 
mechanism, the prospects for further application of engineered antibodies are of 
great potential. However, a major issue in the development of such antibody-based 
reagents is the cost of production because Mabs are very expensive to manufacture 
with the production costs estimated as high as $1,000 per gram (Gura, 2002). In 
order for the industry to maintain an acceptable margin on future production, there 
are significant pressures to reduce manufacturing costs at the commercial scale by 
1-2 order of magnitude from $l,000’s per gram to $10-$100’s per gram (Chadd & 
Chamow, 2001). This has driven the need to investigate the production economics of 
Mabs for commercial use. The design and implementation of the decision-support 
tool (Chapter 3) to facilitate the evaluation of manufacturing options was based on
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the production of Mabs. Two industrial-related case studies (Chapters 5 and 6) are 
presented to illustrate typical issues facing the biomanufacturing industry and the use 
of the tool in addressing them.
The remainder of this chapter is structured as follows. Section 2.2 provides an 
introductory background to antibodies and their applications. Their expression and 
production techniques, as well as typical industrial issues concerning antibody 
production, are discussed in Section 2.3. The generic sequence for the production of 
antibodies, which is derived from commercial manufacturing methods for antibody- 
based products in the market, is presented in Section 2.4. A brief discussion of the 
recent industrial developments in antibody production is given in Section 2.5. 
Finally, a summary is provided in Section 2.6.
2.2. Background
The initial Mab therapeutic products launched in the 1980s and early 1990s were a 
commercial and clinical disappointment. One of the main reasons for failure was the 
fact that the early Mabs induced an immune response in humans, thereby limiting 
their therapeutic benefit (Sherman-Gold, 1997; Reichert, 2001). The success of 
Mabs over the next decade may be attributed to a number of important factors. Now, 
genetic engineering is used to create humanised Mabs with more human antibody 
content and less mouse antibody content to overcome the immunogenicity problem 
(Birch, 1999). Advances in recombinant engineered technologies have also enabled 
the generation of a wide range of new antibody-based molecules, exhibiting virtually 
any desired specificity (King, 1998; Walsh, 1998). The great reproducibility of 
antibodies, coupled with their unique targeting ability, has increased the prospects for 
further application of engineered antibodies in biotechnology. According to the 
market analyst Datamonitor, Mabs are the fastest growing therapeutic protein class 
(Lamble, 2000). Mabs are now used in a variety of clinical circumstances, including 
diagnostic imaging (e.g. cancer, infectious and cardiovascular diseases) and direct 
therapeutic purposes (e.g. cancers, inflammatory and infectious diseases, and 
transplantations). Some typical therapeutic antibodies, their specific indications and 
approval dates are presented in Table 2.1.
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Table 2.1. Typical therapeutic antibodies approved by 2004 and their indications3.
Trade name/ 
Generic name Manufacturer Indication for use and approval date
Avastin/
Bevacizumab
Genentech Treatment o f  patients with metastatic colorectal cancer 
(February 2004)
Humira/
Adalimumab
Abbot Laboratories For reducing signs and symptoms and inhibiting the 
progression o f  structural damage in adult patients with 
moderately to severely active rheumatoid arthritis 
(December 2002)
Xolair/
Omalizumab
Genentech For adults and adolescents (12 years o f age and above) 
with moderate to severe persistent asthma (June 2003)
Campath/
Alemtuzumab
Millennium and 
ILEX
Treatment o f  patients with B-cell chronic lymphocytic 
leukaemia (May 2001)
Enbrelb/
Etanercept
Immunex
Corporation
Reduction in signs and symptoms o f moderately to 
severely active rheumatoid arthritis (November 1998)
Herceptin/
Trastuzumab
Genentech Treatment o f  metastatic breast cancer (September 
1998)
Remicade/
lnflixmab
Centocor
1. Treatment o f  Crohn's disease (August 1998)
2. Reduction in signs and symptoms o f rheumatoid 
arthritis (November 1999)
Synagis/
Palivizum ab
Medlmmune, Inc Prophylaxis o f  serious lower respiratory tract disease, 
caused by respiratory syncytial virus (June 1998)
Simulect/
Basilixim ab
Novartis
Pharmaceutical
Corporation
Prophylaxis o f  acute organ rejection (May 1998)
Rituxan/
Rituximab
Genentech Treatment o f  patients with relapsed or refractory low- 
grade or follicular, B -cell non-Hodgkin's lymphoma 
(November 1997)
ReoPro/
Abciximab
a n  i . .  //
Centocor 1. Prevention o f  blood clots in the setting o f high risk 
percutaneous transluminal coronary angioplasty 
(December 1994)
2. Prevention o f  blood clots in refractory unstable 
angina when percutaneous coronary intervention is 
planned (November 1997)
d Source: http://www.fda.gov/cder
b Enbrel, a soluble receptor fused to an antibody portion, has manufacturing capacity and dosing 
requirements similar to that o f antibodies.
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According to the Tufts Center for the Study of Drug Development, by the year 2001, 
10 Mabs had been approved as therapeutics by the US FDA (Reichert, 2001). To 
date, 17 therapeutic Mabs, comprising of 4 different types (i.e. three murine, five 
chimeric, eight humanised and one human) have been approved (Reichert & Pavlou,
2004). The global therapeutic Mab market generated approximately $2.6 billion of 
sales in 2000, compared to $1.8 billion in 1999 (Ginsberg et al., 2002). The global 
Mab market reached $5.4 billion of sales between 2001 and 2002 (Reichert & 
Pavlou, 2004). Among all the approved products, infliximab (Remicade) from 
Johnson & Johnson, indicated for Crohn’s disease and rheumatoid arthritis, is the 
best-selling product with sales of $1.6 billion, accounting for 30% of the total Mab 
market sales in 2002 (Reichert & Pavlou, 2004).
The estimated market demand, selling prices and dosage level for some typical Mabs 
are tabulated in Table 2.2. Mabs for diagnostic purposes may require a scale of tens 
to hundreds of grams per year. Therapeutic antibodies were initially used in limited 
markets for acute indications but they are now being developed for chronic 
indications in large markets (Grimster, 2003). This implies that tens to hundreds of 
kilograms of active drug substance may be required for a single Mab product per 
year in the market. Due to the large therapeutic doses required and the chronic 
nature of the diseases that Mabs treat, they represent a large potential market and 
demand a significant production capacity. This pressure on capacity is further 
complicated by the number of Mabs presently under development. With more than 
130 such products in the clinical pipeline, as many as 16 Mab products are predicted 
to reach the market between 2004 and 2008 (Reichert & Pavlou, 2004). The value of 
the global Mab market is projected to increase to $16.7 billion in 2008 (Reichert & 
Pavlou, 2004). Furthermore Mabs only represent approximately 25% of the total 
recombinant molecules in the biopharmaceutical development pipeline. The 
remaining 75% in the drug pipeline could put an additional strain on current 
manufacturing capacity (Lias & Fogerty, 2002).
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Table 2.2. Estimated selling price, dosage level and market demand for some 
commercial Mabsa.
Product Selling price ($/g) Dose/patient (g) No. of patients Demand
(kg)c
Campath 2,400b 0.75 21,000 16
Enbrel 5,214 2.5 100,000 250
Herceptin 5,811 3.5 26,000 91
Remicade 7,227 1.8 100,000 180
ReoPro 56,430 0.023 300,000 7
Rituxan 5,000 4.3 60,000 255
Synagis 14,301 0.14 138,000 20
Sources:
a M olowa et al. (2002) 
b Dynamic chiropractic (2003)
c The estimated market demand was based in 2002 (except for Simulect and Zenapax, where the 
values indicated the demand for 2001).
2.3. Production of Monoclonal Antibodies
The market for protein-derived products, especially Mabs, has grown significantly in 
the past decade and continues to accelerate at a rapid rate (Gura, 2002). Mabs have 
long been considered as prospective drug candidates for diagnosing and treating a 
wide spectrum of diseases. As more recombinant therapeutic proteins enter 
development and get through the approval phase, more efficient large-scale 
production of such proteins is necessary to meet the surging demand (DePalma,
2002). The challenge facing the drug companies is to develop or enhance 
manufacturing capabilities during the early stage of process development. The 
requirements of the production system depend on the form of the antibody needed 
and the intended application. For instance, the production of Mabs for use in humans 
requires more stringent controls of the production process to achieve highly purified
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antibody compared to those used for in vitro applications (King, 1998; Matejtschuk 
et al., 1998). Therefore, it is important to identify the particular manufacturing 
system at the beginning of a project.
2.3.1. Antibody Expression Technology
There are various expression systems that can be used for the production of 
recombinant proteins. These include bacterial or mammalian cell cultures and 
transgenic hosts. The choice of expression depends on the intended use of the 
antibody and the antibody yield obtained from each system (Chadd & Chamow, 
2001). Mammalian cell culture is a mature technology and is the most common 
choice for the production of complex macromolecules such as antibodies (Hu & 
Aunins, 1997; Kelly, 2001). The majority of antibody products currently on the 
market are produced by recombinant technology expressed in mammalian cell 
culture using either Chinese hamster ovary (CHO) or mouse myeloma (SP2/0 and 
NSO) cell lines (Chadd & Chamow, 2001). Almost all are secreted in their native 
form into the cell culture fluid (Werner, 1994). Such mammalian cells enable highly 
effective amplification and expression of recombinant genes. Expression levels are 
highly variable from one cell line to another. Typical antibody yields from 
hydridoma cells are between 50-500mg/L (Brown et al., 1992). NSO cell lines are 
capable of producing antibody titres between l-2g/L  (Bebbington et al., 1992; Bibila 
& Robinson, 1995). CHO cell lines have been reported to accumulate antibody 
yields greater than 550mg/L (Brown et al., 1992). Factors affecting antibody yields 
include the culture medium used, stability of the cell line, pH, temperature, and 
feeding strategy (Macmillan et al., 1987).
Both transgenic animals and plants provide an alternative route for the expression of 
recombinant proteins (Larrick & Thomas, 2001; Andersen & Krummen; 2002; 
Houdebine, 2002). High protein expression levels can be achieved in such host 
systems. Transgenic sheep, goats and mice are being investigated for their ability to 
produce large volumes of milk containing the expressed protein. Antibody 
expression levels of l-25g/L in the milk of goats and mice, being 10-fold higher than 
those in CHO culture systems, have been achieved (Young et al., 1998a).
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Increasing interest in the production of recombinant proteins in the milk of 
transgenic animals, the eggs of transgenic chickens and in transgenic plants can be 
attributed to claims of a potentially lower cost of goods compared to mammalian cell 
cultures (Young et al., 1998b). The cost of raw materials is estimated at $150/g for 
mammalian cells and $ 1 —2/g for transgenic goat milk (Dove, 2002). Typical cost per 
gram estimates at different production rates for various expression systems are 
summarised in Table 2.3. The factors affecting the cost of goods of the 
manufactured protein include the annual production capacity, purification yield and 
product titre. The trends in manufacturing indicate that the larger the production 
scale, the lower the cost per gram for a given titre (Berthold, 2002). The cost 
estimates in transgenic hosts reported in the literature range from $15-300/g (Walter, 
2001) as compared to $300-3,000/g for Chinese Hamster Ovary (CHO) cell lines 
(Young et a l, 1997; Walter, 2001; Gura, 2002). These results suggest that 
production in transgenic plants is the cheapest, followed by transgenic goat and then 
mammalian cell culture.
Table 2.3. Estimated cost of goods per gram for various expression systems at given 
production rates3.
Expression system
Cost of goods per gram ($/g)
10 kg/yr 100 kg/yr 1,000 kg/yr
CHO cells 700 3 0 0 -3 ,000b -
Transgenic goats 300 100 40
Transgenic plants - 50 15
a Adapted from Walter (2001) 
b Source: Young et al. (1997)
Onigman (2000) reported that the investment costs for biopharmaceutical facilities 
could range from $70 million to over $100 million. A summary of the capital 
investment estimates for various expression systems at different production rates is 
provided in Table 2.4. These predictions suggest that the capital requirements for 
mammalian-based systems could be more than double those for transgenic-based 
processes. The lower capital investment required in transgenic systems could be
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attributed to replacing low-cost animals with high-cost traditional fermentation 
equipment in mammalian cell cultures.
Table 2.4. Projected capital investment estimates for various expression systems at 
given production rates*
Production system
Capital investment ($ million)
250 kg/yr 500 kg/yr 1,000 kg/yr
Bioreactors 145 205 295
Transgenic goats 75 90 105
* Adapted from Onigman (2000), assuming a titre o f 300m g/L for bioreactor systems.
2.3.2. Industrial Choices for Large-Scale Production
The growing demand for antibody-based products has motivated the development of 
more efficient and reliable mammalian-cell-culture production technologies. Cell 
culture systems can be carried out in different bioreactors such as packed-cell 
perfusion bioreactors (e.g. hollow-fibre and ceramic-matrix reactors) and stirred 
tanks. Recent published literature indicates that the biotech industry has converged 
on using suspension cultures in stirred-tank reactors as the standard technology of 
choice for large-scale cell culture production (Chu & Robinson, 2001). Traditional 
barriers such as the issues of adapting cells to suspension cultures, shear sensitivity 
and oxygen supply, have been resolved. The relative scalability and uniform growth 
environment of the stirred tank culture facilitate monitoring and control of operating 
conditions such as pH, oxygen concentration and temperature. Table 2.5 lists the 
following data for each approved product from 1996 to 2003: the cell line and the 
production method. The products are categorised on the basis of their applications 
(i.e. therapeutic or diagnostic).
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Table 2.5. Approved products generated in mammalian cell-culture systems, 1996 to 
2003a.
Trade name Cell line Method
Therapeutics
Xolair CHO Suspension culture
Campath CHO Suspension culture
Enbrel CHO Not revealed
Herceptin CHO Continuous perfusion
Remicade SP2/0 Continuous perfusion - spin-filterb
Synagis NSO Fed-batch, stirred tank0
Simulect M yeloma Continuous perfusion
Zenapax GS-NSO Not revealed
Rituxan CHO Suspension, stirred tank
ReoPro M yeloma Perfusion culture
D iagnostic products
ProstaScint Hybridoma H ollow fibre perfusion culture
Verluma Mammalian cells Not revealed
M yoscint Hybridoma Not revealed
Sources:
J FDA approval information on http://www.fda.gov 
EMEA authorised products (EPAR) on http://www.emea.eu.int/htms/human/epar/epar.htm  
b D eo et al. (1996) 
c Schenerman et al. (1999)
Fed-batch and perfusion culture are the two dominant modes of operation for 
mammalian-cell-culture based processes, especially for the production of 
recombinant therapeutic proteins and antibodies required in large amounts (Hu & 
Aunins, 1997). Large-scale cell-culture production processes are typically carried 
out in stirred fed-batch or perfusion bioreactors (Chu & Robinson, 2001) (Figures 
2.1a and b). Therefore, the operation of these technologies is investigated further in
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this study. Alternative modes of operation such as batch and repeated-batch 
processing (Birch & Froud, 1994) will not be considered.
(a) (b)
Culture feed Continuous feed of media
Continuous 
removal of culture
>  Spin filter
Figure 2.1. Alternative stirred bioreactor processes for (a) fed-batch and (b) 
perfusion. In stirred tanks, the temperature, pH and dissolved oxygen level are 
controlled.
In fed-batch culture, there is a gradual addition of fresh volume of selected nutrients 
during the growth culture cycle to improve productivity and growth (Figure 2.1a). 
The culture is subsequently harvested and the product recovered. Fed-batch culture 
has been an attractive choice for large-scale production of Mabs due to its 
operational simplicity, reliability and flexibility (Bibila & Robinson, 1995) but there 
has been much interest in perfusion culture in recent years due to the high 
productivity achieved in such culture systems. In perfusion culture, a continuous 
supply of fresh media is fed into the bioreactor while growth-inhibitory by-products 
are constantly removed. The principal aspect of perfusion operation, which is more 
complex than fed-batch, is the procedure of cell retention. Such a culture mode 
requires significantly more management, control and maintenance for successful 
operation. Existing cell retention techniques include cross-flow filters, hollow fibres, 
spin-filters and vortex-flow filters. Table 2.6 provides a list of perfusion culture data 
in selected experiments using cell retention by filtration. Woodside (1998) and 
Voisard et al. (2003) compared and evaluated the relative merits and limitations of 
such retention methods for industrial applications. Voisard et a l (2003) reported that
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internal spin filters appear to be the best technique in the context of industrial scale 
manufacturing processes with perfusion rates of l,000L/day and above. Spin-filter 
based bioreactors are currently used for continuous industrial production processes 
(Chu & Robinson, 2001). The operation mode of a perfused culture system in an 
internal spin-filter based bioreactor is illustrated in Figure 2.1b. The system 
incorporates an internal rotating filter device in a stirred-tank reactor. The cells are 
inoculated and cultivated by continuous feed of fresh nutrient medium to the outside 
of the spin-filter and there is a continuous removal of the product-containing liquor 
from inside the spin-filter. The rotating spin filter minimises the loss of cells when 
spent culture is removed/harvested.
Table 2.6. Cell retention by filtration: Summary of perfusion culture data in the 
literature.
Cell line (system)
Reactor 
volume, RV 
(L)
Duration
(days)
Maximum 
perfusion rate 
(RV/day)
Study
Hybridoma
(Spin-filter) 0.55
30 1.36 Reuveny et al. (1986)
Hybridoma
(Hollow-fiber) 1.5
32 1.3 Martin et al. (1989)
Myeloma
(Spin-filter)
12 14 1 Yabannavar et al. (1992)
Hybridoma
(Spin-filter)
175 5 0.5 Yabannavar et al. (1994)
Hybridoma
(Hollow-fiber) 0.55 70 2.0 B anik&  Heath (1995)
M yeloma
(Spin-filter)
500 30 1 D eo et al. (1996)
CHO
(Spin-filter) 100 14 0.5 Iding et al. (2000)
Hybridoma 
(Vortex-flow filter)
1.6 17 4.3 Mercille et al. (2000)
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2.3.3. Operational Considerations
The key factors of consideration between the modes of operation include reactor 
productivity, ease of scale-up and operation, process economics, product stability and 
up-front investment requirements.
Productivity comparison
Several parameters have been used to evaluate the antibody production performance 
for different bioreactor processes such as the antibody titre in the broth, the quantity 
of antibody produced during a defined period and the volumetric Mab production 
rate. Mahadevan (2003) suggests the volumetric productivity as an optimal metric 
for cross-bioreactor productivity comparisons. It accounts for the amount of Mab 
produced, the time required to produce a certain quantity of Mab and the bioreactor 
volume required to produce the desired quantity of Mab. Table 2.7 summarises the 
key differences in titre and volumetric productivity between fed-batch and 
continuous perfusion systems that have been published in the literature.
Table 2.7. Comparative performances of fed-batch and perfusion cultures.
Fed-batch Perfusion
Titre
(mg/L)
Productivity
(mg/L/day)
Titre
(mg/L)
Productivity
(mg/L/day)
Reference
220 27 400 660 Reuveny et al. (1986)
40 200a Bartley et al. (1992)
1,000-2,000 50-140b Bibila & Robinson (1995)
400-500 260-330° Deo et al. (1996)
2,400 105d X ie & Wang (1996)
2,700
a rr*i_ r
95e Zhou et al. (1997)
j  -I
bMab titres in the order o f l-2g/L  are achieved over a period o f 2-3 weeks.
c The productivity was calculated based on a perfusion rate o f 1 d a y 1 and the production phase from 
day 10 to day 30.
d The final antibody titre reached 2,400m g/L over a 550h culture. 
e The final Mab concentration reached more than 2.7g/L in 672h.
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There have been a number of attempts to increase the viable cell concentration and 
prolong culture lifetimes in fed-batch processes (Bibila & Robinson, 1995; Xie & 
Wang, 1996; Zhou et al., 1997). Typical antibody titres in the order of l-3g/L  have 
been reported using fed-batch cultures of mammalian cells. The cell densities 
achieved in perfusion culture (107-1 0 8 cells/mL) are typically 1 or 2 orders of 
magnitude higher than for fed-batch modes ((l-5 )x l0 6 cells/mL). In some cases it 
has been demonstrated that continuous perfusion offers an approximately 10-fold 
improvements in volumetric productivities compared to fed-batch (Bibila & 
Robinson, 1995; Mahadevan, 2003). Although Mab titres of up to l-5g/L  have been 
reported (Tyler, 1990) for some perfusion cultures, titres are in most cases lower than 
those obtained in fed-batch culture due to the continuous dilution of the harvest 
stream. Published work in the literature indicates antibody titres typically range 
between 40-500mg/L (Reuveny et al., 1986; Bartley et al., 1992; Deo et al., 1996) 
for the perfusion culture of mammalian cells. Mahadevan (2003) concluded that 
perfusion cultures have higher volumetric productivities but lower titre values 
relative to fed-batch.
Investment considerations
There are numerous fed-batch facilities with reactors in the range of 2,000 to 
20,000L. According to the EPAR report (EMEA, 2000) for Herceptin, the cell 
culture is successively scaled up using a seed train and fermenters from 80L up to 
12,000L in a batch/fed-batch operation. Schenerman et al. (1999) described the 
commercial manufacture of Synagis using fed-batch culture in 400, 2,000 and 
10,000L stirred tank bioreactors. The fed-batch production of a Mab using NS0 cells 
was carried out at 8,000L scale (Moran et al., 2000). As a result of the high 
productivity in perfusion systems, significantly reduced plant capacity is required to 
produce comparable quantities of antibodies. Deo et al. (1996) reported the 
production of more than 1kg of antibody per week using a 500L continuous 
perfusion bioreactor and suggested that to produce the same quantity using a fed- 
batch process would require a 5,000-10,000L bioreactor. The fed-batch system 
requires a larger reactor volume for a given production rate and hence demands a 
higher up-front capital investment.
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Product stability
The product stability is also a factor influencing the choice of culture mode. An 
inherently unstable product (e.g. if temporal changes in culture conditions adversely 
affect product consistency or if product is susceptible to degradation) would require 
more rapid processing. Perfusion culture may be preferred, because the mean 
product residence time is in the order of hours instead of days as compared to fed- 
batch (Kadouri & Spier, 1997; Hoorn, 2000).
Design and scale-up
Fed-batch bioreactor design is a relatively straightforward concept adapted from the 
batch reactors. As the fed-batch mode is widely adopted for the commercial scale 
manufacturing of Mabs, typical issues of mixing and parameter controls are well 
understood. The design of continuous perfusion bioreactors is more complicated due 
to additional retention devices in the bioreactors (Dalm, 2003). Fed-batch reactors 
are relatively easy to scale-up while the complexity of perfusion bioreactors poses a 
greater challenge.
Sterility and technical difficulties
The manufacture of therapeutics based on mammalian cell culture is burdened by the 
potential risk of introducing foreign agents or inappropriate operating conditions 
(Hesse & Wagner, 2000). The industry tends to prefer the fed-batch process with its 
shorter duration and lower risk of contamination. Continuous perfusion processes 
are subject to an increased contamination risk due to the prolonged operational time. 
It is difficult to maintain reactor sterility for long periods of time. Possible sources 
of contamination include improperly sterilised feeds, piping failure and process water 
systems contaminated with micro-organisms (Jayme & Smith, 2000). The incident 
of contamination can vary between 10-15% of the batches in continuous 
fermentations producing kilograms of antibodies (Humphrey, 1996).
Continuous perfusion bioreactors with spin-filters suffer from operational difficulties 
such as clogging of pores. The problem of filter-membrane fouling has been 
reported in a number of spin-filter perfusion experiments. For example, filter 
clogging in perfusion cultures has been reported after 7 days of operation elapsed 
(Reuveny et al., 1986) and after 14 days (Yabannavar et al., 1992). The fouling of
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membrane filters may have a significant impact on the process performance. Filter 
clogging results in shortened membrane life, increased running costs and premature 
termination of perfusion cultures.
2.3.4. Typical Industrial Issues
With the growing demand and thriving drugs in the clinical pipeline, manufacturing 
is an emerging issue in the biotech industry. The key manufacturing challenge is to 
produce the drug to the correct quality in an efficient and cost-effective manner. 
This section will highlight typical industrial concerns surrounding the manufacture of 
antibodies for commercial use.
• Pooling strategies in perfusion culture
A major issue in perfusion culture is the need for an efficient pooling strategy in 
order to utilise fully resources and minimise costs. The options are to invest in a 
plant with a smaller downstream process (DSP) capacity and employ more frequent 
pooling of the broth for purification or opt for a plant with a larger DSP capacity 
with less frequent pooling of broth. The strategy of pooling more frequently 
provides improved utilisation of downstream equipment due to frequent processing 
in the downstream equipment and lower investment costs. However, the potential 
disadvantages include increased equipment-preparation and quality control and 
assurance costs. Opting for less frequent pooling leads to fewer ancillary equipment- 
preparation and regulatory-compliance steps but higher fixed overhead costs due to 
the need for larger DSP capacity and ancillary equipment e.g. buffer vessels. The 
product stability is also a factor influencing the choice of pooling strategy. A less 
stable product would require more rapid processing and hence frequent pooling of 
the broth. Indeed overall little modelling work has been carried out to address such 
trade-offs in the perfusion mode of operation. The case study analysis in Chapter 5 
addresses the trade-offs between these manufacturing options via a computer-aided 
approach.
• Fed-batch vs perfusion culture
Developing large-scale production of mammalian cell products would require a 
company to choose between the relative simplicity and high titres of fed-batch
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systems and the high productivity but greater complexity of perfusion processes. 
Fed-batch mode of operation typically also involves high start-up costs, owing to the 
need for a larger bioreactor plant capacity. Increasing interest in the use of perfusion 
system can be attributed to the high productivity and reduction in reactor capacity 
(hence easier to operate, clean and sterilise). This results in a significantly smaller 
plant capacity required to produce comparable quantities of Mabs and allows for a 
lower initial investment. However, since perfusion processes typically require 
increased start-up and operational times, equipment failure, including fouling of the 
device used to retain the growing cells, is more frequently encountered. In addition, 
with a potentially high number of physical interventions over the extended culture 
cycle, the possibility of contamination is increased.
Rouf et al. (2001b) examined the economic potential of batch and fed-batch 
operations for the production of tissue plasminogen activator (t-PA) from CHO cells 
using the simulation package BioProcess Simulator (BPS). It was concluded that 
although the fed-batch process is more complicated in terms of process operation and 
control, it offers a significant profit margin over batch culture. Little modelling work 
however has been done to examine the economics of fed-batch and perfusion 
systems for antibody production. The case study presented in Chapter 6 seeks to 
provide an analysis of the running costs and evaluate the trade-offs between these 
manufacturing options through the use of a computer-aided design tool.
2.4. Generic Antibody Production Processes
The design of a process for the large-scale production of a protein is a crucial step in 
its successful commercialisation. The process development can pose a significant 
hurdle with extended lead times. A potential solution is the use of generic 
purification processes. Figure 2.2 depicts a generic purification process adopted by 
Amgen. Generic approaches offer the advantages of reducing regulatory issues of 
processing and shortening development times (Morrow, 2002).
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Polishing steps
Cell culture harvest
Protein A chromatography
Viral filtration
Bulk drug substance
Viral inactivation
Figure 2.2. Generic purification process for the production of biopharmaceutical 
proteins, such as antibodies, adopted by Amgen (Adapted from Morrow, 2001).
The proposed flowsheet for the production of a typical Mab by mammalian cell 
culture, as depicted in Figure 2.3, is a generic sequence derived from an analysis of 
the production of marketed Mabs (Farid, 2001). The diagram depicts generic 
manufacturing operations for fed-batch and continuous perfusion cultures. 
Downstream purification of Mabs produced in mammalian cell lines is simpler than 
the purification of many other products as the required protein is secreted from the 
cell in a soluble form. Thus, cellular disruption is not required. The next phase of 
downstream processing involves removal of the cells and the concentration of the 
crude product to yield smaller working volumes, which can be subsequently 
processed with greater speed. At industrial scale, the initial volume can amount to 
thousands of litres, it is therefore desirable to reduce the process volume at the 
earliest possible stage for economic and practical reasons. Removal of the cells is 
achieved by centrifugation or filtration. Filtration is also sometimes used to 
concentrate the cell-free broth. The clarified broth is then subjected to Protein A 
affinity chromatography to capture the antibody product and further concentrate it. 
Viral clearance is followed by further concentration of the broth by ultrafiltration. 
The concentrated filtrate is then passed through an ion exchange column. Further 
virus reduction by nanofiltration and concentration of the process stream then takes 
place prior to gel filtration as a polishing step. A final sterile filtration step is used, 
yielding an essentially pure antibody preparation.
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Viral inactivation
Concentration/Buffer exchange
Gel filtration chromatography
Inoculum grow-up
Affinity chromatography
Ion exchange chromatography
Seed  fermentation
Viral removal filtration
Final filtration
Concentration/Buffer exchange
Cell removal by filtration or 
centrifugation
Fed-batch culture/Continuous 
perfusion culture
Figure 2.3. Overview of generic antibody production processes based on mammalian 
cell culture for fed-batch and perfusion cultures. The purification process includes a 
primary capture step using a Protein A affinity chromatography. Further polishing 
steps comprise of an ion-exchange-based and gel-filtration-based processes.
2.4.1. Cell Culture
The upstream part is the production of the desired protein in a raw form and includes 
fermentation/cell culture. Upstream processing commences with the use of a single 
ampoule to inoculate a few litres of media. After growth, this lab-scale culture is 
used to inoculate the media in a small bioreactor. This starter culture is then used to 
inoculate the production-scale bioreactor. The fermentation conditions (e.g. pH and 
oxygen concentration) are continuously monitored and controlled during the growth 
process. At the end of the production fermentation process, the crude product is 
harvested for downstream processing.
- 5 6 -
Chapter 2. Monoclonal Antibodies
2.4.2. Centrifugation
Centrifugation is a unit operation that is commonly used in the downstream 
processing for the removal of cells and debris from the culture supernatant. 
Centrifugation is a separation process, which uses the action of centrifugal force to 
promote accelerated settling of particles in a solid-liquid mixture. It relies on the 
sedimentation of particles based on the difference in the densities and size of the 
particle and the medium. Centrifuges come in many designs, with laboratory size 
handling volumes up to 6L per cycle and industrial scale handling throughputs of up 
to 150,000L/h (Wheelwright, 1991).
2.4.3. Membrane Filtration
Difference in particle sizes is the driving force in filtration methods to separate the 
particles from the mixture. The role of the filter is to create a selective barrier 
through which certain parts of the process stream (the permeate) pass through and 
the remainder of the stream (the retentate) is retained. Membrane systems may be 
operated either in cross-flow mode or dead-end mode. Microfiltration and 
ultrafiltration operations, which are often used to achieve product recovery and 
purification, tend to operate in cross-flow mode while sterile-filtration operations are 
often operated in dead-end mode.
2.4.3.1. Cross-flow filtration
In cross-flow filtration, the flow of liquid is parallel to the membrane with high 
flowing forces, which enables the suspended solids to be carried away in the cross 
flow. This reduces the clogging of membrane by sweeping deposits away from the 
membrane surface. Microfiltration and ultrafiltration are usually operated in the 
cross-flow mode.
Microfiltration is commonly used to recover cells from the fermentation broth. The 
larger particles are unable to pass through the pores in the filter and are retained. 
Microfiltration is generally concerned with particles whose size ranges from about 
0.05pm to 10pm. Typical transmembrane driving forces are in the range of 0.1-2bar 
while the fluxes of molecules across the membrane are usually more than 50L/m2/h.
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With continuous-harvest culture systems, filtration (typically using microfiltration) 
can be performed simultaneously during supernatant collection.
Ultrafiltration is an effective technique for concentrating or separating molecules of 
different sizes. Ultrafiltration deals with particles or molecules of approximately 
0.001 pm to 0.05pm. The driving forces in ultrafiltration typically range from 1- 
5bar. Typical flux values can vary between 10-50L/m /h. The pores of ultrafilters 
are small enough to prohibit the flow of proteins through the membrane and allow 
other components of the process stream to pass through. Ultrafiltration is a popular 
method of concentration as high product recovery yields and fast-processing times 
can be achieved.
2.4.3.2. Dead-end filtration
In the dead-end mode, the flow of fluid is perpendicular to the plane of the filter and 
the particles settle against the filter. Dead-end filtration tends to be employed for 
sterilising purposes that can occur throughout the process. Its application includes 
upstream sterility of fermentation broth and as a final filtration step prior to filling.
2.4.4. Chromatography
After concentration, high-resolution chromatographic purification step is usually 
adopted to purify the protein to a high level. The reduction of process volume can 
also be achieved by using chromatography purification steps. Chromatography is a 
separation technique in which the different components in the fluid migrate through 
the column at different rates. This method consists of interactions between 
molecules in the sample (fluid phase) and the matrix (solid phase). The matrix is 
packed in a column. A variety of different chromatography-capture methods are 
available. There are basically two mechanisms for chromatography: adsorption 
whereby the molecules are adsorbed onto the chromatographic matrix through a 
binding process (e.g. affinity and ion exchange chromatography) and non-adsorption 
process (e.g. gel filtration chromatography). A combination of two to four different 
chromatographic steps is normally employed during the process.
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A typical chromatography step is a batch operation consisting of a load step to feed 
the inlet stream onto the column, a wash step to remove unbound materials and an 
elution step to recover separated fractions from the column by the action of an 
elution buffer. In some cases (e.g. affinity and ion exchange), an additional 
regeneration step is required to restore the column to a state to which the next inlet 
stream can be applied. The components in the inlet stream have different distribution 
characteristics due to their relative affinities for the matrix. As the elution buffer 
flows through the column, the solutes are resolved and are eluted at different times.
Affinity chromatography is often employed to achieve a high degree of purification. 
This technique is based on specific interactions between the molecules with a 
complementary structure bonded to the solid phase that results in a separation from 
other components in the feed. Ion exchange chromatography is a separation process 
based on electrostatic interactions between molecules in the sample and the solid 
matrix. Ion exchange and affinity chromatography steps are both used as 
concentration methods, which handle large volumes of media and produce a small 
volume of concentrated product.
Gel filtration chromatography does not rely upon the adsorption of protein to a solid 
phase and is based on the different rates of diffusion of molecules of different sizes 
in a porous matrix. Larger molecules traverse the length of a column faster than 
small molecules. Those molecules, which are small enough to diffuse an appreciable 
distance into the matrix, slow down in their passage through the column and this 
results in a separation in time between the components in the inlet stream.
2.4.5. Viral Clearance
Mammalian cell lines may contain viruses that could potentially lead to patient harm. 
Comprehensive and integrated strategies are necessary to ensure removal of potential 
virus contaminants in biopharmaceutical production during purification in order to 
meet the requirements for marketing approval by regulatory agencies (Aranha & 
Forbes, 2001). Effective viral clearance can be achieved through existing 
purification steps such as chromatography. In chromatographic operations, 
depending on the resin and binding capacity, critical contaminants can be eliminated.
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Additional steps such as chemical inactivation and virus filtration (e.g. 
nanofiltration) can be used as effective means of enhancing process viral clearance in 
manufacturing biological and biopharmaceuticals products beyond those that can be 
demonstrated by standard protein purification steps.
2.5. Recent Developments in Antibody Production
The previous section has described the current practices for production of 
commercialised Mabs. However, there are a number of developments emerging, 
which may in the future be applied to antibody production. Some of these areas are 
described below. One function of the decision-support tool would be to assess the 
likely impact of these alternatives.
• Bioreactor design
The ATF System™, introduced by Refine Technology, Co. (East Hanover, NJ) and 
used in the alternating tangential flow (ATF) mode, is a low shear filtration system 
that inhibits filter-membrane fouling. Furey (2002) suggested that this external cell- 
separation system is able to maintain continuous perfusion culture for extended 
periods of time and offers a rapid change of filters without compromising a culture 
run. Furthermore, different-sized ATF units are available to scale a perfusion 
process successfully from the small-development scale to a pilot-scale vessel and a 
production vessel of 1,000L.
4C Biotech (Seneffe, Beligum) and GSK Biologicals (Rixensart, Belgium) co­
developed the sono filtration system for perfused cell culture processes. The device, 
BioSep, is manufactured and marketed by Applisens (Schiedam, The Netherlands). 
It relies on an acoustic standing-wave force field to filter the cell suspension. The 
system does not clog and can be maintained without failure for extended period of 
time. De Keyser (2002) indicated that quantities in excess of 500g of Mabs have 
been achieved with productivities and cell densities comparable to that of a tank 
bioreactor. The process proved to be scalable through the range of units available at 
4C Biotech. The BioSep unit has been designed to filter up to 1,000L of cell 
suspension per day.
- 6 0 -
Chapter 2. Monoclonal Antibodies
• Disposable/Single-use technology
As an alternative to the stainless steel reactor, the Wave Bioreactor™, introduced in 
1998 by Wave Biotech (Bedminster, NJ), is a presterilised disposable culture system 
with a scale of up to 500L. This rocking device can be operated in batch or perfusion 
mode. For the perfusion mode, it is equipped with a floating filter and operated in a 
wave-induced agitation motion to prevent filter clogging. Singh (1999) has 
demonstrated its application through the production of monoclonal antibodies using 
the NSO cell line from lab-scale of 10L to pilot-scale of 100L. The experiment 
showed that the bioreactor is well suited for antibody production with comparable 
performance to stirred-tank bioreactors. Wave Biotech (Singh, 1999) claimed that 
this disposable reactor is 10-fold cheaper than a comparable bioreactor, due to the 
elimination of complex instrumentation, and the fact that it does not require cleaning 
or sterilisation. The Wave Bioreactor has been employed in a perfusion mode for 
biotechnology applications (Ohashi et al., 2001). In this study, the bioreactor was 
utilised at a 2L scale to produce a monoclonal antibody based on a hybridoma cell 
line. The study indicated that the reactor could achieve high cell densities and 
perform the perfusion operation without clogging for over 25 days. However, the 
limitation of this system is the accurate controlling of feed media and harvest culture.
The use of bioprocessing plants based on single-use disposable technology appears to 
be an attractive alternative to conventional stainless steel plants. Fixed stainless steel 
vessels would be replaced by pre-sterilised disposable plastic containers incurring 
minimal cleaning costs. Disposable-based engineering could be implemented 
throughout the production plant, such as the use of disposable filtration membranes, 
disposable pre-packed chromatography columns and single-use bags for fluid 
handling. The disposable option has the advantage of switching capital costs to 
consumables costs instead. The benefits of disposable processing include lower 
running costs, less downtime and greater process flexibility (Novais et al., 2001; 
Hodge, 2002; Monge & Hammarberg, 2004). In addition, disposable manufacturing 
enables facilities to run multiple products in a single plant without the risk of cross­
contamination.
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• Transgenic production
The development of efficient antibody expression techniques is essential for the 
economic production of highly purified proteins at large scale. Cultured cells have 
only a limited capacity to produce large amounts of antibodies, even under optimal 
conditions (Andersen, 2002). Recent advances in the expression of antibodies in 
transgenic hosts (e.g. goats, chickens and various plant varieties) indicate that these 
recombinant systems provide alternative platforms to achieve high productivities and 
low cost protein production. The production of recombinant proteins from the milk 
of transgenic dairy animals is technically more mature as compared to other 
transgenic systems (Houdebine, 2002). One of the major advantages of transgenic 
livestock over cultured cells is their robustness. The levels of milk secretion are very 
stable and can be maintained constant for weeks or months.
An example of a transgenic livestock application includes antibody production from 
the milk of goats at Genzyme Transgenics Corporation (GTC) (Young et a l,  1998a). 
Pollock et al. (1999) reported that the purification process of a recombinant antibody 
from transgenic milk at GTC could attain a yield of 65% with a purity of 99.9%. 
Other advantages of transgenic production include the ability to yield high levels of 
antibodies (usually in the g/L range), scale-up flexibility since livestock numbers can 
be increased (or decreased) rapidly and the relative low cost of manufacturing 
facilities (farms) as compared to more traditional cell-culture plants. This mode of 
production has the potential to address limitations in capacity and economics, and 
prove a viable alternative to the large-scale production of proteins. However, 
existing methods of creating transgenic animals are still relatively inefficient and 
time-consuming. Technical challenges in the field of biopharmaceutical production 
in transgenic livestock include improving control over transgenic expression and 
reducing the effective reproductive time among transgenic animals (Rudolph, 1999). 
The production of antibodies from transgenic plants may offer similar cost 
advantages but has other concerns such as environment issues and long timelines to 
achieve protein availability (Hood et a l, 2002; Rosin, 2004).
• Novel downstream processes
In the downstream processing of antibody production, the number of unit operations 
should be minimised to avoid product losses and achieve cost reduction. The
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traditional steps involved during the initial purification process are centrifugation, 
and ultrafiltration, followed by conventional packed bed adsorption (PBA) 
chromatography (Hjorth, 1997). The development of the expanded bed adsorption 
(EBA) technology is of particular industrial interest since it allows the purification of 
the desired protein product directly from the crude feedstock in a single unit 
operation. Such a technique eliminates the need for initial centrifugation, filtration 
and purification prior to other high-resolution steps (Figure 2.4). Several attempts 
have been made to investigate the impact of EBA in antibody production using 
mammalian cell culture (Fahmer et al., 1999; Gonzalez et a l, 2003). They reported 
that the yield and purify of the purified antibodies were comparable to those obtained 
by the standard PBA method. The use of EBA has resulted in a considerably smaller 
capital investment, reduced running costs and a lower demand for processing time. 
However, the pitfalls of EBA include more rigorous cleaning protocols and 
instability due to cell/debris contaminants.
Ultrafiltration
Centrifugation
Cell culture
Purification/Polishing steps Purification/Polishing steps
Packed Bed Adsorption
Expanded Bed Adsorption
Cell culture
PBA process EBA process
Figure 2.4. Process comparison: Packed bed adsorption (PBA) route versus 
expanded bed adsorption (EBA) route.
2.6. Conclusions
Mabs play a significant and increasing role in clinical applications as therapeutic, 
diagnostic and imaging reagents. This chapter has provided an introduction to the 
production of antibodies, their applications and potential market demand. The
- 6 3 -
Chapter 2. Monoclonal Antibodies
various expression techniques and culture systems for the commercial bulk 
production of antibodies have been examined. Mammalian cell culture (hybridoma, 
myeloma or CHO cell lines) is the most common source for the biosynthesis of such 
recombinant proteins. Reviewing the current processes used in the large-scale cell- 
culture production of antibodies indicates that the stirred tank bioreactor, with some 
form of controlled feed (e.g. fed-batch or perfusion), has emerged as the standard 
technology of choice. The comparative performance and operational considerations 
of fed-batch and perfusion systems have been presented. Typical industrial issues, 
which provide the basis for the case studies in this research, are highlighted.
The mammalian-cell-culture production of a typical Mab, based on a generic 
approach, is analysed. The upstream processing consists of the typical inoculum 
grow-up operation and seeding fermentation, followed by the production 
fermentation. The downstream operations comprise primarily of chromatography 
and filtration steps. Recent trends in the developments of antibody commercial 
production are discussed.
The proposed conceptual framework, which is presented in the next section of the 
thesis (Chapter 3), is designed to assist decision-making for biopharmaceutical 
manufacture and is based on mammalian cell culture. The generic processes for 
antibody production presented in this chapter provide the foundation for the unit 
operations included in the tool domain.
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Design Methodology and 
Implementation of BioPharmkit
3.1. Introduction
The manufacture of a drug, in a timely and cost-effective manner, for product testing 
and product launch can have a dramatic influence on the development timescales and 
the financial health of a company (Byrom, 2000). Early process planning, improved 
process yields and efficient resource utilisation are necessary to enhance 
manufacturing operations. The need for software tools, capable of achieving these 
objectives, is becoming increasingly critical. The research reported in this chapter 
sets out to develop a prototype tool, designated as BioPharmKit, for application in 
the production of cell-culture derived products and which addresses key process and 
business issues in the biomanufacturing sector. The design, implementation and 
application of the decision-support tool are based upon the production of Mabs 
expressed in mammalian cells.
This chapter is structured as follows. Section 3.2 describes the manufacturing 
domain that is addressed by the tool. The scope of the tool framework is indicated in 
Section 3.3. Section 3.4 provides an assessment of suitable software platforms for 
the implementation of the decision-support tool. In Section 3.5, the conceptual
- 6 5 -
Chapter 3. Design Methodology and Implementation o f  BioPharmK.it
modelling framework is proposed. A general overview of the tool structure is 
described in Section 3.6. The key features and components of the simulation tool are 
identified in Section 3.7. Finally, a summary is provided in Section 3.8.
3.2. Domain Description
The key issues of the problem domain in biopharmaceutical manufacture are 
highlighted in this section. Manufacturing issues must be addressed during early 
process development to ensure sufficient supplies and timely delivery for 
commercial introduction (Clemento, 1999; Byrom, 2000). At each stage of 
manufacturing process, validation and process controls are important to assure the 
drug products meet the standards for safety, quality and stability of biologies 
(Doblhoff-Dier & Bliem, 1999). However, companies often tend to overlook the 
importance of staff and resource management within the context of regulatory 
compliance. Manufacturing development must therefore proceed concurrently with 
current Good Manufacturing Practices (cGMP) development to prevent pitfalls in 
procedural control.
The majority of commercial antibody products are manufactured primarily by 
mammalian cell cultures in stirred-tanks, operated in either fed-batch or continuous 
perfusion modes. The simulation tool was therefore used to assess the manufacture 
of biopharmaceuticals based on such processes. The unit operations were derived 
based on the generic process for mammalian-based production, as discussed in 
Chapter 2. The resulting protein is usually secreted from the cell. Commercial 
operations to recover the desired product from the cells include membrane filtration 
or centrifugation. Downstream purification steps comprise primarily of column 
chromatography and membrane filtration steps. Viral clearance steps such as 
chemical inactivation and nanofiltration are added to the process to remove potential 
virus contaminants derived from mammalian cells.
In addition to the manufacturing unit operations, ancillary activities are involved 
indirectly with the main production run. These include the preparation of equipment 
such as cleaning-in-place (CIP) and sterilising-in-place (SEP) operations and
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chromatography column preparation steps of equilibration and regeneration. 
Intermediate materials such as media and buffer solutions need to be prepared prior 
to the unit operations. Other regulatory support activities include in-process testing 
steps such as quality control and assurance, and batch documentation.
The process design of a manufacturing operation requires an understanding of the 
technical process and the operational aspects affecting the business. Table 3.1 
illustrates the applications often addressed by both process and business modelling. 
Process modelling investigates technical performance by developing and specifying 
the sequence of operating steps and examining the effects on operating variables. 
Business modelling enhances project management by addressing strategic issues 
such as project costing and risk analysis. Combining process and business modelling 
provides a basis to develop the process in a cost-effective manner for commercial 
production and enhance decision-making in manufacturing.
Table 3.1. Applications of process and business modelling.
Modelling area Application
Process Capacity management
Plant design
Mass balances
Allocation o f resources
Business Capital investment decisions
Cost evaluation
Cash flow analysis
Risk assessment
3.3. Scope of Framework
The purpose of the simulation tool was to provide an evaluation of manufacturing 
options from both the business and process perspectives by capturing process data. 
The framework should cater for the different unique aspects of the 
biopharmaceutical-manufacturing domain while maintaining easy simulation usage. 
The scope of the conceptual framework was defined as follows:
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• to prototype biotech manufacturing unit operations and resources,
• to evaluate process economic, time, yield and resource management,
• to perform process data analysis,
• to generate key output data.
The capabilities of the decision-support tool should include the ability to design new 
processes and evaluate process modifications of existing manufacturing facilities. 
The simulation model should be able to address the following manufacturing 
alternatives:
• capacity issues e.g. selecting the most appropriate pooling strategy in 
perfusion culture given a set of operating constraints,
• process decisions e.g. the use of fed-batch versus continuous perfusion 
cultures,
• facility design e.g. the use of a stainless steel versus a disposable-based 
manufacturing plant,
• retrofit decisions e.g. retrofit of expanded bed chromatography technique in a 
conventional packed bed facility.
The next section of this chapter provides an assessment of the suitability of software 
platforms for the implementation of the simulation tool. The subsequent sections 
focus on the description of the approach adopted to model the operational and 
economic aspects of biopharmaceutical manufacture.
3.4. Assessing Suitability of Software Platforms
The possibility of using a commercially available process simulation package 
configured specially for the bioprocess industry was investigated in detail by Farid 
(2001). The study highlighted the pros and cons of using BioPro Designer. The 
package permits a flowsheet for an entire process to be set up rapidly. It consists of 
many important default values for input data that can be used when experimental 
data are not readily available. The key disadvantages of BioPro designer were found
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to be the inflexibility to customise and model newer unit operations and the inability 
to incorporate probability distributions to represent uncertainties in parameter inputs.
Past work at the Advanced Centre for Biochemical Engineering, University College 
London (UCL), had focused on using ReThink, a graphical application that runs in 
G2 (Gensym Corporation, Cambridge, Massachusetts), an object-oriented 
programming environment. The key advantages of ReThink include useful pre-built 
features that enable extension and customisation for process re-engineering. Such a 
package facilitates rapid prototyping for process development in a modular and 
hierarchical fashion by allowing the description of manufacturing activities at 
various levels of abstraction. However, one of the key disadvantages was found to 
be that the reporting features of the package were not facilitated. The high cost of a 
G2 license was also a major consideration factor.
Current research in UCL is looking into the possibility of using a Windows-based 
software for bioprocess modelling, taking into consideration the benefits of Windows 
environment features, to replace the capital and programming intensive G2 object- 
oriented modelling package. This has two distinct advantages. Windows is a very 
easy domain in which to learn and work and it is the most common environment for 
engineers in industry.
Extend (Imagine That Inc., San Jose, USA) is a visual, interactive Windows-based 
simulation package that is tailored for a broad range of industries. Models are 
constructed graphically by dragging and dropping blocks from library windows onto 
the model worksheet. Data can be entered directly into block dialogs interactively by 
using controls or read from files as the simulation runs. The block development 
environment includes a fully-featured, compiled, ModL language that allows 
simulation modellers to add customised functionalities. ModL is a relatively easy 
programming language to learn and program due to its similarity with the C 
language. This toolkit combines sophisticated statistical analysis with specialised 
blocks (e.g. processing, batching, transportation) to provide a wide variety of 
modelling opportunities. It offers unlimited hierarchical decomposition and consists 
of features to streamline operations, document procedures, identify bottlenecks and 
plot utilisation profiles. Extend Industry Suite (v5), an extension of the basic Extend,
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provides an integrated database system, which is necessary for the storage of process 
data.
A summary of the assessment of the software packages based on several criteria is 
given in Table 3.2. On the basis of the above analysis, Extend Industry Suite (v5) 
was selected as the most appropriate software package and was chosen as the 
simulation package for the implementation of the decision-support tool. Microsoft 
Excel was chosen to provide the database interface as it is transparent to most users.
Table 3.2. A summary of assessment of software packages.
Software packages
Assessment criteria BioPro Designer G2 Extend
Availability o f existing unit 
operations
Yes No No
Ease o f  use o f existing process 
models
Easy N/A N/A
Simple v rigorous process 
models
Only simple Adaptable to 
simple and 
rigorous
Adaptable to 
simple and 
rigorous
Ability to create user-defined 
models
No Yes Yes
Availability o f  numerical- 
solving techniques
Yes No
(Programming
required)
No
(Programming
required)
Reporting feature Less convenient 
(Text file)
Not convenient Convenient
Cost consideration* US$5,500/copy/y r U S$41,780/copy  
(Offline version)
U S2,995/copy  
(Extend Industry 
Suite)
Ability to support stochastic 
variables
No Yes Yes
* Software prices are for industrial licenses as o f 2003.
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3.5. Modelling Framework
A highly structured bioprocess simulation support tool was proposed in order to 
achieve rapid process modelling for the manufacture of biological products. The 
conceptual framework seeks to integrate various aspects, including resource 
management, mass balance analysis, in-process testing and costing, that each relate 
to strategic bioprocess decision-making. Figure 3.1 depicts the structured framework 
of the decision-support tool. The tool proposes the integration of a data bank unit, a 
code repository unit, a process flowsheet model and libraries of blocks. The diagram 
illustrates the constant interaction between the manufacturing tasks, resources and 
the repository of code, allowing mutual transfer of information between them.
Business & Process Data Level
Processing Level
Operational Level
Data Bank
Code 
Repository
Manufacturing
Tasks Resources
Component Level
t
Process Flowsheet Model t
Libraries containing blocks specific for 
bioprocesses
Figure 3.1. A structured framework of the decision-support tool. The framework 
integrates the business and process data, processing, operational and component 
levels for rapid bioprocess modelling.
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3.5.1. Libraries of Blocks
The decision-support tool contains the toolkit of bioprocess components required for 
the simulation of the process flowsheet. The components are classified and stored 
according to their type. The main components of the process flowsheet model are 
identified as the manufacturing tasks and resources.
3.5.2. Process Flowsheet Model
The biological process steps are modelled in this section of the tool. The user 
defines the flowsheet for the entire manufacturing process as well as the interaction 
between the manufacturing tasks and resources.
3.5.3. Code Repository Unit
The code repository unit forms the core of the decision support tool. It enables data 
retrieval and conveyance of information to the data bank unit, forming an efficient 
channel of information to the process flowsheet model. This unit also comprises the 
common functions or procedures initiated by the manufacturing tasks and resources.
3.5.4. Data Bank Unit
In reality, a company would have to analyse a set of process and business input data 
in order to determine the most effective or workable solution. The data bank gathers 
and feeds both the technical and management information into the code repository 
unit. After simulation of the process flowsheet model, output data are sent to the 
data bank unit via the code repository unit.
3.6. General Tool Structure
3.6.1. Implementation
Having delineated the conceptual modelling framework and selected the software 
platform, the framework was then translated into a computer-aided tool. The 
software tool was developed using a task-oriented approach on the platform of the
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visual simulation package Extend Industry Suite (v5). Microsoft Excel was selected 
to provide an interface for viewing results. The tool framework was based on 
previous work carried out using ReThink at UCL (Farid, 2001). The implementation 
involved the translation of the original framework to Extend and adding new features 
to improve the functionalities of the simulation tool. In designing the decision- 
support toolkit, the main challenge was to build the tool so as to ensure modularity, 
reusability and extensibility. Specific blocks to describe the bioprocess steps were 
coded in Extend and linked to represent the whole process within the manufacturing 
environment. Extend provides a wide range of libraries containing blocks to create 
models. New blocks were created in the tool to capture features not provided in 
Extend (Appendix B). The manufacturing processes were configured as time- 
dependent discrete unit operations. Table 3.3 describes the procedures for translating 
the framework into the prototype tool.
Table 3.3. Steps carried out to implement the decision-support tool.
Tool element Procedures
Fundamental structured system Identify the process/operational levels 
Create hierarchical underlying structure
Component definition Identify categories in the manufacturing environment 
Organise the categories into hierarchies 
Specify attributes o f each category 
Assign functions to each category
Capture same characteristics for subcategories from superior 
categories
Component inter-relationship Define interaction between activities and associated 
resources
Determine requirements o f activities and resources
Graphical User Interface (GUI) Create clone items for user inputs 
Add animation features
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The first step was to distinguish and segregate the rudimentary levels of process 
functions. This was achieved by creating a hierarchical workspace, with each 
window containing sub-windows. The next step was to identify the different 
categories involved in bioprocess manufacturing. In this tool, the categories included 
the unit operations to manufacture the product, supporting activities for the proper 
operation of the unit operations, and resources required to carry out the 
manufacturing tasks. Each of these categories was given specific attributes and 
functions to characterise their features. The interactions between the unit activities 
and associated resources were then defined. Finally, the capabilities of the tool were 
enhanced by providing cloned dialog boxes from the coding blocks for users to 
specify the input values and adding in animation features for visualisation of the 
simulation process. The tool architecture was continually refined during the design 
and implementation cycle of this research.
The primary workspace for the decision-support tool is illustrated in Figure 3.2. This 
workspace contains the Executive block for proper tracking of events in the discrete 
model and a clock for displaying the current simulation time of the model. The 
workspace includes the sub-workspaces for the code repository, manufacturing 
template and the libraries for the resource and manufacturing task categories. Each 
category describes components with the common attributes and characteristics. Each 
of the workspaces can be decomposed further into lower hierarchical levels revealing 
more detail. The decomposed engineered platform enabled rapid prototyping of 
process models in an organised and systematic manner. The code repository contains 
the functions shared among the manufacturing tasks to manipulate the activities in 
the model and acts as an interface between the tool and the data bank in Excel. The 
functions in the code repository included mass balance calculations and cost 
calculations. The various types of manufacturing tasks and resources were stored in 
their respective libraries. The declaration of the resource pools and the 
manufacturing campaign details were placed in the manufacturing template. The 
product-manufacture, equipment-preparation and regulatory steps were incorporated 
into the manufacturing recipe windows. The building blocks can be duplicated from 
the libraries and positioned on the appropriate operational level.
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Figure 3.2. A simplified schematic of the prototype template. An executive block 
keeps track of all events occurring in the discrete model. The tool consists of the 
code repository unit, the process flowsheet model and the libraries of resources and 
manufacturing tasks.
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3.6.2. Fundamentals of Discrete Event Modelling
The basic units that were passed between the discrete event blocks are items (Extend 
user manual). Items were individual entities that can have unique properties as 
specified by their attributes and characteristics. In the model, an item may represent 
a resource or a process stream. These items were generated by the Generator and 
Program blocks based on a random distribution, a fixed schedule or demand. Items 
were passed from block to block through item connectors. Extend moved items in 
the model only when an event occurred, which was controlled by the Executive 
block. Events were occurrences such as the activation of an unit operation, 
allocation of resources or batching of necessary resources.
3.7. Key Components/Features
The next phase of the research involved mapping the components into their definitive 
component code in a task-oriented manner to represent the manufacturing operations 
within a biopharmaceutical plant. This involved the categorisation of components 
into relevant groups in a hierarchical layout. The components were given relevant 
characteristics to represent the pertinent features in the biomanufacturing industry. 
In customising the respective operational categories, the code was divided out into 
modules allowing flexibility and extensibility. Capturing common attributes and 
characteristics facilitates reuse of code, achieves rapid prototyping and allows 
extension of declarative code with minimal coding.
The key components of the decision-support tool were identified (Table 3.4). The 
software tool comprised the operational tasks to manufacture a biopharmaceutical 
(e.g. fermentation, chromatography), additional tasks to prepare the manufacturing 
equipment (e.g. CIP, SIP), cGMP activities (e.g. quality control (QC)/quality 
assurance (QA), batch documentation) to test a sample and document a batch, 
resources required to carry out each task (e.g. equipment, raw materials, utilities, 
labour), resultant process streams from each task (e.g. media, cells, antibodies-based 
products, buffer) and cost models. Other key features of the prototype tool consisted
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of mass balance calculations, a capacity for process scheduling, dynamic animation, 
data reporting, and a Graphical User Interface (GUI).
Table 3.4. Key constructs of the prototype tool.
Constructs Description
Primary manufacturing tasks Inoculum grow-up
Seed fermentation
Production fermentation
Chromatography
Viral clearance
Membrane Filtration
Ancillary manufacturing tasks CIP
SIP
Equilibration
Regeneration
Re-equilibration
QC/QA
Batch documentation
Manufacturing resources Equipment
Operator
Equipment-related materials
Chemicals and biochemicals materials
Utilities
Process stream Media
Cells
IgG
Buffer
Cost models Capital investment
Resource costs
Cost o f  goods
Net present value
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3.7.1. Manufacturing Task Category
The manufacturing tasks form one of the key components of the decision-support 
tool and comprise mainly the product-manufacture activities (e.g. fermentation, 
chromatography) and ancillary steps of equipment-preparation (e.g. C1P, SIP) and 
regulatory-compliance (e.g. QC/QA and batch documentation). Each of the unit 
operations was simulated as an activity requiring resources. The same approach was 
applied to the modelling of equipment-preparation and regulatory-compliance 
operations. The hierarchical levels of the manufacturing activities were realised 
through the use of workspaces, upon which components can be placed. Each high- 
level task on a workspace can be broken down into its sub-tasks on their respective 
sub-workspaces. This is illustrated in Figure 3.3, which shows a product- 
manufacture recipe and an equipment-preparation recipe in their respective 
workspaces. In the process flowsheet workspace, a Start block and an End block 
were customised to control the proper simulation of the model. At the start of a 
simulation, the Start block generated an item to characterise the initial process 
stream. The resultant process stream from the final step of the process exited the 
End block. In this block, the total mass of the antibody-based product generated was 
updated.
The tool structure was arranged in a hierarchical task-oriented manner to represent 
the key tasks and resources in a manufacturing operation. Such an approach has 
recently been employed to model the manufacture of biopharmaceuticals (Farid et 
al., 2000b). Similar hierarchical decompositions have also been adopted to represent 
all phases during the process of drug development (Karri et al., 2001; Rajapakse et 
al., 2004). The framework in this research extended the hierarchy further to 
incorporate QC/QA activities and batch documentation (Figure 3.4). As depicted in 
Figure 3.4, the ancillary steps (e.g. equipment-preparation, QC/QA and batch 
documentation) were modelled separately from the product-manufacture steps. The 
hierarchical decomposition method proved useful in conferring maximal flexibility 
since it allows processes to be simulated at various levels of details.
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Figure 3.3. Example of a recipe workspace. The diagram depicts a product- 
manufacture recipe and an equipment-preparation recipe in their hierarchical 
workspaces. It consists of a series of product-manufacture tasks as well as related 
equipment-preparation tasks connected to form part of the biomanufacturing process.
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Equipment-preparation
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Figure 3.4. Hierarchical representation of manufacturing tasks. The ancillary steps 
of equipment-preparation (i.e. CIP, SIP) and regulatory-compliance are modelled 
separately from the product-manufacture tasks.
The manufacturing tasks possess the attributes of “processing time”, “cost of task” 
and “number of cycles”. The “processing time” indicates the duration required to 
carry out the manufacturing task while the “cost of task” represents the total direct 
cost incurred in running the specific task. The task duration was given either a 
deterministic value or a probability distribution was used to reflect the randomness in 
the processing of the task. The “number of cycles” shows the total number of times 
the particular task is executed during a single simulation.
The sequence of functions used to customise a manufacturing task was as follows. 
Functions were configured in the manufacturing tasks to carry out certain actions. 
An “activation” function was created to activate the current task by using the process 
stream item flowing into the customised block from the prior step. This module of 
code included the Batch block to trigger the initialisation of the current block. The 
function compared the required and current equipment status before commencing the 
manufacturing process. If the two equipment states do not match, the relevant 
equipment-preparation tasks were activated. Both the Throw and Catch blocks 
provided in Extend were employed. The Throw block in a product-manufacture task 
was used to manipulate and activate the Catch block in the appropriate ancillary task,
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ensuring the correct co-ordination between these two separately modelled 
manufacturing tasks. In the equipment-preparation tasks, the equipment was routed 
back to the relevant product-manufacture task using the Throw and Catch blocks 
again. The “activation” function also determined if there were available resources in 
the resource pool to meet the required demand and to allocate the required resources. 
The resources were then batched together and delayed by the specified processing 
time using the Activity, Delay block.
After completion of the task, a “cost calculation” function was performed to 
determine the total direct operating cost. This function used the DE Equation block 
to determine the direct costs of running the manufacturing task. The renewable 
resources were routed back to their respective resource pools while the non­
renewable ones are discarded. The Throw and Catch blocks were employed to return 
the resources back to the resource pool and the Exit block was used to discard the 
non-renewable resources. For resources that posses hybrid characteristics, the total 
number of cycles was coded within the manufacturing task to enable the appropriate 
computation of cost and when to dispose of the resource. For instance, the cost of 
chromatography matrices was only added to the operational cost during their first 
cycle of usage. When their cycle limit was reached, the resource was disposed of. 
The task block also had a function to automatically update the status of the 
equipment resource and to invoke the post equipment-preparation tasks. For 
instance, the status of a ‘sterile’ fermenter switches to ‘dirty’ after the fermentation 
process. The status of a ‘dirty’ fermenter changes to ‘clean’ after the CIP process. 
Figure 3.5 shows the libraries containing the common tasks in a mammalian cell 
culture biomanufacturing environment.
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Figure 3.5. Examples of manufacturing tasks in libraries. The task categories 
include the product-manufacture, equipment-preparation and regulatory-compliance 
tasks. Any component in a library can be copied and pasted onto the appropriate 
workspace.
3.7.1.1. Product-manufacture tasks
The product-manufacture tasks, such as the fermentation and chromatography 
processes, come into direct contact with the antibody-based products. This category 
of tasks has the same characteristics as the manufacturing task category. In addition 
to the characteristics of the manufacturing task category, the product-manufacture 
task category possesses a function to perform mass balance calculations during the 
execution of the task. Appendix B shows the sequence of functions for a product- 
manufacture task and the detail of the “Check Equipment Status” function as an 
illustration of the coding within each function. Some tasks such as chromatography 
possess a function to determine the duration of the manufacturing steps. A special 
function is also created to allow the user to specify whether QC/QA steps are 
required for that particular task. In a typical biopharmaceutical plant, quality control 
and assurance is normally carried out for all major process steps. The default value 
to carry out QC/QA for a product-manufacture task is set to true. Since the batch 
documentation steps are carried out for mostly all tasks in the biopharmaceutical 
plant, they are coded as necessary tasks after finishing the product-manufacture 
tasks.
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3.7.1.2. Equipment-preparation/Intermediate-material-preparation tasks
The CIP, SIP, equilibration, regeneration and re-equilibration processes make up 
the equipment-preparation activities in a biopharmaceutical plant. The equipment 
resource is processed in these tasks, prior to the start and after completion of a 
product-manufacture task. These tasks have the common characteristics as the 
manufacturing task category. The equipment item from a product-manufacture task 
was routed to these preparation tasks using the Throw and Catch blocks. Upon 
completion of the preparation process, the equipment status was then updated and 
returned back to the appropriate product-manufacture step or back to the resource 
pool. For example, a ‘clean’ chromatography column resource in the 
chromatography process is routed to the chromatography column equilibration 
preparation step. Its status is modified to ‘equilibrated’ and is then allocated back to 
the chromatography step. The status switches to ‘dirty’ at the end of the 
chromatography process step and is routed to the CIP task before returning back to 
the resource pool.
The intermediate-material-preparation tasks consist of material preparation activities 
such as media and buffer preparation. These tasks have the common characteristics 
as the manufacturing task category. Such tasks are triggered by the product- 
manufacture tasks. Upon activation of the preparation process, the utilisation level 
of the resource pool for the appropriate resource is adjusted.
3.7.1.3. Regulatory-compliance tasks
Manufacturing decisions are often complicated by the need to comply with the ever- 
increasing demands for regulatory conformation and the emphasis on QC/QA. These 
regulatory compliance activities are critical for controlling the consistency, quality 
and safety of biologies. Existing software packages often omit regulatory- 
compliance activities in a cGMP-manufacturing plant. Including these support 
activities is necessary to improve the ability of the model to estimate more accurately 
operative measures such as costs and resource utilisation. The prototype tool permits 
the incorporation of such cGMP activities, which are modelled as explicit ancillary 
tasks in their respective workspace (Figure 3.6).
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Figure 3.6. A typical regulatory-compliance task recipe. The QC/QA step for all the 
manufacturing tasks is modelled as one unit operation. The same applies to the 
modelling of the batch documentation and lot review activity.
The regulatory manufacturing practices within the plant consist of in-process testing, 
batch documentation and lot review steps. These cGMP activities adopt the same 
attributes and functions from the manufacturing task category. The QC/QA step for 
all the manufacturing tasks was modelled as one unit operation. The same applied to 
the modelling of the batch documentation and lot review activities. The batch 
documentation activities were automatically activated at the end of each product- 
manufacture task while the QC/QA steps were triggered based on the user 
specifications. These regulatory-compliance steps were simulated concurrently with 
the main product-manufacture tasks. In a typical biomanufacturing plant, these 
regulatory activities are only carried out during specific working hours. A function 
was configured to customise the scheduling of these regulatory steps for operation 
only during a particular period. A Queue, Decisional block was employed to hold 
the item during out-of-operating work hours and release the item for processing only 
within operating hours.
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3.7.2. Manufacturing Resource Category
Manufacturing resources are required for the proper execution of the tasks within the 
biomanufacturing environment. The resources include equipment, operators, 
materials and utilities. Figure 3.7 depicts the resource categories in a hierarchical 
layout. The manufacturing resources are generally classified as either renewable 
(e.g. equipment, operators) or non-renewable (e.g. chemicals-and-biochemicals 
materials, utilities). Some resources may possess hybrid characteristics (e.g. 
equipment-related materials). Renewable resources are reused and returned back to 
the resources pools after completion of the manufacturing tasks while non-renewable 
resources are discarded.
Manufacturing
resources
Renewable
resources
Equipment Labour Utilities
Hybrid characteristics 
resources
Equipment-related
materials
Chemicals-and- 
biochemicals materials
Non-renewable
resources
Shake flasks
Seed fermenter
Production
fermenter
Production
operator
Purification
operator
QC/Q A staff
Membrane cassettes 
Membrane capsules 
Matrices
Ampoules of cells Steam
Media Cooling water
Buffer WFI
etc. etc. etc. etc. etc.
Figure 3.7. Hierarchical representation of manufacturing resources. The resources 
are categorised into either renewable or non-renewable items. Some resources 
possess hybrid characteristics.
Modelling of a manufacturing resource was achieved through the combined use of 
the resource pool manager, the resource itself and a queue block. The resource pool 
manager was given the attributes of “maximum availability” and “cost”. The 
resource possesses the attribute “utilisation”. The “cost” attribute indicates the 
monetary value of utilising/purchasing the resource. “Maximum availability” refers
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to the usage limit of the resource within the plant while “utilisation” indicates the 
required amount of resources to carry out the manufacturing task properly. These 
conditions cause constraints to be placed on the simulation flow in the model based 
on the availability of resources. During a simulation, a resource remains in the queue 
and is only released when there is a sufficient amount available in the resource pool 
to meet the requirement.
At the start of a simulation, all the resource pools were initialised to the appropriate 
usage limit levels. The amount of resources available in the resource pools was 
managed by the Global Array Manager and Global Array blocks provided in Extend. 
All other necessary resources were then checked for availability by utilising these 
global blocks and batched together to carry out the operation. It was necessary to 
create a function to adjust the resource pool levels based on the consumption. 
During the simulation, the amount of resources in the pools was 
incremented/decremented depending on the type of resources (e.g. renewable or non­
renewable). The batched resources were temporarily associated with one another as 
a grouped item and separated from each other later in the simulation. The resources 
were then delayed by a time interval equal to the duration of the task. Figure 3.8 
illustrates the schematic of the manufacturing resources classified in their respective 
libraries.
3.7.2.I. Equipment and operators
Besides the characteristics of the renewable resources category, all equipment 
resources possess the attribute “equipment status”. More specific attributes were 
given to subcategories such as fermenters and chromatography columns to indicate 
their sizes. These include “equipment volume”, “equipment height” and “equipment 
diameter”. A function was created to determine the diameter of equipment based on 
the values of equipment volume and height. The default value for the initial 
“equipment status” was automatically set to be ‘clean’. On the other hand, further 
definitions are not necessary to characterise the operator resources. The attribute 
“cost” was defined as the purchase cost for the equipment resource and the wage per 
hour for the operator resource.
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Figure 3.8. Examples of manufacturing resources in libraries. The resource 
categories include the equipment, material, labour and utilities. The resource pools 
store the current available number of resources. The appropriate resources are 
attached to a particular manufacturing task to carry out the operation.
3.7.2.2. Materials and utilities
Material resources were classified into the chemical-and-biochemicals materials 
(e.g. media, cells, buffer) and equipment-related materials (e.g. membrane filters, 
matrices). The former has the same characteristics as the non-renewable resources 
category. The “cost” is measured as the usage cost per litre. They were given 
additional attributes such as “mass”, “volume”, “density”, “concentration”, 
“physical-state” and “virus-titre” to permit the mass balance calculations.
The equipment-related materials were categorised as possessing hybrid 
characteristics. The non-renewable materials (e.g. disposable bags, membrane 
filters) possess the same attributes and characteristics as the non-renewable resources 
category. The attribute “cost” is measured as the purchase cost per unit. The 
attribute “membrane area” is also attached to the filter resources in order to describe 
their technical performance. The same attributes apply to those equipment-related 
materials having both renewable and non-renewable characteristics (e.g. membrane 
cassettes, matrices). In addition, they were given the attribute “cycle limit” to
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determine their operating boundaries. For instance, chromatography matrices are 
reused and only discarded after their cycle limits are reached.
The utilities of the manufacturing floor are steam, cooling water and water-for- 
injection (WFI). They have the same characteristics of non-renewable resources and 
did not require any further customisations to define their usage in the plant.
3.7.3. Process Stream
To model the resultant process stream from the unit operations, each was represented 
as a batched item, comprising of several elements (e.g. media, cells, IgG, buffer etc.). 
The batched item was ungrouped later in the simulation to retrieve the values of the 
attributes for mass balance. The process stream carried the attributes (e.g. “mass”, 
“volume”, “density”, “concentration”). Each element in the final product stream was 
also represented as an individual item possessing its own characteristics (e.g. “mass”, 
“volume”, “density”, “concentration”, “physical state”, “virus titre”). Such 
information was then carried over to the subsequent operating task for mass balance 
calculations.
3.7.4. Mass Balance Calculations
The mass balance calculations were computed using the equations compiled in 
previous studies (Farid, 2001) to determine the composition of process streams. The 
process models employed were used to describe manufacturing processes based on 
mammalian cell culture. Each unit operation was modelled by a set of mathematical 
equations coded into the tool software (Appendix C). The complexity of the models 
depends on the current needs and available data. Initially, simplistic mass balance 
process models established on the law of conservation of mass were proposed in the 
framework. They allowed the product yield and performance of each unit operation 
to be determined. Such a mass balance approach was employed as it enabled the 
composition of the different components in the process stream to be determined. The 
architecture of the software is flexible to accommodate more sophisticated models at 
various levels of rigour when more data is available.
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3.7.5. Representing Uncertainties in Parameter Values
Extend provides the Input Random Number block to generate random numbers 
according to a distribution. To measure the potential risk associated with a given 
manufacturing option, probability distributions were assigned to the key uncertain 
factors. The distribution specified the relative frequency with which an event 
occurred or was likely to occur. Existing plant data and advice from industrial 
experts were employed to help the identification of appropriate probability 
distributions. In the case study presented in Chapters 5 and 6, the key uncertainties 
were found to be in the product fermentation titre, downstream process yields, batch 
contamination and equipment failure.
3.7.6. Risk Assessment
The Monte Carlo simulation technique was employed to incorporate the randomness 
inherent in biomanufacture and to evaluate the risks associated with different 
manufacturing alternatives. The method proposed to handle stochastic parameters 
was to employ discrete distributions where each possible value of a parameter is 
given a probability of occurrence. A single trial outcome of the model was 
determined by selecting a value based on the defined input probabilities. Multiple 
output scenarios of a model were generated by repeatedly sampling values from the 
input probability distributions for the uncertain variables. This enabled the resultant 
frequency distributions of key output parameters and useful statistical summaries to 
be generated. Details of the specific probability data were supplied where 
appropriate in the case studies in the relevant chapters.
The decision tree approach to risk analysis was also used to capture the uncertainties 
in biomanufacture. Such a method selected between several courses of action based 
on the expected values of each option. The construction of a decision tree started 
with a decision to be made and branched into possible options. Each branch had an 
associated probability of occurrence and an outcome. The expected value of an 
option was calculated by multiplying the outcome with the probability in each path 
and then adding the weighted values of all the paths for each option. The rule of the 
decision tree is to select the option which either maximises value or minimises cost.
- 8 9 -
Chapter 3. Design Methodology and Implementation o f  BioPharmKit
3.7.7. Data Reporting
The key output parameters from each simulation run are written to Excel and 
constantly updated during a simulation run. The strengths and well-equipped 
facilities of Excel for tabulating data, plotting graphs and analysing statistics are then 
exploited. This facilitates the storage of data for viewing purposes. This is 
extremely useful for handling the extensive amount of data generated during the 
Monte Carlo simulations. Each simulation run increments the row number in Excel 
and logs the output data accordingly in the appropriate cell.
3.7.8. Dynamic Simulation/Animation
In discrete event modelling, discrete entities change state as events occur in the 
simulation. After completion of a single event, the next event or events are triggered 
with the simulation clock advancing with each occurrence. Dynamic modelling 
therefore allows the capability to view the time-based behaviour of the system and 
makes it possible to track the values of time-dependent parameters. Whenever a 
simulation is run, the model is animated to enable the user to view the occurrence of 
events at any instant in time. Animation features enable the visualisation of the flow 
of items throughout the simulation run and aids in the debugging process for the 
developer.
3.7.9. Graphical User Interface (GUI)
The graphical representation of the components provides a high degree of user 
interaction, enables a clear visualisation of various manufacturing stages and offers a 
comprehensive perspective of the simulation application. The cloned dialog boxes 
within the manufacturing tasks and resources enable the specification of usage levels 
with ease. This cloning feature simplifies the communication between the user and 
the software tool. The ‘drag and drop’ feature provided by the tool enables rapid 
development of models.
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3.7.10. Profitability Appraisal Measures
There are several financial performance metrics available to measure and compare 
the profitability of production strategies. The simplest requires a good indication of 
the total installed cost, the working capital and the operating costs at full production. 
The most complicated method needs a detailed layout of investments, costs and 
revenues against time. This section outlines the various appraisal measures. These 
performance metrics are typical profitability measures used in the literature and 
industries to provide an assessment of manufacturing options.
3.7.10.1. Fixed capital investment
Capital cost estimates for a plant are based on a factorial method. The fixed capital 
costs are approximated as a function of the total purchase cost of the equipment in 
the plant. This method is used as a preliminary and quick approximation when little 
or no information is available during the early stages of project design. An order-of- 
magnitude estimate of the fixed capital investment is obtained by multiplying the 
costs of plant equipment by a factor, termed the Lang factor. The factorial equation 
of this technique is given by the following equation:
where Cf  = fixed capital investment,
Ce = equipment purchase cost, 
f L = Lang factor.
The other cost factors included in the estimation include installation, piping, 
insulation, instrumentation, electrical auxiliary, storages, utilities, site preparation 
and contingency costs. The Lang factor depends on the type of process plant. 
Estimates in the range of 3-5 for chemical plants are recommended (Sinnott, 1993). 
For biopharmaceutical plants, discussion with industrial experts (e.g. A. Sinclair, 
Biopharm Services Ltd, Chesham, UK) suggested suitable values in the range of 4-8. 
These were used as default values in the model.
(3.1)
/ = i
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3.7.10.2. Cost of goods (COG) model
Instead of using built-in cost features in Extend, costing was modelled using existing 
blocks in the libraries. Both the customised global arrays, Capital Cost and 
Operating Cost, were employed to keep track of the running costs incurred during 
the simulation run. These arrays allow access of data globally in the model by 
sharing information between blocks in different hierarchies without direct 
connection. The key cost data entries and outputs were created in Excel and linked 
to Extend using the Data Receive and Data Send blocks in the Inter-Process 
Communication library.
The tool employed a typical cost model, as tabulated in Table 3.5, to calculate the 
cost of goods (COG). The COG model was derived from cost equations originally 
developed for conventional chemical engineering facilities (Sinnott, 1993). The 
factors employed to estimate some of the cost categories (e.g. miscellaneous 
materials, supervisors, general management, maintenance etc.) were derived from 
chemical engineering textbooks and were the only data available at the time of 
implementation. It is recognised that they do not provide definitive values of actual 
costs (All factors were implemented as fixed values in the simulation tool.). Since 
the main purpose was to illustrate how such cost categories could be implemented in 
the tool to compute cost estimates so as to support decision-making in 
biomanufacturin, the precise values were deemed not to be critical. In addition, 
supplementary costs associated with the compliance to cGMP in the 
biopharmaceutical manufacturing industry were considered. The indirect/fixed 
overheads were derived as a function of the fixed capital investment. The direct 
costs were computed based on the utilisation of resources such as materials, utilities 
and staff. The cost of each manufacturing task was computed according to the usage 
levels of resources.
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Table 3.5. Cost of goods model.
Cost category Equation
Direct Direct raw materials 
M iscellaneous materials
f(utilisation o f  raw materials) 
0.5 * Direct raw materials
Direct utilities f(utilisation o f utilities)
Operating labour f(utilisation o f  labour)
Supervisors 0.2 * Operating labour
General management 1.0 * Operating labour
Indirect Maintenance 0.1 * Capital investment * Project duration
Local taxes 0.02 * Capital investment * Project duration
Insurance 0.01 * Capital investment * Project duration
Depreciation
Interest
Capital investment * Project duration / 
Depreciation period 
Interest rate o f  10%
General utilities Cost per unit area per year * Facility size * 
Project duration
Based on bioprocessing plant data (Personal communication: R. Francis, Protherics 
Pic., London, UK), it was possible to predict the cost contributions arising from in- 
process testing and documentation steps (Table 3.6). The costs of the QC/QA and 
batch documentation labour were calculated as a function of utilisation. The cost of 
staff per hour was indicated in the resource pool. For each unit operation in the 
process flowsheet, the requirements of the QC/QA and batch documentation 
activities were either user-specified or default values employed. The user needed to 
specify the time taken to complete the QC/QA and batch documentation task. Upon 
activation of the QC/QA or batch documentation task, the labour cost was computed 
based on the utilisation rate and cost of the resource. The miscellaneous materials 
(e.g. equipment and raw materials) associated with the QC/QA and documentation 
tasks were related to the utilisation of labour. The costs included taking samples, 
transfer to the QC/QA laboratory, testing, reviewing data and reporting results.
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Table 3.6. Cost of goods model for QC/QA and documentation activities.
Cost category Equation
Quality control/Quality assurance labour f(utilisation)
Batch documentation labour f(utilisation)
M iscellaneous materials 10-20%  o f  operating labour time
The cost of goods per gram (COG/g) was presented using a cost category (e.g. 
indirect costs, labour, material and utilities), a task category (e.g. product- 
manufacture, equipment-preparation and regulatory-compliance tasks) and a process- 
specific category (e.g. fermentation, recovery and ancillary steps). This provides the 
capability of viewing where the bulk of manufacturing costs are distributed for 
different production strategies. These features of the tool are explored further in the 
case studies presented in Chapters 5 and 6.
3.7 J  0.3. Net present value (NPV) model
The economics of a project can be viewed as a series of net cash flows (NCF) 
throughout the lifetime of a project. To take into account the value of money, these 
cash flows are discounted to the present time for evaluation (Happel & Jordan, 1975; 
Allen, 1991). The present value (PV) of a cash flow at the end of a project year t is 
given by
„T7 NCF
PVt =  (3.2)
(1 + r)'
where NCF = net cash flow at end of a project year t,
r = applied discount rate (expressed as a decimal fraction).
The discount factor is chosen to reflect the earning power of money and is equivalent 
to the current interest rate that the money could earn if invested in a bank. A default 
value of 9% was assumed for the operating lifetime of the plant (Myers & Howe, 
1997).
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The NPV of a project is the present value (discounted) of future cash inflows less the 
present value of the investment and any associated future cash outflows. This factor 
describes adequately the lifetime profitability of a project by giving appropriate 
weight to each year’s cash flow and indicates whether a project will 
enhance/diminish the company’s financial performance at a particular discount rate. 
The NPV of a given project is evaluated as follows:
n
NPV = Y ,PV' (3-3)
/= o
where n = complete project life in years.
The typical worksheet for presenting the annual cash flow, discounted cash flow and 
net present value of a project is tabulated in Table 3.7 (Peters & Timmerhaus, 1991). 
The PV is normally calculated at a convenient point in time (e.g. start of construction 
or time of starting the plant into operation). In the model, the PV is calculated at the 
time of the start of construction i.e. Year 0. The probable life of a project will 
depend on the type of market and a 5-10 years life is usually achievable. The 
biomanufacturing plant in the model is assumed to have a construction period of 3 
years and a subsequent plant operating life of 10 years.
3.7.10.4. Other profitability metrics
The cost analysis is extended to include other profitability indicators such as the 
internal rate of return (IRR) and the payback time. The IRR of a project is the 
discount rate where the NPV at the end of the project is zero. It represents the 
average return over the lifetime of a project. Typical IRR values for attractive 
projects are 30% (Peters & Timmerhaus, 1991). The payback time is the period over 
which the cumulative cash flow is negative. The elapsed time between the start of 
the project and payback time is the length of time needed to recoup the capital 
investment.
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Table 3.7. A typical worksheet for presenting the annual cash flow, the discounted 
present value and net present value of a project.
Year (t)
Category 0 1 2 ... n
A. Total capital investment
B. Revenue
C. Running costs (without depreciation)
D. Profit (B-C)
E. Depreciation
F. Taxable profit (D-E)
G. Tax (33% o f F)
H. Net cash flow  (-A+B-C-G)
1
I. Discount factor ( ------------ )
d  + r)'
J. Annual present value (H*I)
n
K. Net present value ( ^  7 ,  )
t= o
3.8. The Implementation Process
3.8.1. Model Testing
The unit operations built in BioPharmKit were tested against the original 
manufacturing units implemented in ReThink. The sequence of manufacturing tasks 
was connected according to the original case study (Farid, 2001) and the same mass 
balance data was specified within each unit operation. The model was then 
simulated to evaluate the composition of the process stream from each unit operation 
in the tool and such results were compared with that obtained from the previous 
ReThink model. The cost estimates from the tool were also computed and evaluated 
in a similar fashion. The outcome of the testing provided confidence in the accuracy 
of the tool to represent pertinent features in the biomanufacturing environment.
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3.8.2. Debugging
The Generic and Discrete Event libraries provide many blocks that are useful for 
model debugging. These blocks include the ReadOut, Information, Stop and 
Animation Slower/Faster blocks. The ReadOut and Information blocks display the 
value and information about the items respectively. The Stop block terminates a 
simulation run if the value of an item fails a certain threshold value. The animation 
blocks enable the developer to view the value or items in a block to determine if the 
simulation is performing as expected. For instance, if the unit operation block show 
materials passing through, but no material leaves the block, then such information 
can be used to debug the model. The Animation Slower button enables the model to 
run more slowly in order to debug or critically visualise what the model is doing.
3.9. Conclusions
The development and implementation of a prototype tool to model bioprocesses, 
including in-process testing and documentation, in a hierarchical task-oriented 
approach have been presented. Developers can exploit the decomposed framework 
to add additional features accordingly. Modelling at the higher hierarchical levels 
provides an overview of the entire process with its key operational and economic 
parameters. Subsequent details of each higher-level activity can be obtained by 
breaking down into sub-tasks. The prototype tool developed enables users to capture 
both process and business knowledge of a manufacturing process in a transparent and 
organised manner. The modelling of the manufacturing operation provides a 
transparent representation of the processes. The organised structure acts as a 
common platform between users and models and enables the systematic evaluation 
of key performance metrics. The model serves as a bridge for effective 
communication between different departments within a company such as process 
development, manufacturing, investment and financial. The simulation results can 
be applied in assessing the manufacturing options among the decision makers of the 
company. The next chapter highlights the capabilities of the decision-support tool 
for industrial applications and outlines the procedure to assemble simulation models 
of typical manufacturing processes.
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C hapter  4
Overall Discussion of Tool and its Utility
4.1. Introduction
The previous chapter presented the design and implementation of a prototype tool to 
model bioprocesses in a hierarchical, task-oriented manner. The proposed 
framework aims to integrate both business and process perspectives of 
biopharmaceutical manufacture. Such a computer-aided analysis tool can aid in the 
facilitation of process design and the appraisal of the relative operational benefits and 
cost-effectiveness of various manufacturing strategies. The purpose of this chapter is 
to provide an overall discussion of the decision-support tool, BioPharmKit, and 
illustrate the functionalities of the tool to model cost summation, perform mass 
balance calculations and simulate resource handling. The benefits of bioprocess 
simulation are demonstrated by illustrating how plant data can be captured in a 
flowsheet model to assess process economics.
This chapter is divided as follows. An overview of the decision-support tool and its 
utility is provided in Section 4.2. The specific capabilities of the prototype tool 
developed in the previous chapter and the utilisation of such a tool to address key 
issues in the biomanufacturing industry are discussed. The key input factors required 
to perform the simulation and the parameter outputs from the prototype tool are also
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identified. The steps to assemble a typical model for a specific biopharmaceutical 
manufacturing process flow are outlined in Section 4.3. Finally, a summary of the 
conclusions is provided in Section 4.4.
4.2. Tool Overview
4.2.1. Tool Utility
Bioprocess simulation permits a process development team to use available 
information together with some initial assumptions to begin the creative task of 
conceptualising process designs and identifying promising options. In this thesis, a 
prototype tool has been developed to assist the process of decision-making by 
providing the ability to address key industrial questions and to calculate quantitative 
metrics for evaluation purposes. Several uses of the simulation tool are highlighted 
and discussed below:
• Act as a “blank sheet” for choice o f new plant in the design stage
During the early design stage, there exist a wide range of manufacturing options 
available to produce a particular drug. The simulation tool was developed to 
facilitate decision-making during early phase of process development. The user 
devises a process flowsheet of all unit operations (e.g. fermentation train, purification 
steps) and supporting ancillary tasks (e.g. cleaning-in-place (CIP), sterilising-in-place 
(SIP)) based on literature sources or existing industrial practice. Based on these 
assumptions, the user is able to replicate a flowsheet model of the process. Once the 
initial model is established, the next step is to examine how the overall process could 
be improved. The software tool could be employed to analyse alternative processing 
options from both profitability and feasibility viewpoints.
• Simulate best usage o f plant using existing operating capacity
To simulate the manufacturing process of an existing operation, it is necessary to 
model each unit operation in the process. The user is required to specify certain 
information about each operation in the plant. The unit operations can then be 
connected to represent the entire process flowsheet. Based on the specifications, the
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model will determine the performance of the process. The tool could then be used to 
expose bottlenecks due to resource constraints. The user can then assess the impact 
of process modifications so as to find a strategy that minimises production costs, 
maximises existing plant resources and thus improves the overall viability of the 
process in the manufacturing plant.
• Set up a range o f case studies to reflect real manufacturing situations
The tool enables the formulation of models to establish various case studies and to 
explore the feasibility of different manufacturing strategies through a computer-aided 
approach. The model could act as a communication channel within the departments 
of a company such as finance, process development and manufacturing. The 
simulation results can aid in the appraisal of manufacturing alternatives.
• Provide a user-friendly interface
The configuration of the decision-support tool provides a user-friendly interface 
between the tool platform and the user. The “drag” and “drop” features of the tool 
enable the user to select the desired block and place it on the relevant workspaces. 
The dialog boxes within the manufacturing tasks and resources allow users to enter 
the required values without entering the coding blocks. The graphical user interface 
of the tool aids in the visualisation of the simulation platform and facilitates the 
building of a process flowsheet.
• Investigate scaling-up options
The scale-up of biological products from clinical trials to commercialisation poses a 
major obstacle during the development process. The manufacturing challenge for all 
biopharmaceuticals is to meet the varying demand during the drug development 
cycle. An increase in product demand may require a simultaneous change in process 
capacity. Computer-aided design tools could help achieve this goal by formulating 
models at different scales so as to reduce the time involved in process development.
• Model ancillary tasks explicitly
The tool configuration enables ancillary manufacturing tasks (e.g. equipment- 
preparation and regulatory-compliance tasks) to be modelled explicitly. The task-
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oriented approach means that such activities can be modelled separately from the 
main product-handling tasks in their respective hierarchical workspaces. It is 
possible to view the cost, duration and yield of each specific manufacturing task. 
Consequently, the performance metric models (e.g. cost, resource-utilisation profiles) 
could account for each relevant task category that may otherwise been overlooked.
• Customise new unit operations
The modular and extensible framework offers a high degree of flexibility to 
accommodate improved and more sophisticated models at various levels of details. 
Such an architecture allows the developer to build and customise new unit operations 
with ease. Hence, users interested in the feasibility of new technologies may simply 
model and evaluate these techniques based on the determination of industrial 
performance metrics. Furthermore, the developer can add features to existing unit 
operations accordingly to achieve more rigorous and predictive models. Each 
increase in rigour requires more fundamental data and improves the accuracy of the 
models while testing against industrial case studies.
• Incorporate uncertainties and carry out risk analysis
Existing process modelling and software packages are often deterministic, assuming 
all processes occur with certainty. In reality the manufacturing environment is 
subject to numerous random elements inherent in process systems. These risk- 
related factors may impair the measurement of performance metrics and vitiate 
project appraisal. In addition to specifying deterministic point entries for parameters, 
the tool enables variables with probability distributions to be incorporated in process 
models in order to imitate the underlying randomness in biopharmaceutical 
manufacture. Combining such risk analysis into the evaluation allows the 
assessment of potential risks associated with different manufacturing alternatives to 
be captured and enhances the quality of decision-making within a company.
4.2.2. Simulation Flow
The flow of information during a simulation run is illustrated in Figure 4.1. To 
develop a process model, the initial task was to formulate the problem and devise a 
flowsheet. The next step was to gather relevant information for use in the model.
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The user then modelled the sequence of unit operations and captured the data in 
manufacturing recipes. The chemical and physical properties of the process streams 
were specified in the model. Finally, the operating requirements and conditions were 
indicated for each unit operation. The task-oriented representation transformed the 
process knowledge into a graphical model and created a user-friendly interface. 
After the initial model had been set-up, the simulator can then help to perform 
bottleneck analysis, cost evaluation and process optimisation. The animated features 
of the tool aid in the debugging process and enable the visualisation of the 
occurrence of events during the simulation. The tool generated a report comprising 
of the capital and operating costs of the plant in an Excel spreadsheet and predicted 
the process performance, including the compositions and properties of the process 
streams. The simulation results can be used to determine the profitability and 
feasibility of the manufacturing option.
: !•!: LI
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Manufacturing Data Inputs
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Discrete Event Simulation Graphical User Interface
Key Outputs
Figure 4.1. Flow of information during a simulation run.
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4.2.3. Input/Output Parameters
Figure 4.2 depicts the key input and output parameters of the prototype tool. The 
tool required that the user either indicated the purchase cost/cost per use of the 
resources or applied built-in cost models based on cost-estimation factors for 
bioprocess equipment (Remer & Idrovo, 1991). The Lang factor used to estimate the 
capital cost and the operating life of the plant was either specified or the default 
value in the tool was used. Other cost-associated input parameters included the 
interest rate charged, depreciation period, facility size and cost per unit area of 
facility. The model required the specification of the maximum availability of all the 
resources within the biopharmaceutical plant. The series of process operations to 
manufacture the product, prepare the equipment, test the sample and document the 
batch were then defined on the relevant hierarchical workspaces. The duration of 
certain manufacturing tasks were then indicated and the resources required attached 
to the manufacturing tasks with their usage levels specified. The overall process 
yield per batch was determined by specifying data for mass balance calculations such 
as the yield, concentration factors and dynamic binding capacities. Some of the key 
input risk factors included the fermentation titre, downstream process (DSP) yield 
and possibility of contamination in the process.
C ost data C ost report
R e so u rc e  c o s t 
L ang fac to r 
P ro jec t duration
4 4 C apital in v es tm en t C o s t of g o o d s  (COG) 
N et p re se n t  v a lu e  (NPV)
Plant sp ecification Plant output
M axim um  p lan t re so u rc e  
T a s k s  s e q u e n c e s  
R e so u rc e  req u irem en ts
4
TO O fl
4 A nnual ou tp u t N u m b er of b a tc h e s  
R e so u rc e  utilisation
M ass balance data Stream  com position
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C o n c en tra tio n  facto r 
D ynam ic binding cap ac ity
4 4 M a ssV olum e
C o n c en tra tio n
Risk factors Risk analysis
F erm en ta tio n  titre 
D S P  yield
P ossib ility  of co n tam ination
4 4 E x p ec ted  valu e  S ta n d a rd  dev iation  
P robab ilities
Figure 4.2. Key input and output parameters of the prototype tool.
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The total capital investment, which is a crucial factor in estimating the up-front costs 
needed to start the project, was calculated based on the equipment costs and the Lang 
factor. The cost of goods (COG) indicated the cost of producing a gram of product 
taking into account the indirect costs, variable costs and overheads, and was used to 
gauge the viability of a given manufacturing option. The net present value (NPV) 
analysis could be used to determine the profitability of a particular manufacturing 
option over a period of time. The tool computed the annual output generated and the 
number of batches of product, which can be used to determine whether a particular 
manufacturing strategy is able to meet a required market demand. The tool also 
generated the dynamic utilisation profiles of each resource over time. Such 
utilisation profiles illustrate the demands on resources depending on the 
manufacturing option and would prompt a company to allocate the appropriate level 
of resources to carry out any manufacturing task efficiently. Finally, the composition 
of the components in the process streams from each product-manufacture task was 
computed. The mass balance inputs were employed in determining the mass and 
volume of each component in the output streams and other variables such as task 
processing times and membrane areas. In the risk analysis, the outcomes from the 
Monte Carlo simulations were used to generate frequency distributions for the 
performance measures (quantities of Mabs generated, annual COG/g). The expected 
values and standard deviations of such performance metrics were then derived. In 
addition, the probabilities of the likelihood of these measures failing to meet a certain 
demand and exceeding a critical threshold value were determined.
4.2.4. Data Collection/Verification
The simulation work process involved gathering and verifying information for the 
models. The proposed flowsheet for the production of a typical Mab by mammalian 
cell culture was based on a generic sequence of manufacturing operations of 
commercialised Mabs, as highlighted in Chapter 2. Certain variables in the models 
within the simulation tool have default values. The values were derived from 
literature sources, vendors (e.g. Amersham Biosciences, PerBio) and industrial 
experts. The data used in the models were then validated through a series of 
discussions with experts (e.g. R. Francis from Protherics Pic., London, UK; A. 
Sinclair from Biopharm Services Ltd., Chesham, UK; B. Fish from Cambridge
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Antibody Technology, Cambridge, UK; J. Wayte from Lonza Biologies, Slough, UK 
and E. Hoglund from Lonza Biologies, Portsmouth, USA) to ensure the values were 
reasonable. The model data resided in both the Extend database and Excel files. The 
results of the simulation model were verified by consulting the experts.
4.2.5. Default Input Values
Table 4.1 summarises the default input values used in the model. These values were 
derived from literature, vendor sources and discussions with industrial experts. As 
described in the previous chapter, the method for calculating the fixed capital 
investment was obtained by multiplying the total equipment purchase cost by a 
factor, traditionally termed the Lang factor. The specific value for the Lang factor 
depends on the type of process plant being used. For biopharmaceutical engineering 
facilities, suitable values in the range of 4-8 have been suggested through discussions 
with industrial experts (e.g. A. Sinclair, Biopharm Services Ltd, Chesham, UK). The 
Lang factor was assumed to have a base value of 6. The default value for the annual 
facility cost of general utilities per unit floor area was assumed to be $300/m2 (M. 
Sawyer, Lonza Biologies, Portsmouth, US).
Table 4.1. A summary of default input values used in the model.
Category Assumptions Input value
Econom ic data Lang factor 6
Facility cost per unit area $300/m 2
Interest rate 10%
Depreciation 10% o f fixed capital investment
Cost-estimation factors 0.3 -0 .7
Time factors Project duration 10 years
Plant operating time 48 weeks/year, 7 days/week, 24 hours/day
QC/QA & documentation Operating hours, i.e. ~8 hours a day
Test a batch manually 0 .5-1  day
Document a batch manually 15%-20% o f operating time
Plant capacity Operator unit 10
QC/QA & documentation unit 40% o f total plant operating force
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The interest charges relating to capital expenditure should be taken into account in 
the economic evaluation of a project. The interest rate on the investment was taken 
as 10% (Personal communication: A. Sinclair, Biopharm Services Ltd, Chesham, 
UK). The operating life of a biotech facility is usually taken as 10 years, which gives 
a depreciation rate of 10% per annum.
A key stage in calculating the capital investment for a production plant is 
determining the total equipment purchase cost. An estimate of the cost of a new 
equipment can be obtained from a known cost for that type of equipment and the 
ratio of their capacities raised to an index value. The cost is related to the capacity 
by the following equation:
C2 =C,
/  \ n 
%
\  Q\ j
(4.1)
where n = index value,
C2 = cost of equipment with capacity Q2, 
C, = cost of equipment with capacity Qx.
Process engineers often use the well-known six-tenths rule, where the value of the 
index, n, is traditionally taken as 0.6 (Sinnott, 1993). However, Remer & Idrovo 
(1991) warned against the blind use of such exponent value and indicated 
exponential scaling factors for 58 different types of sizes of bioprocess equipment. 
This exponential method was used to provide a quick estimate of the investment 
likely to be required. The costs for known resources are tabulated in Table 4.2, 
indicating that purchase costs were specified for equipment and unit costs for the 
remaining resource categories. The cost inputs were determined from industrial 
experts and vendor sources (e.g. Biopharm Services Ltd, Protherics Pic., Millipore, 
Pharmacia, PerBio Science). The costs of related resources in subsequent case 
studies were calculated based on cost-estimation factors (Remer & Idrovo, 1991). 
Some of the key factors for the mass balance calculations are indicated in Table 4.3. 
The default values for the process data was estimated using information supplied by 
vendors and discussions with industrialists.
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Table 4.2. Base cost data for the resources.
Resource Description Cost ($)
Equipment Shake flasks (10), V = 0.5L 300
Seed fermenter, V = 20L 80,000
Production fermenter, V = 1,000L 525,000
Centrifuge 250,000
Affinity chromatography rig & column, D = 60cm  280,000
Virus retrovirus inactivation tank 45,000
Diafiltration rig 75,000
Ion exchange chromatography rig & column, D  = 60cm  280,000
Nanofiltration rig 75,000
Gel filtration chromatography rig & column, D  = 60cm 280,000
Dead-end filtration rig 75,000
Vessel/Holding tank, V = 1,000L 37,500
Container used to hold a 200L disposable bag 1,000
CIP vessel 120,000
Ef ; P ment . . Membrane cassettes 1936/m2related materials
50nm virus reduction filter (0.05m 2) 1,000/unit
0.22p  cartridge filter (0.05m 2) 75/unit
Protein A matrix 7,500/L
Ion exchange matrix 420/L
Gel filtration matrix 330/L
200L disposable bag 300
Chemicals Media 20
Buffer 5
Labour Operator 25/h
QC/QA staff 40/h
Utilities WFI 1/L
Steam 0.05/kg
Cooling water 0 .0 0 1/L
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Table 4.3. Key mass balance inputs.
Task Input factor Input value
Fermentation Mass stoichiometry coefficients Media: -1.5; Cells: 1; 
IgG: 0.5; Others: 0
Limiting substrate Media
Reference component IgG
Fermentation titre 0.2g/L
Affinity chromatography Binding capacity, g/L 20
Linear flowrate, cm/h Load: 150; Wash: 150; 
Elution: 75
No o f column volumes Wash: 10; Elution: 5
Product-stream-column-volumes 4
Yield fraction Media: 0; Cells: 0; 
IgG: 0.9; Others: 0
Ultrafiltration Average flux, L/m2/h 20
Concentration factor 10
No o f cycles 1
Rejection coefficients Media: 0; Cells: 1; 
IgG: 1; Others: 0
Diafiltration Average flux, L/m2/h 20
No o f diafiltration volumes 4
No o f cycles 1
Rejection coefficients Media: 0; Cells: 1; 
IgG: 0.99; Others: 0
Ion exchange chromatography Binding capacity, g/L 20
Linear flowrate, cm/h Load: 150; Wash: 150; 
Elution: 100
No o f column volumes Wash: 10; Elution: 10
Product-stream-column-volumes 2
Yield fraction Media: 0; Cells: 0; 
IgG: 0.96; Others: 0
Gel filtration chromatography Volumetric capacity 10% column volume
Linear flowrate, cm/h Load: 12.5; Elution: 12.5
No o f column volumes Elution: 1
Product-stream-column-volumes 0.3
Yield fraction Media: 0; Cells: 0; 
IgG: 0.95; Others: 0
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4.3. Using the Prototype Tool
The following procedure takes the user through the steps of simulating an upstream 
process (USP) operation. Each of the resource pools was first declared in their 
respective workspaces. The series of product-manufacture tasks were connected in 
the relevant task recipe. The required resources were then linked to the input 
connectors of these tasks. The same procedure applied to those of the supporting 
manufacture tasks (e.g. CIP, SIP). The key input variables were entered prior to the 
start of the simulation.
4.3.1. Declaration of Resource Pools
The manufacturing resources were cloned from their respective resource category 
and positioned on the relevant workspaces. The resource element comprised both the 
resource pool manager and the resource. Figure 4.3 illustrates the placement of the 
resource managers in the resource pool declaration windows.
Equipm ent Pool Declaration
Shake flask Pool
20L fermenter Pool
1000L fermenter Pool
Labour Pool Declaration
Operator Pool
QC/QA staff Pool
Materials Pool Declaration
Media Pool
Ampoules of cells Pool
Utilities Pool Declaration
Cooling water Pool
Steam Pool
WFI Pool
Figure 4.3. Declaration of resource pools. Each of the resources was cloned from 
the main category and positioned on their respective workspaces.
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The resource itself was attached to the manufacturing task. For example, the shake 
flask resource manager was duplicated from the equipment library and placed on the 
equipment pool declaration window. The USP operation consisted of the equipment 
resources (i.e. shake flasks, seed and production fermenter), labour resources (i.e. 
operator and QC/QA staff}, material resources (i.e. media and cells) and utilities 
resources (i.e. cooling water, steam and WFI). Each of the input entries in the 
resource pool was then declared. Figure 4.4 shows the user inputs in solid boxes. 
The user specified the resource pool name, maximum utilisation and cost. For the 
equipment resource, the initial equipment status and equipment size were entered. 
The dashed boxes indicated output values; the “number of resources available” was 
constantly updated during a simulation run to indicate the current available resources 
in the pool while the total purchase cost for the equipment resource was determined 
at the start of the simulation.
Equipment Resource Pool Manager
Resource Pool Name:
Maximum Utilisation: 
Equipment Volume, L: 
Initial Equipment Status: 
Total Purchase cost, $:
# of Resouces Available:
Shake flasks
10
0.5
sterilise
300
10
Materials Resource Pool Manager
Resource Pool Name:
Maximum Utilisation, L: 
Unit cost, $/L:
# of Resouces Available, L:
Media
1000000
20
1000000
Labour Resource Pool Manager
Resource Pool Name:
Maximum Utilisation: 
Unit Cost, $/h:
# of Resouces Available:
Operator
10
25
10
Utilities Resource Pool Manager
Resource Pool Name:
Maximum Utilisation, L: 
Unit cost, $/L:
Cooling water
1000000
0.001
# of Resouces Available, L: | 1000000
Figure 4.4. Examples of resource pool managers. The solid boxes represent user 
inputs while the dashed boxes indicate output values.
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4.3.2. Set-up of Manufacturing Tasks Recipes
After specifying the manufacturing resources in the plant, the series of 
manufacturing tasks were defined. Figure 4.5 illustrates the detailed graphical 
representation of a typical USP generated by cloning the customised manufacturing 
task blocks from libraries and then positioning them on the respective recipes. In the 
process-flowsheet workspace, the sequence of product-manufacture tasks was 
established. The product-manufacture steps of inoculum grow-up and seed 
fermentation to the production fermentation were linked in series with the resources 
attached to the input connectors. The top input connector from the inoculum grow- 
up task was linked to the output connector of the Start block. The 20L and 1,000L 
fermentation processes were then linked accordingly, with the End block being the 
last block. The necessary resources were then connected to each of these tasks. The 
user specified the utilisation level of each of these resources or the default values 
were employed. The current task was activated by the process stream item flowing 
into the block from the prior step. In the equipment-cleaning-in-place window, the 
equipment resource was connected to the top connector of the preparation task. The 
relevant resources were then connected. The preparation tasks ended with an Exit 
Block. This block displayed the run number for the particular task. The same 
procedure applied to the equipment-sterilising-in-place and regulatory-compliance 
recipes. Figure 4.5 also illustrates part of the process flowsheet in action. The 20L 
fermentation process was animated during the simulation, allowing the user to view 
what was happening at a particular time of the simulation.
4.3.3. Input Parameters
The cost-associated input parameters (e.g. Lang factor, project duration, facility size) 
for the model were entered. The factors for mass balance calculations were input to 
determine the characteristics (i.e. mass, volume) of the process streams from each 
process step. The key mass balance data included the fermentation titres, process 
yields, and dynamic binding capacities. These statistics were either selected from the 
list of available distributions in the tool or user-defined distributions with known 
probabilities were used. Finally, the simulation set-up parameters, including the 
simulation time (in days) and the number of runs, were then specified.
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Process Flowsheet Details
S h a k e  f l a s k  
A m p o u l e  o f  c e l l s  
M e d ia  
O p e r a t o r
2 0 L  f e r m e n t e r  
M e d ia  
O p e r a t o r
1 0 0 0 L  f e r m e n t e r  
M e d ia  
O p e r a t o r
" I n o c u lu m  g r o w - u p "
" 2 0 L  f e r m e n t a t io n "
" 1 0 0 0 L  f e r m e n t a t io n "
Equipment Sterilising-in-Place Recipe Details
S h ak e  flask
SI .  Mi l l
C o o l in g  w a t e r
Operator " S h a k e - f la s k -S I P "
2 0 L  f e r m e n t e r  
S t e a m  
C o o l i n g  w a t e r  
O p e r a t o r '2 0 L -f e r m e n te r - S I P "
1 0 0 0 L  f e r m e n t e r  
S t e a m  
C o o l in g  w a t e r  
O p e r a to r 1 0 0 0 L - f e r m e n t e r - S I P "
Regulatory Compliance Recipe Details
S a m p l e  
Q C /Q A  s t a f f
Exit
B a t c h
O p e r a t o r
" B a tc h  d o c u m e n t a t i o n '
Exit
L o t
O p e r a t o r
“L o t  r e v ie w "
E x it
Equipment Cleaning-in-Place Recipe Details
S h a k e  flask
C IP  b u f fe r
O p e r a t o r
20L fe rm e n te r
C IP  b u f fe r
O p e ra to r
“S h a k e - f la s k - C I P "
“2 0 L - f e r m e n t e r - C I P "
1 0 0 0 L  f e r m e n t e r  
C IP  b u f f e r  
W FI 
O p e r a t o r " 1 0O O L -f e r m e n t e r - C I P "
Figure 4.5. An example of a typical USP defined in the recipes, with the required 
resources attached to the tasks. The diagram depicts an instance of the discrete 
simulation process in action, with an active 20L fermentation task being animated 
during the simulation cycle. The resources (e.g. equipment, material, labour, 
utilities) in the model were generated by cloning the customised blocks from the 
libraries and then connected.
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4.3.4. Graphical Representation
The graphical representation of the USP example modelled on the platform of 
BioPharmKit is depicted in Figure 4.6. The diagram illustrates the main operating 
window of the simulation tool at the most front, which can be decomposed further 
into lower hierarchical levels. The hierarchical architecture allowed processes to be 
simulated at different levels of details. BioPharmKit’s interface was fully graphical. 
The specification of a flowsheet was done through appropriate dialog boxes and 
Excel spreadsheets. The tool provided the capabilities to rapidly develop, simulate 
and evaluate a flowsheet. For a given model, it carried out mass balance 
calculations, computed cost estimates and handled process-scheduling events. The 
activation of a task was triggered by the prior item flowing into the current task. The 
processes were modelled as discrete events with the simulation time advancing at 
each occurrence of event. The Executive block at the top left corner of the main 
window kept track of the simulation time.
r~ V T ^ r ^ in r T U I I * !  ‘ f^TiI-X »74glCf ''SHHBHHHHHHBBHRIfifiMliHBEMMHMi
File Ldt Library Model I ext Define Kun Window Help
inf
jnjxj'
01 A)1/2002 — I j t J
t TVie OOPO | _ J
i^ couni
ZZI
| Organizer |
Kaoositorv M odal
Code Manufacturing 
Repository Tem plate
Libraries
R esources Manufacturing 
Tasks
117 h F .?7 j / ]  P rm lu rt .jgjxi
jnusj
[Manufacture Details]
jU J *r
Product-Manufacture recipe
Equipment-Preparation recipe
Regulatory-Compliance recipe
| Product-f I ow sheet Details |
J^Olxj
Product-M anufacture Details
R ftk-p .ram .t« r-ln ltl .ls .tlon
JiaiaJL
Media
'Inoculum grow-up"
"20L Fermentation"
“1000L Fermentation"
Figure 4.6. Graphical representation of the USP example modelled on the platform 
of the simulation tool BioPharmKit.
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The tool provided an interface with Excel for the input of data and reporting of 
simulation results from the models (Figure 4.7). The user entered the input data prior 
to the start of a simulation run. The output entries were computed and automatically 
updated during the simulation. The transparent platform of Excel provided the user 
with the flexibility of modifying them.
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Figure 4.7. An Excel spreadsheet with an interface to the decision-support tool 
BioPharmkit for the input of data and reporting of simulation results.
4.3.5. Output Parameters
Some typical outputs from the tool are shown in Figure 4.8. The cost outputs were 
updated constantly in Extend and Excel during a simulation run. Such data could 
then be manipulated in Excel to plot out useful graphs for comparing and evaluating 
the manufacturing option. The utilisation curves in Figure 4.8 suggest the current 
utilisation level of media and operator over a period of time. These utilisation
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profiles could be used to compare the demand on resources for different 
manufacturing strategies and to allocate the appropriate number of resources to carry 
out a manufacturing task efficiently. The operator plot indicates that typically, a 
maximum of 2 operators were employed during the majority of the simulation time. 
Such figures could be used to optimise resource utilisation to improve productivity 
and throughput.
Cost Outputs
Direct Raw Materials, $: i 253535
Miscellaneous Materials, $: ) 53554
Direct Utilities, $: j 4878
Operating Labour, $: j" 5456
QC/QA staff, $: j 1256 !
cGMP-related materials, $: j 1256 !
Supervisors, $: i 1255 j
General Management, $: f 32506 j
Time (Days)
6
5
4
3
2Z
1
0
1500 50 100
Tima (Days)
Figure 4.8. Key output parameters. The diagram illustrates cost outputs in different 
categories (e.g. direct materials, raw materials, utilities etc.). The utilisation curves 
depict the usage level of resources at a particular time.
4.4. Key Influencing Variables
The decision-making process is influenced by various input variables to the model. 
In this thesis, a range of typical key variables which each have an impact on the 
output parameters (i.e. cost of goods, annual throughput) were selected for study. 
These included process factors such as fermentation yields, titres, turnaround time, 
possibilities of contamination and equipment failure. Other factors included the 
Lang factor and cost of resources. Other input factors that impact the performance 
metrics of manufacturing alternatives were excluded following discussions with
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industrial experts. As a result, the key input factors considered were typical variables 
influencing the process and business aspects of biomanufacturing and were selected 
to demonstrate the functionalities of the decision-support tool.
4.5. Conclusions
This chapter has provided an overall discussion of the prototype tool. Its utility in 
the biomanufacturing industry has been highlighted. Such a bioprocess simulator is a 
potentially valuable and powerful tool to aid the understanding of the complexities of 
a manufacturing operation and assess the process performance with speed and ease. 
The input parameters required for the successful formulation of the models and the 
key outputs generated by the tool have been identified. An example of the 
simulation of an USP has been used to demonstrate the application of such a 
software tool to model bioprocesses. The procedure to assemble the model of the 
USP operation has been presented. This effectively permits the manufacturing 
operation to be evaluated in terms of key process performance metrics such as the 
running costs and resource utilisation profiles. The next two chapters use this 
formula and present two industrial-related case studies that examine alternative 
processing routes with respect to the technical and financial aspects of 
biopharmaceutical manufacture. The studies have been configured so as to reflect 
real manufacturing situations and are typical of current issues facing the 
biomanufacturing industry.
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C hapter 5
Application of BioPharmkit for 
Strategic Biopharmaceutical Manufacture
5.1. Introduction
During the early stage of process development, biopharmaceutical companies 
typically have a range of manufacturing options by which to produce a particular 
drug. The decision to operate a given manufacturing option is largely determined by 
financial budgets, plant capacity and market demand but is further complicated by 
technical and market uncertainties occurring in the biomanufacturing environment. 
This chapter explores the utility of the simulation tool, BioPharmKit, developed and 
implemented in Chapter 3, to provide cost estimates, perform mass balance 
calculations, simulate resource handling, model regulatory-compliance activities, and 
evaluate potential risks so as to predict the feasibility of different manufacturing 
options for the production of a biopharmaceutical drug for commercial use. A case 
study, based upon the assessment of pooling strategies in the perfusion culture of 
mammalian cells to deliver a therapeutic protein for commercial use, is used to 
demonstrate the functionalities of the tool The study aims to investigate the most 
appropriate pooling strategy given a particular set of operating constraints and goals 
in a biopharmaceutical-manufacturing environment.
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The biomanufacturing environment is often subject to numerous technical and 
market uncertainties. The Monte Carlo simulation technique is commonly used to 
study the effect of such uncertainties on the performance measure of stochastic 
processes. The probability functions of uncertain factors are specified to capture the 
randomness inherent in bioprocesses. During a single trial of the model, the outcome 
is determined by randomly selecting a value from the defined input probabilities for 
each uncertain variable. The expected outcomes of stochastic processes are obtained 
by running many iterations of the model process and averaging the outcomes 
together. Such a technique enables a range of possible outcomes to be generated and 
tabulates useful statistics such as the likelihood of achieving or exceeding a threshold 
value. The use of such risk analysis method for decision-making is investigated in 
this chapter.
The remainder of this chapter is structured as follows. In Section 5.2, an overview of 
the case study, which assesses pooling strategies in perfusion culture, is described 
and the procedure carried out to simulate the case study model is also outlined. A 
deterministic analysis of the problem is provided in Section 5.3. In Section 5.4, a 
sensitivity test is carried out to identify variables influencing key output parameters. 
A Monte Carlo simulation technique is then applied in Section 5.5 to incorporate the 
randomness inherent in biomanufacture so as to investigate the effect of variability of 
process parameters. The case study is extended to explore the impact of different 
scenarios on the key performance measures in Section 5.6. Finally, a summary is 
provided in Section 5.7.
5.2. Case Study Background
5.2.1. Case Study Set-up
To evaluate the functionalities of the prototype tool, the production of a therapeutic 
Mab for commercial use using perfusion culture was considered. The case study was 
based on a biopharmaceutical company interested in producing an antibody using 
perfusion culture of mammalian cells. During early phase of process development, 
they wanted to investigate how often to pool harvested liquor during perfusion 
culture and hence determine the pooling interval that minimises costs and uses
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resources more effectively at commercial scale. There was little information 
available about how to select the most efficient pooling interval; hence the tool was 
applied in the case study to explore the impact of pooling intervals on the feasibility 
of the different manufacturing alternatives. The company considered 3 pooling 
strategies at 1-, 15- and 30-day pooling intervals. The downstream process (DSP) 
equipment was sized according to the pooling interval, i.e. a short pooling interval 
(e.g. 1-day) will require smaller DSP equipment than a high pooling interval (e.g. 30- 
day). The antibody product was assumed to be stable. As discussed in Chapter 2, 
the advantages of pooling more frequently include better utilisation of downstream 
equipment and lower investment costs. However, this strategy suffers from 
increased equipment-preparation and regulatory costs due to more frequent 
processing. A less frequent pooling option possesses higher capital costs due to the 
need for larger DSP and ancillary equipment but has reduced ancillary equipment- 
preparation and regulatory-compliance steps.
Table 5.1 specifies the key assumptions of the case study validated through 
discussions with industrial experts (A. Sinclair, Biopharm Services Ltd, Chesham, 
UK; B. Fish, Cambridge Antibody Technology, Cambridge, UK; R. Francis, 
Protherics Pic., London, UK). Such advice from industrialists was critical in 
identifying the logistics of processes within a biopharmaceutical plant and selecting 
sensible inputs. However, the main concern was to demonstrate the functionalities of 
the support tool through a case study so as to prove its use as a general approach 
towards process design and development, and ultimately as an aid in the process of 
decision-making in the biomanufacturing industry. Hence, the case study does not 
provide definitive answers but is a representative of such process assessment. In this 
case study, it was assumed that the commercial facility/plant would have a single 
production train to manufacture the antibody drug (This scenario might not reflect 
real manufacturing situations but was used here to demonstrate the use of the tool to 
investigate different manufacturing options.). The size of the plant would vary 
according to the pooling interval. A typical product titre of 200mg/L was assumed 
and the bioreactor was operated at a perfusion rate of 1 reactor volume per day. The 
collection of the product-enriched liquor commenced after 5 days when a constant 
growth state was achieved. In each strategy, the unit operations in the downstream 
recovery steps generated the same overall product yield. All three options were
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designed to produce an annual product output of 20kg, which is a typical industrial 
figure, to meet the anticipated demand. This case study was focused on the 
operational aspects of the process; hence, the construction and start-up time for the 
plant was not incorporated in the model. The output parameters of interest were the 
annual cost of goods per gram (COG/g) and the demand on resources. The 
feasibility of each of the pooling options was then evaluated and ranked according to 
these performance measures.
Table 5.1. Key process assumptions in the case study.
Assumptions Input value
Length o f single perfusion run 35 days
Pooling intervals 1, 15, 30 days
Fermentation titre 200mg/L
Size o f production bioreactor 1,000L
Seed bioreactor train 20L ;100L
No. o f days to achieve constant growth 5 days
No. o f production trains 1
Perfusion rate 1 reactor volume/day
Downstream process yield 55%
Product stable Yes
Annual operating time 48 weeks/year, 24 hours/day
An overview of the process used in the case study for the production of a therapeutic 
Mab using mammalian cell culture is illustrated in Figure 5.1. The upstream 
processing commenced with the use of a single ampoule to inoculate a few litres of 
media. After growth, this lab-scale culture was used to inoculate the media in a 
small bioreactor. This seed culture was used to inoculate another seed bioreactor and 
the subsequent culture was then used to inoculate the production-scale bioreactor. 
During the perfusion culture, cells were retained in the bioreactor and liquor 
containing the product was collected. The harvested liquor was loaded onto the 
affinity column, eluted as purified product and stored in disposable bags. The eluate 
from successive chromatography runs was then pooled for further purification; this 
was defined as a lot. Viral clearance was followed by further concentration of the 
broth. The concentrated filtrate was then passed through an ion exchange column.
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Further virus reduction by nanofiltration and concentration of the process stream then 
took place prior to gel filtration as a polishing step. A final filtration step was used, 
yielding an essentially pure antibody preparation. At the end of the downstream 
steps, there was a lot review to determine product acceptance/rejection. The key 
equipment and material requirements for the main product-manufacture tasks in the 
process flow are tabulated in Table 5.2. For each pooling interval, the size of the 
equipment used in the upstream stages (i.e. cell culture/fermentation) and affinity 
chromatography was the same. The sizes of the DSP equipment (boxed in Figure 
5.1) for each pooling option are given in Table 5.3.
Inoculum S e e d  
grow-up ferm entation ferm entation
C ontinuous feed  
of m edia
U J
S e e d
C ontinuous  
removal of culture
Spin  filter
ferm entation
V e s se l
Hold
Affinity
chrom atography Hold
*
«■
Lot review
Figure 5.1. Process diagram of the case study: Production of a therapeutic Mab from 
mammalian cell culture using perfusion culture. The equipment sizes for the DSP 
steps (shown in the box) varied accordingly to the pooling interval.
In addition to these product-manufacture steps, the model also considered ancillary 
operations such as equipment-preparation steps (e.g. cleaning-in-place (CIP) and 
sterilising-in-place (SIP)) and regulatory-compliance activities (e.g. quality control 
(QC), quality assurance (QA) and batch documentation) running in parallel with the 
main production train. The requirements of these ancillary operations for each 
product-manufacture task are shown in Table 5.4. In this case study, for simplicity, 
media and buffer were assumed to arrive pre-made and pre-sterilised in disposable 
bags and hence no media and buffer preparation steps were needed.
Final Gel filtration C oncentration/ Viral Ion e x c h a n g e  C oncentration/ Viral 
filtration chrom atography Diafiltration c learan ce  chrom atography Diafiltration c learan ce
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Table 5.2. Key resource requirements for the manufacturing tasks in the case study.
Materials
Manufacturing task Equipment Equipment-related materials Chemicals- & -Biochemicals
Inoculum grow-up 
Seed fermentation 
Production fermentation 
Affinity chromatography
Chemical retrovirus inactivation
Ion exchange chromatography
Virus reduction nanofiltration
Gel filtration chromatography
Final filtration
Shake flasks 
Seed fermenter 
Production fermenter 
Chromatography rig & column
Virus inactivation tank
Concentration/Buffer exchange 1 Diafiltration rig
Chromatography rig & column
Nanofiltration rig
Concentration/Buffer exchange 2 Diafiltration rig
Chromatography rig & column
Dead-end filtration rig
Protein A matrix, disposable bags
Membrane cassettes 
Ion exchange matrix
Membrane capsules 
Membrane cassettes 
Gel filtration matrix 
Membrane capsules
Media, Ampoule o f cells
Media
Media
Protein A wash & equilibration buffer, 
Protein A elution buffer
Low pH solution 
Diafiltration buffer
Ion exchange wash & equilibration buffer, 
Ion exchange elution buffer
Diafiltration buffer
Gel elution buffer
1
2
3
Table 5.3. Equipment sizes for the downstream process steps*.
Manufacturing task Resource pool name 1-day
Sizes
15-day 30-day
Chemical retrovirus inactivation Virus inactivation tank V = 200L V =  1,500L V = 3,000L
Concentration/Buffer exchange 1 Diafiltration pellicon cassettes A =  2m2 A =  20m 2 A =  30m2
Ion exchange chromatography Ion exchange chromatography rig & 
column
V = 9L; H =  15cm; 
D = calculated
V = 45L; H =  15cm; 
D = calculated
V = 65L; H =  15cm; 
D = calculated
Virus reduction nanofiltration Virus reduction filter A =  0.3m 2 II
<
A =  4.5m 2
Concentration/Buffer exchange 2 Diafiltration pellicon cassettes A =  3m2 A =  30m2 A =  45m 2
Gel filtration chromatography Gel filtration chromatography rig &  
column
V =  18L;H  =  50cm; 
D =  calculated
V =  80L; H =  50cm; 
D =  calculated
V =  120L; H =  50cm; 
D =  calculated
Final filtration Cartridge filter A =  0.2m 2 6
(NII< A =  3m2
* Verified through discussions with industrial experts (e.g. R. Francis, Protherics Pic., London, UK; J. Savery & R. Spurling, Biopharm Services Ltd., Chesham, 
UK).
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Table 5.4. Specifications for the requirements of ancillary operations.
Manufacturing task
Ancillary operations
CIP SIP Equilibration Regeneration Re-equilibration QC/QA Documentation
Inoculum grow-up y y X X X y y
Seed fermentation V y X X X y y
Production fermentation y y X X X V y
Affinity chromatography y X y V y V y
Chemical retrovirus inactivation V y X X X y y
Concentration/Buffer exchange 1 y X X X X V y
Ion exchange chromatography V X V y V y y
Virus reduction nanofiltration V X X X X V y
Concentration/Buffer exchange 2 y X X X X V y
Gel filtration chromatography V X y X y y y
Final filtration y y X X X y y
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5.2.2. Methods
Declaration of resource pools
The resource pools for each of the resources (e.g. equipment, materials, labour, 
utilities) were cloned from their respective libraries and placed on the manufacturing 
template accordingly. For instance, the resource fermenter was created from the 
renewable equipment category while the resource steam was created from the non­
renewable utilities category. The user specified the purchase cost/cost per use of the 
resources or built-in cost models based on cost-estimation factors for 
biopharmaceutical process equipment were used. The base cost input data for the 
resources in the manufacturing plant are given in Chapter 4. Additional inputs of the 
attributes of equipment included their sizes (e.g. “equipment volume”, “equipment 
height”, “equipment diameter”) and their initial status (e.g. ‘dirty’, ‘clean’, ‘sterile’, 
‘equilibrated’).
Equipment-related materials such as membrane cassettes, capsules and 
chromatography matrices were assumed to be re-usable for a given number of cycles. 
The cycle limit of the renewable equipment-related materials was set to 100. For the 
membrane filtration materials, the working-area was either specified by the user or 
determined by process and mass balance data. The chemicals-and-biochemicals 
resources were created from the non-renewable material resource category. For 
simplification, the culture media was defined as one element without breaking down 
into the individual components such as glucose, water etc. Further attribute inputs 
(e.g. “mass”, “volume”, “density”, “concentration”, “physical state” and “virus titre”) 
were required for the chemicals resources (e.g. wash, equilibration and elution 
buffer) to feature their characteristics.
Definition o f main/ancillary tasks sequences
The next step was to define the sequences for the product-manufacture steps and the 
ancillary tasks of equipment-preparation, in-process testing and batch 
documentation. An example of the graphical representation of the product- 
manufacture recipe for the perfusion case is illustrated in Figure 5.2. The series of 
unit operations from fermentation to the final filtration were linked to represent the 
whole process within the manufacturing environment.
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Figure 5.2. Graphical representation of the product-manufacture recipe for the 
perfusion case.
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The ancillary steps of equipment-preparation and regulatory-compliance were 
defined on their respective workspaces according to the specifications set out 
previously in Table 5.4. The steps of QC/QA, batch documentation and lot review 
were each modelled as one unit operation. The requirements for QC/QA in each of 
the product-manufacture task were either specified or the default value in the tool 
was used. The batch documentation was triggered upon the completion of each 
product-manufacture task. The lot review activity was initiated at the end of the 
process flow to determine product acceptance/rejection.
Specifications of manufacturing resources/tasks requirements
All the necessary resources were then allocated to each manufacturing task using the 
input connectors as demonstrated in Figure 5.2. The user specified the utilisation of 
each of the input resources or employed the default value to set the resource demands 
for each task. The utilisation levels of some input resources, such as chromatography 
matrices and buffers, were calculated based on equipment sizes and process data.
Estimates of processing times for the manufacturing tasks (e.g. fermentation) were 
made based on literature sources, calculations or discussions with industrial experts. 
The duration of certain tasks (e.g. chromatography, filtration) was computed within 
the simulation tool using the equipment or membrane sizes, volume of materials to 
be processed and process variables (e.g. flow rates, concentration factor, membrane 
fluxes). In addition, the product-manufacture tasks required the specification of the 
correct equipment status in order to proceed. For example, fermentation tasks 
required ‘sterile’ fermenters while chromatography tasks required ‘equilibrated’ or 
‘re-equilibrated’ columns.
Mass balance inputs
The default values for the key input factors for the mass balance calculations are 
given in Chapter 4. The process data was estimated using information supplied by 
vendors and discussion with industrialists. The mass balance inputs were employed 
in determining the mass and volume of each component in the output streams, certain 
task processing times and membrane areas. In each pooling scenario, the mass 
balance models for the unit operations in the product-manufacture tasks generated 
the same overall product yield.
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Initialisation
The emergence of the process stream of the previous task was used to trigger the next 
task. The activation of the unit operations was further controlled by the equipment 
status and the availability of all required resources. In this case study, a new batch 
was initiated after completion of the production fermentation step. This assumption 
was applied in this particular case study to illustrate the functionalities of the tool and 
do not reflect real manufacturing situations. However, the user could define the 
commencement of a new batch to be triggered by any upstream process step. The 
ancillary tasks were activated using the Throw and Catch blocks as described in 
Chapter 3.
Having set up the flowsheet model and gathered the relevant inputs, the software tool 
was used to run the different scenarios independently and to compare the results. 
The simulation outputs were again verified with industrial experts to validate the 
findings. A deterministic study of perfusion culture was initially carried out using 
single-point measures. To take into account the inherent variability of process 
factors, key uncertainties in the system were identified and subjected to a degree of 
change so as to investigate the impact on output parameters. The uncertainties 
considered in this case study were the fermentation titre, process yield, turnaround 
time, Lang factor, media cost, WFI cost and operator cost. In reality, there exist 
other random factors in bioprocesses and the variables chosen in this study were used 
mainly to investigate the impact of uncertainties on the stability of the base case.
A Monte Carlo analysis was then performed to help minimise the risk of incorrect 
conclusions based on the variability in the process parameters. The key uncertain 
factors used for the Monte Carlo simulation were derived from the sensitivity 
analysis. The factors investigated were those variables that had the most impact on 
the output parameters. The input probability distributions of these uncertain 
variables were specified to represent the inherent randomness in such parameters. 
The outcome for a single trial of the model was determined during a simulation 
where values were sampled from the input probability functions of each uncertain 
variable. A range of possible outcomes was obtained by running many iterations of 
the model. By monitoring the running averages of the output parameters, the number 
of simulation runs was repeated until convergence was reached. The frequency
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distributions of performance measures were then plotted and useful statistical 
summaries (i.e. expected values, standard deviations and likelihood of achieving or 
exceeding a criterion value) tabulated. Some possible scenarios were identified to 
explore the impact of such implications on key performance metrics. The Monte 
Carlo simulation technique was employed in each scenario and the manufacturing 
options were ranked according to the statistics derived from such an approach.
5.3. Initial Deterministic Analysis
5.3.1. Resource Utilisation Profiles
To view the demand on the manufacturing resources, the utilisation curves were 
plotted. The tool generates the current utilisation of operator resources highlighting 
the daily peak levels in demand and when they occur. The demand on the production 
operators is shown in Figures 5.3a for pooling intervals of 1, 15 and 30 days. In this 
example, the production operators do not include QC/QA staff. Since QC/QA tasks 
require specialised personnel to carry out the process control activities, such 
operators are considered as belonging to another separate unit in the plant. Figures 
5.3a illustrates that at a pooling interval of 1 day, a maximum of 9 production 
operators are engaged in the production activities at any time. On the other hand, a 
maximum of 5 operators are utilised for a 15-day pooling interval while the 30-day 
pooling strategy requires a maximum of 4 operators. The average utilisation of staff 
in all cases was also probed. This value corresponded to 6.0, 2.0 and 1.6 in the case 
of 1-, 15- and 30-day intervals respectively.
Examples of the demand on the QC/QA staff for successive batches are illustrated in 
Figures 5.3b for pooling intervals of 1, 15 and 30 days. Figures 5.3b indicates that 
typically, a maximum of 4 QC/QA staff are employed at any time in the process at a 
pooling interval of 1 day. At a longer pooling interval, Figures 5.3b shows that a 
maximum of 2 staff are used during the majority of the production time. The 
average utilisation of staff corresponded to 2.5, 1.5 and 1.3 in the case of 1-, 15-day 
and 30-day intervals respectively. The utilisation of QC/QA staff at a daily pooling 
interval was more intensive due to the fact that such operation necessitates more
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parallel processing while more idle time is associated with a longer pooling interval. 
These results demonstrate the impact that different manufacturing options have on 
the demand for resources. Such utilisation performance metrics could be used to 
prompt a company to allocate the appropriate number of staff to carry out tasks 
efficiently depending on the manufacturing option selected.
The utilisation of USP and DSP equipment for two successive batches is plotted in 
the Gantt charts (Figures 5.4a-c) for pooling intervals of 1, 15 and 30 days 
respectively. The horizontal bars represent the duration of the equipment in use 
against time. In this example, the equipment can be in use for either the product- 
manufacture or equipment-preparation steps such as CIP and SIP. Since the two 
manufacturing strategies only differ in the downstream pooling sections, they possess 
similar USP equipment utilisation characteristics. As illustrated in Figure 5.4a, there 
are more lots being processed in the downstream section due to the need for daily 
pooling of eluate from the affinity chromatography in the 1-day option. Hence the 
DSP equipment is better utilised. In this case study, the next batch was initiated after 
the production fermentation had been completed. Hence there was more idle time 
between the completion of a current batch and the initialisation of the next batch. As 
explained previously, this situation was simplified to demonstrate the use of the tool 
to investigate different manufacturing options. Such charts can help to monitor the 
scheduling of resources and track the progress of the project.
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Figure 5.3. Utilisation of (a) production operators and (b) QC/QA staff for 1-, 15- 
and 30-day pooling strategy. The utilisation refers to the current utilisation of 
operator resources indicating the daily peak levels in demand.
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Figure 5.4. Gantt charts: Utilisation of equipment for (a) a daily (b) a 15-day and (c) 
a 30-day pooling strategy. The long bar indicates the equipment is used for a longer 
time while the short bar represents shorter usage time.
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5.3.2. E con om ic E valuation
Direct cost o f goods
The annual direct cost outputs on a task category basis for pooling intervals of 1, 15 
and 30 days are plotted as shown in Figure 5.5. The direct costs represent the cost of 
resources (i.e. materials, labour and utilities) required by each of the tasks. The costs 
are relative to the case of a pooling interval of 1 day. The figure illustrates that the 
direct COG/g is dominated by the equipment-preparation and product-manufacture 
tasks in the base case, accounting for 86% of the total direct costs. As the pooling 
interval increases, the direct COG/g drops as fewer QC/QA and documentation steps 
are required. These activities contribute about 14% of the COG/g in the base case 
and this falls sharply so that at an interval of 15 days, it is about 4%. This is due to 
the additional QC/QA and documentation tasks earned out during the 1-day pooling 
option. Further examination indicates that there is only a slight drop in the cost of 
the equipment-preparation steps as the pooling interval increases. The costs of the 
product-manufacture tasks are almost constant (54%) across all pooling intervals. 
This can be attributed to the fact that the costs of the upstream and affinity 
chromatography tasks are the same across all pooling strategies and the remaining 
product-manufacture tasks have relatively similar costs. This can be seen from the 
breakdown of the cost data presented in Figure 5.6.
R elative d irec t c o s t  of 
g o o d s  p e r  g ram
100%
20%
1 15 30
Pooling in terval (D ay s)
□  R egu la to ry -C om pliance  T ask s
□  E qu ipm en t-P repara tion  T a sk s  
■  P ro d u c t-M a n u fa c tu re  T a sk s
Figure 5.5. Annual direct COG/g on a task category basis for pooling intervals of 1, 
15 and 30 days. Values are relative to a pooling interval of 1 day.
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The annual direct COG/g can be broken down further to view the operational cost 
distributions of individual unit operations in the process flow. Figure 5.6 shows the 
direct costs (i.e. operators, materials, utilities) for each of the manufacturing tasks 
during the first year of production as a function of the pooling interval. The figure 
indicates that the production fermentation and CIP steps are the most expensive in all 
three pooling options. The high fermentation production costs are due to large usage 
of media and the associated labour over the extended culture cycle. This implies that 
the process development team must look for ways to cut down costs such as 
engaging in in-house media preparation rather than using ready-made media in 
disposable bags. Although the in-house media preparation is not considered in this 
analysis, options include making up and holding of such solutions in-house in either 
disposable or stainless steel equipment.
The costs of the upstream and affinity chromatography tasks are invariant with 
pooling interval due to the fact that the strategies differ only in the scale of the 
downstream recovery steps. Further examination illustrates that the affinity 
chromatography task contributes a substantial amount to the total direct COG/g. The 
costs of the buffer exchange/concentration task increase at longer pooling intervals as 
a result of the larger membrane filters used in such options. The figure indicates that 
the drop in CIP costs as the pooling interval increases is not as significant as might 
be expected. This can be attributed to the fact that although a longer pooling interval 
requires fewer CIP tasks, each CIP task that is undertaken requires more CIP buffer 
and WFI owing to the larger DSP equipment size. The cost of regulatory- 
compliance activities (i.e. QC/QA and documentation) is significant relative to the 
remaining unit operations in the 1-day pooling strategy. Even though the costs of the 
regulatory-compliance tasks are relatively higher in the 1-day pooling option, they 
are only a small proportion (14%) of the direct costs and thus have a lesser impact on 
the cost of goods.
The above cost analysis on a task basis provides an indication of cost estimates of 
specific tasks, thereby providing the capability to view where the running costs are 
concentrated and may be useful in focusing cost reduction efforts within a company.
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Figure 5.6. Breakdown of annual direct COG/g into each manufacturing task for 
pooling intervals of 1, 15 and 30 days.
Total cost o f goods
The economics of the three pooling strategies were evaluated by the total COG/g, 
broken down into the indirect and direct costs (Figure 5.7). The costs are relative to 
the base case of a 1-day pooling option and show a close similarity for the three 
cases with the simulation result predicting the 30-day pooling option to have a slight 
cost advantage over the other two options with a 3% decrease in COG/g relative to 
the base case. Although longer pooling intervals have lower direct costs, the larger 
equipment scale contributes to high indirect costs, thus increasing the overall costs. 
A comparison of the indirect costs revealed a 7% increase for the 30-day pooling 
option. A 1-day pooling option has higher labour costs (8%) due to the frequent 
processing of the downstream steps. In order to compare the effect of different 
manufacturing strategies, such labour costs are computed based on their utilisation 
rather than considering them as a fixed annual cost. The main purpose of computing 
the labour costs based on utilisation was to highlight which manufacturing options 
were more labour-intensive. However, it should be emphasised that in industry, it is 
common practice to consider labour costs as fixed costs. The material and utilities 
category is the most significant contributor to the cost in each strategy.
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Figure 5.7. Total COG/g on a cost category for pooling intervals of 1, 15 and 30 
days. Values are relative to a pooling interval of 1 day.
5.4. Sensitivity Analysis
As mentioned in Chapter 1, sensitivity analysis provides an organised and systematic 
way to examine the effects of parameters in a model on the key outputs. 
Accordingly the input variables in the case study were identified and subjected to 
±x% change (Table 5.5). The range of values for the input variables was determined 
from literature sources and through discussions with industrial experts (e.g. R. 
Francis, Protherics Pic., London, UK). In this case study, the company was assumed 
to produce a single Mab in the facility, and hence these values were likely variations 
between similar batches for a single product. A sensitivity analysis was then earned 
out for each of the variables in the extreme (worst and best) scenarios, keeping all 
other variables fixed at the baseline value.
The range of outcomes for the annual product output and COG/g at a pooling interval 
of 15 days was monitored and displayed via Tornado plots (Figures 5.8a and b). 
Figure 5.8a indicates that the annual output is most sensitive to the fermentation titre, 
followed by the DSP yield. A 25% increase in fermentation titre results in a 
comparable increase in the amount of antibodies produced to 25 kg/year. On the 
other hand, a 25% reduction in the titre causes the annual output to drop to 15 
kg/year. (Variables such as the Lang factor, media cost, water for injection (WFI) 
cost and operator salary, as expected, have no impact on the annual output.) As
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illustrated in Figure 5.8b, the main factors affecting the annual COG/g were also the 
fermentation titre and the DSP yield. The media cost and the Lang factor each 
contribute but to a relatively less significant level. Uncertainties in the WFI, operator 
wage and turnaround time each have only a minor effect on the cost of goods.
Table 5.5. Sensitivity scenarios set-up.
Input variable Units W orst Base Best
Fermentation titre mg/L 150 200 250
Downstream process yield % 50 55 60
Turnaround time days 5 2 1
Lang factor - 7 6 5
Media cost $/L 25 20 15
WFI cost $/L 2 1 0.5
Operator wage $/h 35 25 15
(a) (b)
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D SP yield 
T u rn aro u n d
W o rst
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D SP  yield 
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Figure 5.8. Tornado diagrams depicting the sensitivity of each variable of interest on
(a) annual quantity of Mabs generated and (b) annual COG/g for a pooling interval of 
15 days. The vertical axes intersect the horizontal axes at the baseline value.
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5.5. Monte Carlo Analysis
5.5.1. Monte Carlo Set-up
In this study, fixed market demand and dose levels were assumed for the production 
of material for commercial use and were not considered as factors in the risk 
analysis. The fermentation titre was subjected to a variation of ±50 mg/L and the 
DSP yield ranged between ±5% of the base value respectively (Table 5.6). These 
two variables were assumed to vary according to a discrete Normal distribution. Due 
to the long cycle times in perfusion culture, the possibility of contamination was a 
significant factor influencing the cost of goods and output. This risk was reflected in 
the model by adding a contamination probability associated with this mode of 
operation. The likelihood of contamination of 5% was incorporated into the model. 
The probability value indicated that the chance of a single perfusion run being 
contaminated was 5%. The Input Random Number block provided in Extend was 
used to generate random numbers according to the distributions specified in Table
5.6. When executed, the model randomly selected the particular day between Day 1 
and Day 30 on which a contamination occurs according to a negatively-skewed 
triangular distribution (i.e. contamination is more likely to occur towards the end of 
the perfusion run). Such a distribution was reasonable as it indicated the increased 
likelihood of contamination over time. Upon the detection of contamination, the 
perfusion culture was then terminated and a new batch initiated.
Having validated the results of a single simulation in the deterministic analysis, 
Monte Carlo simulations were applied to generate random occurrences for 
probabilistic factors in 1-, 15- and 30-day pooling options. The number of 
simulation runs required to reach convergence was determined by monitoring the 
running averages of the simulation results until they levelled off. The number of 
simulation runs to reach convergence was 300. The outcomes from the Monte Carlo 
simulations were obtained so as to generate frequency distributions for the 
performance measures. The results for the different pooling interval strategies were 
then compared.
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Table 5.6. Monte Carlo simulation set-up: Input risk parameters and their discrete 
probability distributions.
Variable Units Value Probability
Fermentation titre mg/L 150 0.1
175 0.2
200 0.4
225 0.2
250 0.1
DSP yield % 50 0.1
53 0.2
55 0.4
58 0.2
60 0.1
Perfusion run contaminated? - Yes 0.05
No 0.95
5.5.2. Monte Carlo Simulation Results and Discussion
Figures 5.9a and b illustrate the frequency distribution plots and cumulative 
frequency curves for the annual quantity of Mabs generated and COG/g at a pooling 
interval of 15 days respectively. From the deterministic results, given a titre of 
200mg/L, the company may expect that the typical quantity of Mabs generated in 
their facility in a year to be 20kg after purification. It was assumed that the process 
output was sufficient to satisfy initial market demand. However, by considering 
uncertainties in titre and DSP yield together with the risk of contamination, the data 
in Figure 5.9a indicates that although the modal annual output is 20.0kg, the 
computed mean is only 19.3kg. This demonstrates that the impact of contamination 
is skewing the mean to the left of the modal value, consequently producing a lower 
value for the expected amount of Mabs generated.
In the deterministic case, the annual output of 20kg was achieved without 
considering the occurrence of risk or failure. With a contamination probability of 
5% in the process, a more rational target of at least 19kg is chosen for the purpose of
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discussion. It can be seen that the probability of achieving an annual output of at 
least 19kg is 0.88. Hence, there is a 12% chance that the output would fall below 
19kg. These results highlight the limitations of relying on deterministic outputs for 
decision-making in processes subject to randomness and risk. The company may 
seek to improve the process in order to raise the output given the inherent 
randomness expected and to gain confidence in the ability to deliver the target 
amount of Mabs product.
Figure 5.9b shows that there exists a corresponding range of possible outcomes for 
the COG/g. Such results can be used to determine the likelihood of exceeding a 
particular COG/g limit. As illustrated in Figure 5.9b, the likelihood of exceeding the 
cost obtained by deterministic methods is about 68% and again reinforces the 
dangers of using single-point forecasts. A company should take into account such 
variations in costs into their financial planning.
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Figure 5.9. Frequency distribution plots and cumulative frequency curves for (a) 
annual quantity of Mabs generated and (b) annual COG/g for a pooling interval of 15 
days. The left axes correspond to the number of occurrences (histogram) and the 
right axes refer to the cumulative percentage (line). The solid column indicates the 
deterministic base value.
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Table 5.7 summarises the results of the Monte Carlo simulation for the three 
different pooling strategies. The results are ranked in order with the best first. The 
1-day pooling strategy offers the lowest likelihood of failing to meet the market 
demand and of exceeding the baseline cost budget as compared to the other two 
alternatives when operated under uncertainty. Only the 30-day pooling process has 
an expected production mean below the 19kg target. This pooling strategy is the 
riskiest in terms of the likelihood of failing to meet demand and of exceeding the 
baseline COG/g.
Table 5.7. Summary of key results for the Monte Carlo analysis of the 3 alternative 
strategies.
Statistics
Pooling option
1-day 15-day 30-day
Expected annual output (kg) 1 9 . 4 1 9 . 3 1 8 .9
P(Failing to yield at least 19kg o f Mabs annually) 1 1 % 1 2 % 2 4 %
P(Exceeding baseline COG/g* obtained by 
deterministic methods)
6 4 % 6 8 % 7 0 %
* The baseline COG/g was $ l,0 1 0 /g , $990/g and $980/g in the 1-, 15- and 30-day pooling options 
respectively.
To compare COG/g for the manufacturing alternatives, it is useful to consider both 
the expected costs and associated risks. Figure 5.10 depicts the risk (standard 
deviation) against the expected annual cost of goods per gram for each pooling 
strategy. The choice between long and short pooling intervals would require a trade­
off between the cost budget and risk of each strategy be established. Options with 
low expected costs and risks are preferred. Although the deterministic analysis 
predicted that the 30-day pooling strategy has a slight cost advantage over the other 
two alternatives, the Monte Carlo simulation results indicate that the three pooling 
options have comparable expected annual COG/g. It is apparent that the 30-day 
pooling strategy is the least favourable of the options because of its higher risk
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(larger standard deviation). The COG/g outcomes for the 30-day option are more 
disperse and hence this option carries a greater risk.
100 
80
3? 60
.52
DC 40  
20 
0
700 800 900 1000 1100 1200 1300 1400
Expected annual co st of goods per gram ($/g)
Figure 5.10. Plot of the risk versus the expected annual COG/g for each pooling 
strategy. The risk refers to the standard deviation of the cost of goods distributions. 
The three pooling options have comparable expected annual COG/g of $l,020/g.
Based on the COG performance metric, the company would probably opt for the 1- 
or 15-day pooling option with their associated lower risks. The final decision may 
relate to the utilisation of DSP resources. Since DSP activities are performed less 
frequently with a longer pooling interval, this potentially leads to more idle capacity 
in the DSP purification train. On this basis, the 1-day pooling strategy with a smaller 
manufacturing plant seems more favourable since the DSP equipment is better 
utilised.
B  30-day
^  15-day 
^  1-day
H--------------------- 1---------------------1----------------------1--------------------- h
- 1 4 2 -
Chapter 5: Application o f  BioPharmKit fo r  Strategic Biopharmaceutical Manufacture
5.6. Scenario Analysis
Scenario analysis is a process of analysing possible future events by considering 
alternative possible outcomes (scenarios). The basic principle of scenario planning is 
to understand as best as possible likely trends and to make strategic decisions based 
on an analysis of the consequences of the most likely scenarios. The analysis is 
designed to allow improved decision-making by allowing more complete 
consideration of outcomes and their implications.
5.6.1. Scenarios Set-Up
The following possible scenarios were envisaged and verified through discussions 
with industrial experts. The tool was used to run these scenarios independently. The 
same stochastic analysis was performed to evaluate the impact on key performance 
metrics and determine the ranking of the three pooling alternatives under different 
scenarios.
a) The product is unstable and the product degrades as the holding time increases.
In the previous base-case scenario, the product was assumed to be stable and all three 
pooling strategies achieved similar product titres. The first alternative scenario 
examined the possibility that the product was unstable and hence it would not be 
possible to achieve the same titre levels in all three options. This is reasonable as the 
product degrades as the holding time increases. In this case, the following 
modifications were made to the models. A 20% reduction in the average recoverable 
product titre (i.e. 160mg/L instead of 200mg/L) for the 30-day pooling option was 
assumed (A. Sinclair, Biopharm Services Ltd, Chesham, UK; R. Francis, Protherics 
Pic., London, UK). As for the 15-day pooling option, the average recoverable titre 
was reduced by 10% to 180mg/L. For the Monte Carlo analysis, a discrete normal 
distribution was applied to both cases. The probability distribution for the 
fermentation titre of the 1-day pooling option remained unchanged. The changes in 
titre values for the scenario are summarised in Table 5.8. Again, the Input Random 
Number block was employed to generate random numbers according to the 
distributions.
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Table 5.8. Changes to inputs for scenario ‘a’.
Pooling option Possible titre values (mg/L) Probability
15-day 130 0.1
155 0.2
180 0.4
205 0.2
225 0.1
30-day 110 0.1
135 0.2
160 0.4
185 0.2
210 0.1
b) The company has existing downstream equipment in their facility and the product 
is stable.
The second scenario considered the situation where the biopharmaceutical company 
had an existing downstream purification suite in their plant. The company wished to 
assess the most appropriate pooling strategy (i.e. 1-, 15- or 30-day intervals), given a 
fixed downstream process scale. In this case, the downstream equipment scale of the 
1-day pooling option was assumed and the pooling interval was then varied to 15 and 
30 days. With an existing facility, multiple cycles or longer cycle times are likely to 
be used as the harvest volume increases rather than linear scaling of column volume 
or membrane area (Personal communication: R. Spurling, Biopharm Services Ltd, 
Chesham, UK). This scenario examined the impact of such changes. The 
downstream process yields remained unchanged and the product was assumed to be 
stable.
c) The product is unstable and the company has existing downstream equipment in 
their facility.
The last scenario was a combination of scenarios ‘a’ and ‘b’. The company was 
assumed to have a fixed downstream equipment scale in their facility. In addition, 
the product was considered to be unstable.
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5.6.2. Scenarios Results and Discussion
Table 5.9 summarises key statistics used to compare the process alternatives in each 
scenario. The ranking of the results in each scenario is also tabulated in the table. 
The plots of risks versus the expected COG/g for each pooling alternatives in the 
different scenarios are shown in Figures 5.11a-c.
Table 5.9. Summary of simulation results for the different scenarios.
Scenario Statistics
1-day
Values
15-day 30-day
Ranking
order
(best first)
Unstable
product
Expected annual output (kg) 19.4 17.4 15.4 1, 15, 30
Expected COG ($/g) 1020 1120 1230 I, 15, 30
P(Failing to yield at least 19kg o f  
Mabs annually)
11% 100% 100% 1*
Stable product; Expected annual output (kg) 19.4 19.0 18.1 1, 15, 30
same DSP
equipment Expected COG ($/g) 1020 840 810 30, 15, 1
scale
P(Failing to yield at least 19kg o f  
Mabs annually)
11% 15% 28% 1, 15, 30
P(Exceeding baseline COG/g 
obtained by deterministic methods 
for each strategy)
64% 71% 75% 1, 15, 30
Unstable 
product; same
Expected annual output (kg) 19.4 17.0 14.8 1, 15, 30
DSP equipment 
scale
Expected COG ($/g) 1020 900 1080 15, 1, 30
P(Failing to yield at least 19kg o f  
Mabs annually)
11% 100% 100% 1*
* In these cases, the 15- and 30-day pooling options fail to meet the output criterion and hence are not 
feasible.
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Figure 5.11. Plot of the risk versus the expected annual cost of goods per gram for 
the different scenarios examining the effects of (a) an unstable product, (b) fixed 
DSP equipment across all pooling options and (c) combination of scenarios ‘a’ and 
‘b \  The grey symbols represent the simulation results from the original Monte Carlo 
base case analysis. The risk refers to the standard deviation of the cost of goods 
distributions.
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a) The product is unstable and the product degrades as the holding time increases. 
From the results presented in Table 5.9 and Figure 5.11a, when the product is 
unstable, the 1-day option appears to be the most desirable strategy with the highest 
likely output, lowest expected COG/g and associated risk. Due to the drop in titre 
levels, the 15- and 30-day options fail to meet the output criterion and are therefore 
not feasible. So the 1-day case is the only option under such circumstances. With a 
20% reduction in product titre, the expected COG/g for the 30-day option has 
increased by 23% with respect to the 1-day pooling option. This is due to the loss in 
annual output. The drop in titre due to instability has accentuated the difference 
between the options. Given the results drawn from this scenario, if the product cell 
line is not stable, the best strategy is to operate at a low pooling interval i.e. the 1-day 
pooling option.
b) The company has existing downstream equipment in their facility.
As indicated in Table 5.9, in the second scenario where the downstream equipment 
scale was similar across all pooling options, the expected total COG/g decreases as 
the pooling intervals increases. Since the pooling options have similar indirect 
overheads, as the pooling interval increases, the decrease in expected COG/g is 
attributed to the differences in the direct costs incurred. The expected direct cost 
outputs on a task category basis for pooling intervals of 1, 15 and 30 days are plotted 
as shown in Figure 5.12. The costs are relative to the case of a pooling interval of 1 
day. Longer pooling intervals require less lot processing in the downstream due to 
less frequent pooling of eluate from the affinity chromatography. The direct COG/g 
drops as fewer equipment-preparation and regulatory-compliance steps are required. 
As the processing volume from the affinity chromatography increases for longer 
pooling intervals, multiple cycles (e.g. chromatography tasks) and longer cycle times 
(e.g. membrane filtration tasks) are used for each lot in the downstream recovery 
steps, thereby reducing the number of equipment-preparation steps. In addition, with 
less lot processing, operating at longer pooling intervals results in reduced 
regulatory-compliance overheads since such tasks are executed at the end of each lot 
rather than each cycle. It is apparent that the 1-day pooling strategy is inferior to the 
other two options, because of the higher annual running costs. The significant cost 
difference can be attributed to the increased lot processing in the downstream section 
at lower pooling intervals. The 15- and 30-day strategies are seen to offer significant
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reductions (18% and 21% respectively) in operating costs relative to the 1-day 
pooling case. However, the 1-day pooling option possesses improved utilisation of 
DSP equipment since such strategy processes more lots in the downstream section 
due to the daily processing of eluate from the affinity chromatography.
In the plot of risk against the expected cost, the results are conflicting. Examining 
the data in Figure 5.11b indicates that the 30-day option has the lowest expected 
COG/g. However, this option possesses the highest risk. On the other hand, the 1- 
day pooling option has the lowest risk but highest expected cost. The expected 
COG/g results between the 15- and 30-day options are close, though the 30-day 
option offers a slight advantage. However, as seen in Table 5.9, the 30-day option 
fails to meet the output criterion of 19kg and is therefore rendered non-feasible. The 
15-day strategy emerges as the more favourable option, which meets the output 
target. In this particular scenario, the simulation results suggest that given the fixed 
DSP capacity of the 1-day pooling option, the strategy of pooling every 15 days 
combined with maintaining the output target is more practical.
Relative direct cost of 
goods per gram
□  Regulatory-Compliance Tasks
□  Equipment-Preparation Tasks 
■  Product-Manufacture Tasks
Pooling interval (Days)
Figure 5.12. Expected annual direct COG/g on a task category basis for pooling 
intervals of 1, 15 and 30 days. The pooling options have the same DSP equipment 
scale. Values are relative to a pooling interval of 1 day.
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c) The product is unstable and the company has existing downstream equipment in 
their facility.
Examining the cost data in Table 5.9 reveals that the 15-day option is ranked first 
based on the COG/g criterion. However, the 15- and 30-day pooling options fail to 
meet the output criterion and are therefore not viable. Given the existing operating 
conditions, the 1-day option appears to be the only solution. These results again 
indicate that the 1-day pooling strategy is the most appropriate option when the 
product cell line is unstable.
5.7. Conclusions
The case study demonstrates the functionalities of the tool to output the cost of goods 
on a task basis, view the demands on resources and compare the effect of QC/QA 
and batch documentation activities under different production strategies. The 
simulation results show the cost reduction of QC/QA overheads at longer pooling 
intervals. The results drawn from the study provide indications of the operational 
costs incurred to accomplish project execution. The tool also generates indication of 
the appropriate resources (staff) to carry out the manufacturing tasks efficiently. The 
analysis of the outcomes of the Monte Carlo simulations highlights the benefits of 
incorporating uncertainties that may affect operational costs and output. In this 
particular case study, the 1-day pooling option was shown to be favourable when the 
perfusion process was subject to numerous risk factors. Critical factors such as the 
stability of product and downstream equipment scale that may affect the decision 
were identified through scenarios analyses to improve the robustness of the decision­
making process. The simulation tool could be used to minimise the risk of adopting 
an inappropriate operating strategy and enhance the quality of decision-making 
within a company. The application of such a tool is taken a step further in the next 
chapter to compare the economic feasibility of fed-batch and perfusion cultures.
The configuration of the tool enabled the scenarios set out in this case study to be 
evaluated efficiently. Customised features for user-defined probability distributions 
of uncertain parameters were incorporated so as to provide the capability to represent 
the inherent randomness in biomanufacturing. Such a tool facilitated the Monte
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Carlo simulation approach to be carried out by specifying the relevant input 
probability distributions for each of the process uncertainties. The tool output the 
simulation results from each trial run to Excel and hence generated a range of 
possible outcomes. This enabled the plotting of the frequency distributions of key 
output parameters and the tabulation of various useful statistical summaries. The 
main disadvantage of the tool was the lengthy computational time required to 
complete a Monte Carlo simulation run. The latter issue is addressed in the further 
work section in Chapter 7.
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C hapter 6
A Further Application: 
Fed-batch versus Perfusion Culture
6.1. Introduction
Recombinant expression in mammalian cell cultures is the principal means for the 
commercial production of therapeutic proteins such as monoclonal antibodies 
(Mabs). The cultivation of such cultures can be operated in fed-batch or perfusion 
modes. The fed-batch operation has been widely adopted due to its operational 
simplicity. However, considerable progress has been made to improve the operation 
of perfusion cultures, thus making large-scale perfusion an increasingly feasible 
option for cell culture. To date, limited research however has been published to 
compare the production economics of fed-batch and perfusion culture. In this 
chapter, the simulation tool, BioPharmKit, was employed to evaluate the economic 
feasibility of both culture modes via a case study. The case study is based upon the 
large-scale production of a therapeutic Mab. The study aims to investigate the 
relative economics of the two operational modes through the application of the tool 
by examining key performance metrics such as the cost of goods per gram (COG/g) 
and the net present value (NPV). Other parameters of interest include the capital 
investment, media consumption and the resource utilisation profiles.
Chapter 6. A Further Application: Fed-Batch versus Perfusion Culture
The decision-making situation is often characterised by uncertainties arising from the 
manufacturing process. Incorporating the effects of risk analysis would help to 
estimate the potential risks associated with probabilistic factors that may impact key 
performance measures. Decision trees and Monte Carlo simulations are typical tools 
used for risk analysis (Doctor et a l, 2001). The decision tree technique provides a 
highly effective framework where possible options are laid out with their values of 
outcomes and associated probabilities of achieving them. Such a technique provides 
a simple but useful method to compute the expected values of output parameters and 
make decisions based on such values. The expected value of each option is 
computed by multiplying the outcome with the probability in each path and then 
adding the weighted values of all the paths. However, the decision tree approach 
does not explicitly acknowledge the range of uncertainty and is not ideal for events 
that could happen simultaneously. For more complicated problems, the Monte Carlo 
simulation technique is a practical way of specifying the input probability functions 
of uncertain factors to imitate the randomness inherent in biopharmaceutical 
manufacture. Sample values are randomly generated by using the input probability 
distribution for each uncertain quantity and then used to determine a trial outcome 
for the model. Such a sampling process leads to a range of possible outcomes for a 
desired measure of metric. These can be used to generate the frequency probability 
distributions of designated outputs and key statistics such the likelihood of not 
achieving or exceeding a critical threshold value. The relative ease of using such risk 
analysis methods for decision-making is also investigated in this chapter.
For this chapter, Section 6.2 focuses on the case study that describes the fed-batch 
and perfusion modes of operation used for the commercial production of Mabs. A 
detailed analysis of the deterministic simulation results is provided in Section 6.3. In 
Section 6.4, the uncertainties in the process are identified and a sensitivity analysis 
carried out to investigate the impact of influencing factors on key output parameters. 
In Section 6.5, a risk assessment is performed using a simple decision tree method to 
imitate the randomness inherent in the process. A Monte Carlo simulation technique 
is also employed to provide a more complete estimation of the overall uncertainty so 
that the possible range of outcomes can be obtained and the resulting frequency 
distributions can be used to make probabilistic statements about the original problem. 
Lastly, a conclusion is provided in Section 6.6.
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6.2. Case Study Background
6.2.1. Case Study Set-up
The examples developed in this chapter are based on a biopharmaceutical company 
developing a therapeutic Mab expressed in mammalian cells for commercial use. 
The company faces the question of whether to adopt fed-batch culture in the 
manufacturing facility or to opt for a plant utilising perfusion culture. During early 
phase process development, a company may expect to have little supporting data 
regarding the feasibility of fed-batch and perfusion cultures but they may wish to 
investigate the differences between such operational modes. The case study was 
used to explore the functionalities of the tool to provide cost estimates, perform mass 
balance calculations, simulate resource handling, and evaluate potential risks so as to 
predict the feasibility of fed-batch and perfusion cultures. The potential advantages 
and disadvantages of the two operational modes are highlighted in Chapter 2. The 
decision to manufacture the therapeutic Mab using the fed-batch operation typically 
requires an investment that is largely front-loaded owing to the need for a larger 
bioreactor capacity. The use of perfusion culture is attractive since such an 
operational mode can achieve a higher productivity in a relatively small size 
bioreactor as compared to fed-batch culture. However, perfusion processes can 
suffer from increased contamination and equipment failures due to the extended 
culture cycle.
The relative merits and limitations of these two operational modes are explored with 
the help of technical and financial indicators. The key performance metrics used to 
compare the manufacturing strategies were the utilisation profiles of resources and 
COG/g. The cost analysis was extended to include other profitability indicators such 
as the NPV and the internal rate of return (IRR). Other key outputs included the 
capital investment, payback period and the levels of media consumption.
Table 6.1 summarises the key assumptions in process inputs between fed-batch and 
perfusion modes of operation validated through discussions with industrial experts 
(e.g. B. Fish, Cambridge Antibody Technology, Cambridge, UK; J. Wayte, Lonza 
Biologies, Slough, UK and R. Francis, Protherics Pic., London, UK). As indicated in
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the table, a more extensive seed fermentation train is needed with fed-batch culture 
due to the larger volume of the final production bioreactor. By comparison the 
continuous perfusion systems have shorter seed trains but increased operational cycle 
times and lower titres. Both processes were designed to produce 51kg of a Mab 
product per year, which is a typical industrial figure. The duration of the production 
fermentation for the fed-batch and continuous perfusion processes were given typical 
average values of 15 and 35 days respectively. Typical antibody titres in fed-batch 
cultures are in the range of grams per litres, with lg/L being the norm (Personal 
communication: J. Wayte, Lonza Biologies, Slough, UK). The fed-batch process 
was assumed to have a titre of lg/L. In order to achieve the same annual product 
output as the fed-batch option, the fermentation titre of the perfusion process was 
designed to be 0.35g/L. Such a titre value was reasonable, as discussed in the 
literature review provided in Chapter 2. In this case study, emphasis was placed on 
the application of the tool to compute cost estimates, perform mass balance 
calculations and carry out risk analysis. While sensible inputs were sought, the main 
purpose was to demonstrate the functionalities of the tool to asses manufacturing 
alternatives, hence the simulation results were not definitive answers.
Table 6.1. Key assumptions for fed-batch and perfusion modes of operation.
Assumption Fed-batch Perfusion
Size of production bioreactor (L) 
(working volume)
5,000 1,000
Seed bioreactor train (L) 20; 100; 500 20; 100
No. of production bioreactors 1 1
Duration of production fermentation (days) 15 35
Fermentation titre (g/L) 1.0 0.35
Figure 6.1a illustrates the process flowsheet for the production of a therapeutic Mab 
from mammalian cell culture produced by a fed-batch mode of operation. There are 
a number of feeding approaches for a fed-batch process operation, each of which 
affects the initial starting volume. Typically strategies involve one or two continuous 
feeds of 10-50% of the final reactor volume added over a period corresponding to
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40-70% of the total process duration. In this case study, one continuous feed volume 
of 30% added over approximately 65% of the total process time was considered, i.e. 
3,500L initial volume with addition of 1,500L over 10 days. Centrifugation was then 
used for the removal of cells from the product-containing media. This was followed 
by a series of purification steps.
Figure 6.1b depicts the production process for the antibody-based product using a 
perfusion mode of operation. A continuous perfusion rate of 1 reactor volume per 
day was assumed. During the perfusion culture, cells were retained in the bioreactor 
and liquor containing the product was collected. The collection of the product- 
enriched liquor commenced after 5 days when a constant growth rate was achieved. 
The harvested liquor collected daily was loaded onto the affinity column, eluted as 
purified product and stored in disposable bags. The concentrated eluate from 15 
successive chromatography runs was then pooled and passed through the other 
purification steps comprising the complete process.
(a) (b)
Centrifugation Affinity chromatography
Pool
Series of purification steps
Affinity chromatography
Inoculum grow-up
Series of purification steps
Inoculum grow-up
Seed fermentation 
20L, 100L, 500L
Seed  fermentation 
20L, 100L
5.000L Production fermentation by 
fed-batch culture
1,000L Production fermentation by 
perfusion culture
Figure 6.1. An overview of the mammalian-based process flowsheet for Mabs 
production using (a) fed-batch and (b) perfusion culture. In each case, the recovery 
stages are assumed to have the same product yield.
- 1 5 5 -
Chapter 6. A Further Application: Fed-Batch versus Perfusion Culture
Besides these product-manufacture tasks, ancillary activities such as equipment- 
preparation (e.g. cleaning-in-place (CIP), sterilising-in-place (SIP)) and regulatory- 
compliance (e.g. quality control (QC), quality assurance (QA) and batch 
documentation) ran simultaneously during the simulation in both modes of operation. 
The CIP task for the equipment resource and the regulatory-compliance steps was 
invoked after the completion of each unit operation. The SIP task for certain 
equipment was activated prior to the start of the unit operation.
Both processes were designed to use the same sequence of purification steps and to 
have similar equipment sizes (Table 6.2). Since the fed-batch and perfusion systems 
have almost similar downstream steps, it was assumed that equivalent overall 
recovery yields were achieved. There was only one production train in each 
manufacturing option. The plant would operate seven days a week and 48 weeks a 
year. In the fed-batch case, a new batch was initialised after the completion of the 
inoculum grow-up stage (allowing for turnaround). For the perfusion case, the 
duration of the production fermentation step (35 days) was more than double that of 
the fed-batch case (15 days); hence the new batch was initialised such that the seed 
fermentation sequence would finish just in time for the production fermenter to be 
available again. This scenario reflected a typical situation in industry where 
scheduling is set so as to fully utilise the process equipment. A simplification for the 
case study was that media and buffer arrived pre-made and sterile in disposable bags. 
In this case study, the aspects of product stability were not dealt with.
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Table 6.2. Downstream equipment sizes for the fed-batch and perfusion systems.
Size*
Manufacturing task Resource pool name ---------------------------------
Fed-Batch/Perfusion
Affinity chromatography Affinity chromatography rig & 
column
V = 45L; H = 15cm; 
D = calculated
Chemical retrovirus inactivation Virus inactivation tank V =  1,500L
Concentration/Buffer exchange 1 Diafiltration pellicon cassettes A = 20m2
Ion exchange chromatography Ion exchange chromatography rig 
& column
V = 45L; H = 15cm; 
D = calculated
Virus reduction nanofiltration Virus reduction filter A = 3m2
Concentration/Buffer exchange 2 Diafiltration pellicon cassettes A = 30m2
Gel filtration chromatography Gel filtration chromatography rig 
& column
V = 80L; H = 50cm; 
D = calculated
Final filtration Cartridge filter A = 2m2
* Verified through discussions with industrial experts (e.g. R. Francis, Protherics Pic., London, UK; J. 
Savery, J. & R. Spurling, Biopharm Services Ltd., Chesham, UK)
6.2.2. Methods
In this case study, the perfusion model built in the previous chapter based on a 
pooling interval of 15 days was employed. The input value for the fermentation titre 
was changed to 0.35g/L. For the fed-batch model, the same model was employed 
with some modifications. The perfusion block was replaced by the customised fed- 
batch fermentation block with a fermentation titre of l.Og/L. A centrifugation unit 
operation was connected to the output connector of the fed-batch production 
fermentation block. An additional seed train block was cloned from the library and 
connected to the USP sequence. The equipment-preparation tasks of CIP and SIP 
were created for this seeding step. The sizes of the seed train were updated 
according to the specifications in Table 6.1.
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The decision-support tool, BioPharmKit, developed in Extend was used to model the 
two scenarios independently and the results compared at the end of the simulations. 
Initially deterministic cases were simulated to establish the values of the base case 
output parameters. The simulation outputs were again verified with industrial 
experts to validate the results. The deterministic analysis does not account for risk 
factors that may affect the performance metrics (i.e. annual output, COG/g and 
NPV), which are pertinent to the process of decision-making. To take into account 
the inherent variability of process factors, the key uncertainties in the system were 
identified and a sensitivity analysis was then performed to investigate the impact on 
output parameters. The uncertainties were the fermentation titre, process yield, Lang 
factor, media cost, CIP reagents cost and processing reagents cost, which were used 
in the approach to determine the sensitivity of the base case to variability in process 
parameters. Each of these variables was subjected to ±x% change, keeping all other 
variables at the baseline values.
Both the decision tree and Monte Carlo simulation techniques were then employed to 
incorporate risk factors such as contamination and filter fouling. The decision tree 
method was used to provide a simple and efficient evaluation of manufacturing 
alternatives by incorporating the probabilities of contamination and filter fouling. 
The probable scenarios were envisaged and the tool was used to run each of these 
scenarios independently. For example, one possible scenario involved the situation 
where only one bioreactor run was being contaminated. The risk-adjusted values in 
each probabilistic case were determined and set-up using a decision tree in an Excel 
spreadsheet so as to compute the expected values. To simplify the decision tree 
analysis, process uncertainties (e.g. fermentation titres and downstream process 
(DSP) yields) were given typical average values. In order to provide a more 
complete estimation of such uncertainties, a Monte Carlo analysis was then 
performed to incorporate the randomness in biopharmaceutical manufacture subject 
to fluctuating fermentation titres and process yields. Probability distributions were 
assigned to these inputs and simulations were run to determine the distribution of 
possible outcomes for the outputs. The simulation results from each method were 
analysed in order to compare the relative usefulness and limitations of these two risk 
analysis methods for decision-making.
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6.3. Deterministic Results and Discussion
The tool predicted that the fed-batch plant would be able to achieve 19 bioreactor 
runs (19 lots) per year, as opposed to 9 bioreactor runs in the perfusion case. The 
lower number of runs in the perfusion option can be attributed to the longer 
fermentation cycle. By pooling the concentrated eluate from 15 successive 
chromatography runs in the perfusion case, the plant generated a product output of 
18 lots per year.
6.3.1. Resource Utilisation Profiles
Figures 6.2a and b depict the media utilisation over time for fed-batch and perfusion 
operation respectively. Figure 6.2a indicates a variable demand for media during 
successive fermentation runs in the fed-batch system. The spiky peaks during the 
start of the fed-batch process are due to the sequence of build-up seed steps and the 
high initial starting volume assumed followed by a gradual addition of fresh medium. 
Figure 6.2b highlights a constant demand on media over the bioreactor runs in the 
perfusion process. The simulation results predicted a 2.6 fold increase in media 
consumption in perfusion relative to fed-batch operation. This is due to the need in 
perfusion for a continual addition of a steady volume of media over the extended 
fermentation cycle time. This is one factor that has implications for the direct costs 
of the two processes.
3500
3000
|  2000
§  1500
S  1000
500
50 100 150 
Time (Days)
200 250 300
(b)
3500 
3000 
S  2500
ID TJ
g 2000
0
|  1500
M
1  1000
500 
0
0 50 100 150 200 250 300
Time (Davs)
Figure 6.2. Utilisation of media for the (a) fed-batch and (b) perfusion mode of 
operation. The curves show more spiky peaks in demand for media in the fed-batch 
system.
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Examples of the demand on the production operators for successive batches are 
illustrated in Figures 6.3a and b for the fed-batch and perfusion processes 
respectively. The average utilisation of staff is 3.4 and 3.6 operators respectively but 
demand on the production operators is highly intermittent. The graphs highlight the 
level of peak demand and when they occur. In practice these peak demands could 
be accommodated with four operators and occasional double-shift working, balanced 
by days off during the less busy parts of the process. The peaks could also be 
reduced or removed by adjusting the detail of the production schedule or adopting 
flexible use of operators from other parts of the facility.
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Figure 6.3. Utilisation of production operators for the (a) fed-batch and (b) perfusion 
mode of operation. The computed average utilisation of operators was 3.4 and 3.6 in 
the fed-batch and perfusion systems respectively.
The utilisation of USP and DSP equipment for successive batches is plotted in the 
Gantt charts in Figures 6.4a and b for the fed-batch and perfusion option 
respectively. The horizontal bars represent the utilisation time of the equipment. 
The equipment can be in use for either the product-manufacture or equipment- 
preparation steps. The seed train fermentation is scheduled such that there is 
minimum lead time between the completion of one batch and the initialisation of the 
next batch. The two manufacturing strategies possess different USP equipment 
utilisation characteristics. The figures indicate that there are more seeding batches in 
fed-batch as compared to the perfusion option. The shorter culture cycle in fed-batch 
necessitates more upstream seeding batches, hence the USP equipment is more fully
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utilised in the fed-batch option. The affinity chromatography has a higher rate of 
utilisation in the perfusion mode due to the need for the daily harvest of liquor to be 
loaded onto the column. The remaining DSP equipment in both options possess 
similar utilisation characteristics.
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Figure 6.4. Gantt charts: Utilisation of equipment for (a) fed-batch and (b) perfusion 
mode of operation.
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6.3.2. Economic Evaluation
The economic feasibility of the fed-batch and perfusion processes is summarised in 
Table 6.3. The perfusion values are relative to the fed-batch case. As expected, the 
use of fed-batch culture translates into a higher capital burden. The tool predicted 
that the perfusion option offers a significant reduction (42%) in the fixed capital 
expenditure relative to the fed-batch case due to the need for a smaller seed 
fermentation train and lower overall fermentation volume. Hence, the perfusion 
plant benefits from lower initial investment costs and seems attractive for a start-up 
company with potentially tight cash reserves. Comparison of the annual COG/g 
shows the two systems to be very similar, although the perfusion option offers a 
slight edge with a 3% reduction in the COG/g as compared to the fed-batch. The 
NPV of the perfusion strategy increases by 12% relative to the fed-batch process. 
The IRR of both cases was also computed. This value corresponded to 36% and 
52% in the case of fed-batch and perfusion respectively. The perfusion option seems 
more economically feasible because of its higher NPV and IRR.
Table 6.3. Simulation results for key economic parameters. The perfusion values are 
relative to the fed-batch case.
Output parameters Fed-batch %  change in perfusion relative to fed-batch
Fixed capital investment $24 million -42%
Cost o f goods per gram, COG/g $530/g -3%
Net Present Value, NPV $57 million +12%
Internal rate o f return, IRR 36% +16%
Figure 6.5 illustrates the cumulative cash flow of the two manufacturing options 
assuming a construction period of 3 years and a subsequent plant life of 10 years. 
The intersection of the curve with the x-axis indicates the payback time. The fed- 
batch option would take a longer time (5.4 years) to recover the original investment 
as opposed to the perfusion option (4.6 years). This can be attributed to the initial 
higher up-front investments required in the fed-batch option.
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Figure 6.5. The diagram illustrates the cumulative cash flow of the process at a 
given year with a discount factor of 9%. The intersection of the curve with the x-axis 
indicates the payback time of the project.
It is possible to view the operating costs on a category basis (Figures 6.6a-c). Figure 
6.6a shows the total COG/g broken down into direct (variable) costs such as the 
materials, utilities, staff and indirect (fixed) overheads such as the capital charge, tax, 
insurance and maintenance. The costs are relative to the fed-batch case. Although 
the total annual COG/g is similar for both options, the ratio of direct to indirect costs 
varies in each case. It is apparent that the COG/g in both the fed-batch and perfusion 
processes is dominated by the direct costs, which represent 62% and 76% of the total 
costs respectively. Although the fed-batch plant has lower direct costs as compared 
to the perfusion culture, the larger equipment scale contributes to higher indirect 
costs, thus increasing the overall costs. The capital charge is computed at an annual 
compound interest rate of 10% on the fixed capital investment over an operating 
plant life of 10 years. On this basis, it was expected that the perfusion plant would 
have a lower annual capital charge. The simulation results predicted a 10% decrease 
in the annual capital charge relative to the fed-batch case. Since the other fixed 
overheads costs (local tax, insurance, maintenance and general utilities) are 
proportional to the capital investment required, which is higher in the fed-batch case, 
these costs are significantly higher at about 14% of the total COG/g in the fed-batch 
option and decrease to about 9% in the perfusion system.
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Figure 6.6b shows the annual direct cost outputs categorised under fermentation, 
purification and ancillary task headings. Again the costs are relative to the fed-batch 
case. Comparing these direct costs revealed a 21% increase in fermentation costs for 
perfusion culture due to the higher levels of usage of media and associated labour 
over the longer fermentation cycle. Examining the costs of the ancillary tasks 
(equipment-preparation and regulatory compliance activities) indicates that they 
represent 60% of the total direct costs in the fed-batch process, which falls to 42% in 
the perfusion process. The ancillary operation costs are higher under fed-batch 
operation due to the increased amount of resources required to clean and sterilise a 
larger production fermenter, as well as the higher frequency of CEP and SIP steps 
required with more bioreactor runs per year.
The annual direct COG/g can be further broken down to view the operational cost 
distributions of individual unit operations in the process flow. This reflects the cost 
of the direct materials, utilities and labour allocated to each manufacturing activity, 
thus providing the capability to view where the resource costs are concentrated. 
Figure 6.6c shows the annual direct costs for each of the manufacturing tasks for 
both the fed-batch and perfusion processes. In the fed-batch process, the CIP step is 
the most resource intensive and the most expensive task. The CIP costs include the 
direct costs incurred in the utilisation of labour and WFI, CIP buffer. This highlights 
the cost burden of cleaning operations in the fed-batch operation. In the perfusion 
process, the production fermentation contributes the most to the direct costs, 
followed by the CIP activities. The high fermentation production costs are mainly 
due to the higher usage of costly pre-made media in disposable bags over the 
extended perfusion culture cycle. This result implies that the process development 
might usefully seek ways to cut down the costs of media perhaps by in-house 
preparation rather than using ready-made media in disposable bags. Affinity 
chromatography tasks in both systems contribute to the direct cost but to a relatively 
less significant level. The remaining unit operations each make a minor contribution 
to the total direct COG/g.
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Figure 6.6. Distribution of production cost showing breakdowns for the (a) relative 
total annual expenses, (b) relative annual direct COG/g and (c) annual direct COG/g 
on a manufacturing task category. The perfusion values in (a) and (b) are relative to 
the fed-batch option.
6.4. Sensitivity Analysis
The range of values for the key input uncertainties in the process (Table 6.4) was 
determined from literature sources and through discussions with industrial experts. 
These values were selected to be a reflection of likely fluctuations occurring within 
similar batches for a single product. A sensitivity analysis was carried out for each 
variable to investigate the impact of variations in the initial assumptions on the 
output parameters. Such sensitivity analysis could help to determine the feasibility 
and attractiveness of the fed-batch and perfusion systems when individual financial 
and technical parameters in the process vary. The results in Figures 6.7a-f depict the
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percentage change in the COG/g for key process uncertainties (e.g. fermentation 
titre, DSP yield, Lang factor etc.) for both fed-batch and perfusion systems. The 
perfusion values are relative to the fed-batch case.
Table 6.4. Sensitivity scenarios set-up.
Input variable Worst Base Best
Fermentation titre -25% 1 .Og/L (fed-batch) 
0.35g/L (perfusion)
+25%
DSP yield -5% 55% +5%
Lang factor 8 6 4
Media cost +25% $20/L -25%
CIP reagents cost +25% $5/L (CIP buffer) 
$1/L (WFI)
-25%
Processing reagents cost +25% $5/L -25%
The main factor influencing the COG/g is the fermentation titre, followed by the 
DSP yield. As indicated in Figure 6.7a, a ±25% change in fermentation titre 
represents a ±17% change in the annual COG/g in the fed-batch process. In 
perfusion, a 25% increase in the fermentation titre corresponds to a 19% drop in the 
COG/g relative to the fed-batch.
Since both manufacturing options were designed to have similar overall recovery 
yields and generate the same quantity of product annually, the gradients of the curves 
indicate that the COG/g of both strategies have the same degree of sensitivity to a 
change in the DSP yield (Figure 6.7b).
As indicated in Figure 6.7c, the COG/g in the fed-batch system is less susceptible to 
changes in media cost than under the perfusion mode of operation. A 25% reduction 
in media cost lowers the COG/g by 11% in the perfusion system as compared to a 
2% decrease in the fed-batch process. The COG/g value of the perfusion system is 
relative to the fed-batch case. This is attributed to the fact that the media cost is a 
major contributor to the COG/g in the perfusion system. A point of intersection
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occurs at a 10% increase in the cost of media ($22/L), where both modes of 
operation have the same COG/g values. As the cost of media increases beyond 
$22/L, the lower sensitivity of the fed-batch mode to this variable results in this 
mode of operation being more economically attractive than perfusion.
The CIP reagents cost has a relatively significant effect on the COG/g in both culture 
modes (Figure 6.7d). The CIP reagents included the CIP buffer and WFI, which are 
used for cleaning equipment (e.g. fermenters, chromatography skids). This reflects 
the large usage of buffer for cleaning steps. A 25% increase in the cost of CIP 
reagent leads to increases in the annual COG/g by about 7% and 2% in the fed-batch 
and perfusion systems respectively. Again, the perfusion value is relative to the fed- 
batch case. In the best scenario, given a 25% reduction in the cost of CIP reagents, 
both the fed-batch and perfusion options have the same annual COG/g. The 
perfusion strategy seems more favourable than fed-batch as the CIP reagents cost 
increases from the best case.
The indirect costs of the COG/g are proportional to the Lang factor and the total 
equipment purchase cost. Since the fed-batch system has higher indirect costs, the 
COG/g is fairly sensitive to the Lang factor assumed (Figure 6.7e). The perfusion 
process is marginally less sensitive.
Figure 6.7f indicates that the cost of processing reagents contribute to a relatively 
less significant change to the COG/g in the fed-batch option. With a 25% increase in 
the reagents cost, the fed-batch option is comparable to the perfusion culture on the 
basis of COG/g.
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Figure 6.7. Sensitivity plots for (a) fermentation titre, (b) DSP yield, (c) media cost, 
(d) CIP reagents cost (e) Lang factor and (f) processing reagents cost. The values are 
relative to the fed-batch case.
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6.5. Decision-Making using Probability Information
Sensitivity analysis was employed in the previous section to determine the behaviour 
of the COG/g performance measure to ±x% changes in each uncertain factor and 
hence determine the stability of the base case. The analysis had considered 
uncertainties such as the fermentation titre, DSP yield and media cost. The variables 
that have the greatest impact on the performance measure were the fermentation titre 
and DSP yield. Risk factors such as batch contamination and filter fouling, which 
may affect the performance metrics, could not be captured by the sensitivity analysis 
method. Therefore, in this section, both the decision tree and Monte Carlo 
simulation techniques were employed to incorporate such uncertainties in order to 
evaluate the potential risk associated with each manufacturing option.
The construction of a fully expanded tree to take into account uncertainty in the 
fermentation titre, DSP yield, contamination and filter fouling would require a large 
number of possible outcomes to be considered and could be a time-consuming 
process. Hence, the fermentation titre and DSP yield were given average values. 
The effect of the range of such uncertainties could be investigated one at a time via 
sensitivity analysis using the decision tree framework. However, such an approach is 
not efficient. A Monte Carlo simulation method could be used to capture the degree 
of variability in the key influencing factors. The simulation results from each 
method can be interpreted in several ways to aid the decision-making process. The 
performance measures may show conflicting outcomes and the company may devise 
a strategy to indicate their preferences.
6.5.1. Decision Tree Analysis
6.5.1.1. Decision tree set-up
The key risk factors were the possibilities of contamination in both modes of 
operation and equipment failure due to filter fouling in perfusion culture. To take 
these factors into account, contamination probabilities, denoted as PFB and PPF , of
1% and 10% were incorporated in fed-batch and perfusion options respectively. The 
higher probability of contamination (10%) reflected the increased chance of a 
bioreactor run being contaminated in perfusion culture. In addition, the probability
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of filter clogging, PPF , (10%) was added to reflect the risk of equipment failure in
perfusion culture. These values were determined through discussions with industrial 
experts (e.g. Francis, R., Protherics Pic., London, UK; Hoglund, E., Lonza Biologies, 
Portsmouth, USA). In reality, the risk of contamination and equipment failure could 
occur randomly during the fermentation process. For the decision tree analysis, the 
day on which the risk factors occurred were chosen to reflect likely events that could 
happen. The main purpose was to demonstrate the use of the decision tree 
framework to carry out risk analysis. It was assumed that the point of contamination 
occurred on Day 15 in both processes. In fed-batch, the entire broth in a bioreactor 
run would be lost. In perfusion, the daily pooling process results in the continual 
retrieval of the broth in a bioreactor run until contamination occurs. The mechanical 
failure of the filter was assumed to occur on Day 20 in the perfusion option. Upon 
the detection of contamination or filter clogging, the culture was then terminated and 
a new batch initiated. The average recoverable fermentation titres were lg/L and 
350mg/L for the fed-batch and perfusion systems respectively while the average DSP 
yield was 55% for both systems.
The different probable scenarios were envisaged and illustrated using a decision tree 
(Figure 6.8). The decision tree was set-up using an Excel spreadsheet. Each branch 
has an associated probability of occurrence. The Choose function, nCk , in
probability mathematics is employed to determine the number of total possible 
outcomes and the subsequent computation of the probability of each path. The index 
n equals the total scenarios to choose from and k equals the number of scenarios to 
be chosen. For example, 9CX (which equals 9) in the fed-batch option computes the 
number of possible outcomes where one out of nine bioreactors is contaminated. In 
the fed-batch option, the possible scenarios were the situations where none of the 
nine bioreactor runs were contaminated, followed by one bioreactor run being 
contaminated and so on. The software tool was used to run each scenario 
independently and to obtain the risk-adjusted performance metrics (i.e. annual 
output, COG/g and NPV). Simulation was carried out for subsequent scenarios, 
where the number of contaminated bioreactor runs was incremented by one, till the 
weighted value of the path became insignificant. The expected value of a given 
output parameter was calculated by multiplying the risk-adjusted value with the
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probability in each path and then adding the weighted values of all the paths for each 
manufacturing option. As shown in Figure 6.8, the expected value for the NPV of 
each manufacturing strategy was indicated in a box.
„  . ...... , .  o R isk-adjusted
Probability of contam ination, P f b c
No contamination in bioreactor runs/yr $57 million
(base  case)$56 m illion
1 bioreactor run is contam inated/yr
$51 million
,9C,*(0.01)(0.99),8=0.159
Fed-batch
2 bioreactor runs are  contaminated/yr
$45 million
'9C2*(0.01)2(0.99)17=0.014
Probability of contam ination, P p P robability  of filter fou ling, P p f ,
No filter fouling/yr
Tree
No contamination in bioreactor runs/yr Filter fouled in 1 bioreactor run/yr
9C ,*(0.1 )(0.9)8=0.387
Filter fouled in 2 bioreactor runs/yr
9Cj*(0.1 )2(0.9)7= 0 .172
No filter fouling/yr
Perfusion
1 bioreactor run is contam inated/yr Filter fouled in 1 bioreactor run/yr
9C,*(0.1)(09)8=0.387 9C,*(0.1)(0.9)8=0.387
$55 million Filter fouled in 2 bioreactor runs/yr
9Cj*(0.1 )2(0.9)7= 0 .172
No filter fouling/yr
2 bioreactor runs are contam inated/yr Filter fouled in 1 bioreactor run/yr
9C2*(0.1 )2(0.9)7=0.172 9C 1*(0.1)(0.9)8=0.387
Filter fouled in 2 bioreactor runs/yr
9C2*(0.1 )2(0.9)7=0.172
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NPV
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$57 million
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Figure 6.8. Decision tree with different probabilistic scenarios. Each branch has an 
associated probability of occurrence. The expected value for the NPV of each 
manufacturing strategy is indicated in the box.
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Besides the expected values, the standard deviation of each performance measure 
was also computed. The equation for the standard deviation, a , can be derived from 
statistical textbooks and is given by
where [i = expected value,
X  = random variable.
6.5.1.2. Decision tree results and discussion
Using the decision tree analysis, the expected values and standard deviations for the 
annual output, COG/g and NPV are tabulated in Table 6.5. From the deterministic 
analysis, both processes were expected to yield a typical annual output of 51kg after 
purification. With the inherent risks in the processes, a more rational annual output 
criterion of at least 49kg is chosen for the purpose of discussion. By accounting for 
the risk of contamination, the expected value for the annual output of the fed-batch 
process has fallen by 0.5kg to 50.5kg with a standard deviation of 1.2kg. The drop in 
annual output is more significant for the perfusion process with a 4% shortfall in the 
amount of Mabs generated with respect to the output criterion value. The company 
may seek to improve the process in order to deliver the target demand of Mabs 
products. The expected values for the annual COG/g of both processes are similar. 
However, the perfusion strategy carries a greater risk in the annual COG/g since it 
has a higher standard deviation. The inherent randomness within the process has 
lowered the NPV to $56 million and $55.4 million in the fed-batch and perfusion 
systems respectively. It is apparent that the perfusion option seems less favourable 
because of its lower expected NPV and higher associated risks based on all the 
performance measures. In addition, the perfusion mode fails to meet the output 
criterion by a considerable amount (4% loss) and is therefore rendered non-feasible.
(6.1)
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Table 6.5. Decision tree analysis: Expected values and standard deviations for the 
key performance measures.
Performance metric Statistic
Value
Fed-Batch Perfusion
Annual output (kg) Expected value 50.5 47.0
Standard deviation 1.2 4.0
Cost o f goods per gram ($/g) Expected value 540 540
Standard deviation 10 40
Net present value ($ million) Expected value 56.0 55.4
Standard deviation 2.6 7.2
The primary benefit of the decision tree is that it provides an illustration of the 
decision-making process. Such a method emphasises the two competing alternative 
choices and identifies possible outcomes and their probabilities of occurrence. The 
rule for interpreting the decision tree is to select the path which either maximises 
value or minimises cost. For example, based on the decision tree analysis, the 
company would probably opt for the fed-batch option, which yields a higher 
expected NPV value. The decision tree facilitates the calculation of revised 
probabilities of occurrence and the subsequent computation of the expected values. 
As an illustration, the probabilities of the risk factors were varied and contour plots 
were generated to determine the feasible operational regions for the perfusion option.
Figures 6.9a and b illustrate the regions where percentage change in the annual 
output and NPV of the perfusion option are plotted as a function of the 
contamination and fouling probabilities, PPFf and PPF . The NPV values are relative
to that of the fed-batch option ($56 million) with PFB =1%.  The annual output is
relative to the annual criterion of 49kg. As illustrated in Figure 6.9a, any operation 
within the white area would result in a negative NPV relative to the fed-batch. The 
region below the white area indicates the feasible operational domains where the 
perfusion is economically more attractive than the fed-batch process in terms of 
NPV. However, in order to meet the annual output criterion of 49kg, the shaded
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region above the solid line (Figure 6.9b) is not feasible. For example, although 
operating at point ‘A’, where PPF = 10%, and PPF = 8%, can achieve a higher NPV
relative to fed-batch, it has an expected production mean of less than 49kg and hence 
is unacceptable. On the other hand, operating at point ‘B ’ can meet the output 
criterion and yield a higher NPV than the fed-batch option. If the process was 
believed to be operating with a PPF of 10%, then the maximum tolerable PPF would
be 5% (point ‘C ’).
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Figure 6.9. The surface contour plot illustrates the percentage change in (a) NPV and 
(b) both the annual output and NPV of the perfusion culture as a function of PPF and
PPF/ . AMabs represents the percentage change in the annual output relative to the
output criterion of 49kg and ANPV is the percentage change in NPV relative to that 
of the fed-batch culture.
6.5.I.3. Conclusions
The decision tree method is both simple and effective. The tool facilitated the setting 
up and simulation of the probable scenarios in the decision-tree. However, decision 
trees do have some weakness associated with their use. The actual construction of a 
decision tree can be a time-consuming process for each project. In this particular
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case study, the fermentation titre and DSP yield were given average values to 
simplify the assessment of the decision tree approach. If the variations in these 
factors were taken' into account during the analysis, the tree would become very 
complicated to account for all the possible combinations of titres, DSP yields, 
possibilities of contamination and filter fouling. This would require several 
additional simulation runs for all the possible scenarios and it would become 
inefficient to carry out the decision tree method. Also, decision trees are not ideal for 
parallel events that could happen. An example is the simultaneous occurrence of 
both contamination and filter clogging in a single perfusion run. Such an approach 
does not explicitly acknowledge the underlying uncertainty in each of the 
contributory estimates such as the range of process yields and the day on which 
contamination or filter fouling occurs. This is explored further in the next section 
using a Monte Carlo simulation technique to provide a more complete estimation of 
uncertainties.
6.5.2. The Monte Carlo Approach
6.5.2.I. Monte Carlo set-up
The Monte Carlo model captured the same information as the decision tree method, 
but used it in a different way. The overall uncertainty was made more explicit in the 
Monte Carlo simulation, where the model quantified the uncertainty by allowing the 
ranges for the various activities to be estimated. Table 6.6 specifies the key input 
risk parameters considered, together with their ranges of values. The fermentation 
titre was subjected to a variation of ±25% and the DSP yield ranged between ±5% of 
the base value for both the fed-batch and perfusion systems. These two variables 
were given a discrete Normal distribution. PFB and PPF values of 1% and 10% were
incorporated in the fed-batch and perfusion systems respectively. A PPF value of
10% was added to the perfusion culture. The Input Random Number block provided 
in Extend was used to generate random numbers according to the distributions 
specified in Table 6.6. When executed, the model randomly generated a particular 
day between Day 1 and Day 30 on which a contamination or filter clogging occurs 
according to a negatively-skewed triangular distribution (i.e. contamination and filter 
fouling are more likely to occur towards the end of the fermentation run). Such a
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distribution was sensible since it represented the increased chances of failure over 
time. The Monte Carlo simulation technique was used to characterise the variability 
in the performance measures due to uncertainties in titre, DSP yield and risk factors. 
The following discussion highlights possible analyses that can be performed to 
interpret the data obtained from the Monte Carlo simulations and to compare the 
relative merits of the two options.
Table 6.6. Monte Carlo simulation set-up: Input risk parameters and their discrete 
probability distributions.
Variable
Fed-batch Perfusion
units
Value Probability Value Probability
Fermentation titre g/L 0.75 0.1 0.26 0.1
0.88 0.2 0.31 0.2
1.0 0.4 0.35 0.4
1.13 0.2 0.39 0.2
1.25 0.1 0.44 0.1
DSP yield % 50 0.1 50 0.1
53 0.2 53 0.2
55 0.4 55 0.4
58 0.2 58 0.2
60 0.1 60 0.1
Perfusion run contaminated? - Yes 0.01 Yes 0.1
No 0.99 No 0.9
Filter in perfusion run - - - Yes 0.1
clogged? No 0.9
6.5.2.2. Monte Carlo simulation results and discussion
The Monte Carlo simulation technique enables the range of possible outcomes to be 
generated by running the model many times and creates various statistical summaries 
featuring the designated outputs. Figures 6.10a-c depict the comparison of the 
probability frequency distributions for the performance metrics of both the fed-batch
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and perfusion systems. In addition to the computation of expected values and 
standard deviations of key performance measures, other statistics such as the 
likelihood of not achieving or exceeding a certain value are tabulated. Table 6.7 
summarises the key results of the Monte Carlo simulation for the fed-batch and 
perfusion systems and the ranking of the alternatives.
Comparing the distribution graphs in Figures 6.10a-c reveals that the fed-batch 
option presents a less risky alternative because the probability distributions of 
outcomes are much narrower. The actual standard deviations of each performance 
measure are given in Table 6.7. The perfusion strategy has higher associated risks 
based on all performance measures. The frequency distributions of all the 
performance metrics in the fed-batch option are nearly symmetrical.
Figure 6.10a indicates that the frequency distribution curve for the annual output of 
the perfusion option is bimodal. The two modes occur at 46kg and 50kg, with 
frequency probabilities of 12% and 18% respectively. The minor peak at 46kg 
represents a 5kg drop in the annual output as compared to the deterministic case. 
This corresponds to an average output of one perfusion run being lost. The loss in 
such a situation can be due to the occurrence of either contamination or filter fouling, 
or even both occurring simultaneously. The simulation results suggest the output 
will usually be around 50kg. However, there would also be a relatively high 
occurrence of an output of 46kg. From the data presented in Table 6.7, the 
uncertainties in process titres and yields, together with the risk factors, have shifted 
the annual production means to 49.5kg and 48.0kg in the fed-batch and perfusion 
options respectively. The probability of not achieving at least 49kg of Mabs 
annually is 21% in the fed-batch option. The perfusion strategy has a higher risk 
(42%) of not meeting the output criterion.
There exists a wide range of possible outcomes for the annual COG/g in both options 
(Figure 6.10b). The annual COG/g distribution graph for the perfusion option is 
skewed positively. While the majority of the COG/g values are clustered toward the 
lower end of the scale, the risk factors in the process have resulted in a relatively 
high score of COG/g values at the upper end of the scale. Although the modal 
COG/g is $520/g, the mean value has been shifted to $540/g. As indicated in Table
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6.7, both processes have comparable expected COG/g value but the perfusion option 
possesses a greater risk. In the fed-batch case, there is a 64% chance that the 
projected cost would exceed the baseline COG/g value derived from the 
deterministic analysis. This probability is higher (80%) in the perfusion case. These 
outputs draw attention to the need to reduce the variance in the cost of goods, which 
is especially true for the perfusion option.
For the NPV analysis, a threshold criterion of at least $56 million may be chosen to 
decide if the particular manufacturing strategy is feasible. Figure 6.10c indicates that 
the uncertainties in the process have shifted the curve towards the lower end of the 
scale. Interestingly the perfusion option is ranked first based on its expected NPV 
but second based on its standard deviation (Table 6.7). The probability of not 
achieving a NPV of at least $56 million is higher (52%) in the fed-batch option 
compared to 32% in the perfusion option. However, the results generated by the tool 
indicate that even though the perfusion option has a higher NPV, it has expected 
production mean below the 49kg target and is therefore not feasible. The fed-batch 
emerges as the more favourable option with a higher likely output and lowest 
associated risks based on all performance measures.
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Figure 6.10. Frequency distributions for the (a) annual quantity of Mabs generated, 
(b) annual COG/g and (c) NPV of both the fed-batch and perfusion systems.
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Table 6.7. Summary of key results for the Monte Carlo analysis of fed-batch and 
perfusion systems.
Performance metric Statistics
FB*
Value
PF*
Ranking 
order 
(best first)
Annual output (kg) Expected value 49.5 48.0 FB, PF
Standard deviation 1.9 4.5 FB, PF
P(Failing to yield at least 49kg of 
Mabs annually)
21% 42% FB, PF
Cost of goods per gram Expected value 540 540
($/g)
Standard deviation 20 70 FB, PF
P(Exceeding baseline COG/g 
value obtained by deterministic 
analysis)
64% 80% FB, PF
Net present value Expected value 55.4 57.0 PF, FB
($ million)
Standard deviation 5 .0 10.5 FB, PF
P(Failing to achieve an NPV value 
of at least $56 million)
52% 32% PF, FB
* FB/PF = Fed-batch/Perfusion
It is possible that the assumed chances of contamination and filter clogging in 
perfusion cultures are too pessimistic (Personal communication: Francis, R., 
Protherics Pic., London, UK; Hoglund, E., Lonza Biologies, Portsmouth, USA). 
Accordingly, two further scenarios ‘a’ (PPF = 5%; PPFf = 5%) and ‘b’ ( PPFr = 3%;
PPFj =3%)  were selected by varying both the probabilities of contamination and 
filter fouling in the perfusion option. The Monte Carlo simulation was used to run
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each scenario and determine the key output measures and their associated risks. 
Figure 6.11 is the bubble plot corresponding to the different scenarios. The various 
scenarios are plotted on an axis of the expected annual quantity of Mabs generated 
versus the probability of contamination. The size of the bubble is proportional to the 
reward/risk ratio. This ratio measures the expected NPV over the standard deviation 
in each scenario. The rejected scenarios are marked with a cross.
LU
52
51
48
47
Scenario 'b'
Fed-batch 
(base case)
Perfusion
Ppf, =3%
Scenario 'a'
Perfusion
PpFf =5%
Output criterion
Perfusion 
(base case)
P p p . = 1 0 %
8 10 12
Probability of contamination (%)
Figure 6.11. Bubble plot for the different scenarios. The x-axis corresponds to the 
expected annual quantity of Mabs generated and the y-axis represents the probability 
of contamination. The size of the bubble is proportional to the reward/risk ratio. 
This ratio measures the expected NPV over the standard deviation in each scenario.
It is intuitive that scenarios with a low probability of contamination, high likely 
output and high reward/risk ratios are preferred. The prioritisation of options based 
on bubble plots depends upon the risk attitude of the management. A risk-averse 
management might prefer scenarios with high returns and low risks, i.e. a high 
reward/risk ratio. The annual output criterion was set to be at least 49kg and the 
scenarios were ranked based on the reward/risk ratio. The perfusion base case, 
where PPF = 10% and PPF = 10%, is rejected since it fails the output criterion of
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49kg. Based on the bubble plot, for scenario ‘a’ where PPF = 5% and PPF = 5%,
although the perfusion option has expected production mean above 49kg, the 
reward/risk ratio is smaller than the fed-batch option. This is evident from the 
relative size of the bubble to the fed-batch process. This option is therefore rejected. 
Examining the data in Figure 6.11 indicates that by reducing both PPF( and PPF to
3% (scenario ‘b’), the perfusion option has a higher reward/risk ratio compared to the 
fed-batch strategy. Hence, considerable efforts are required to reduce both the 
probabilities of contamination and filter fouling in order to improve the reward/risk 
ratio so that the perfusion strategy is economically more feasible than the fed-batch 
option.
6.5.2.3. Conclusions
The tool developed and implemented in Chapter 3 has provided the built-in features 
for user-defined input probability distributions of uncertain variables. Such a tool 
enabled the setting up and simulation of the Monte Carlo technique efficiently. The 
number of simulation runs to reach convergence was determined by monitoring the 
running averages of the output parameters. The Monte Carlo approach offers more 
accurate results by quantifying and analysing uncertainties. Such a Monte Carlo 
simulation technique incorporates input values with probability distributions, 
generates the range of possible outcomes and enables the frequency probability 
distributions of performance metrics to be plotted. Besides the expected values of 
output parameters, it allows the determination of useful statistics such as the 
likelihood of failing to meet or exceeding a threshold value. However, unlike 
decision trees, Monte Carlo simulations do not explicitly recommend a course of 
action or make decision. Although the tool provided the ability to enable the input 
probability distributions of uncertain factors to be specified, the Monte Carlo 
approach is very time-consuming in terms of computation. Each simulation carried 
out in the decision-support tool required a substantial amount of time to complete a 
Monte Carlo run.
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6.5.3. Decision Tree versus Monte Carlo
The previous two sections have presented the use of the decision-support tool to 
evaluate the uncertainties inherent in bioprocesses using the decision tree analysis 
and the Monte Carlo simulation method. The tool had provided a suitable platform 
for these two different risk techniques to be carried out. Both techniques were 
efficiently implemented in the tool to obtain the simulation results. However, there 
were some weaknesses associated with the use of the tool to perform the risk 
assessment. Since the decision tree analysis required each possible scenario to be 
simulated independently to determine the outcome, the application of such a 
technique was unsuitable when there were a large number of scenarios to be 
considered. Hence, the application of the decision tree technique was efficient by 
limiting the number of possible scenarios. The main disadvantage of using the tool 
for the Monte Carlo approach was its relatively high computational time required to 
reach convergence. The computational aspect of the tool could be enhanced by 
improving the coding efficiency; this would be discussed in the future work in the 
next chapter.
6.6. Overall Chapter Conclusions
A computer-aided approach to the evaluation of the process economics of fed-batch 
and perfusion culture for the commercial production of Mabs has been presented via 
a case study. The deterministic analysis shows that whilst on the basis of COG/g, 
there is little difference between the two routes, the perfusion option benefits from 
lower capital investment and higher projected NPV. A sensitivity study indicated 
that the annual COG/g of both processes is most sensitive to the fermentation titre, 
followed by the DSP yield. The decision tree and Monte Carlo simulation 
techniques were employed to account for the possibilities of contamination and 
equipment failure. The information generated by the simulation studies can help to 
assess the feasibility of alternatives and provide a more holistic approach to the 
evaluation of manufacturing strategies. The decision tree analysis demonstrated that 
the perfusion option is inferior to the fed-batch process because of its lower likely 
output, lower expected NPV and higher risks based on all the performance measures.
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The viability of the perfusion process could be improved by reducing the rate of 
contamination and filter fouling. The feasible operational domains were illustrated 
in a surface contour plot where the perfusion option meets the output criterion and 
has a higher projected NPV than fed-batch. The Monte Carlo simulation technique 
demonstrated that although the perfusion option has a higher expected NPV, it fails 
the output criterion and hence is non-feasible. The critical failure rate at which the 
perfusion option is more favourable than fed-batch was identified.
This chapter highlights the benefits of using the decision tree technique to provide a 
graphical illustration of the decision-making process and as an aid in the evaluation 
of manufacturing alternatives based on expected values. Although the decision tree 
method provides a simple and efficient approach for risk analysis, it does not 
explicitly quantify the overall uncertainty. The Monte Carlo simulation method was 
therefore applied to provide a more accurate estimation of process uncertainties. 
Such a technique provides a way of incorporating probability distributions of input 
parameters to identify the range of possible outcomes and generate frequency 
distributions for performance measures. The main disadvantage of the Monte Carlo 
approach is its relatively high computational time required to reach convergence.
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Conclusions and Future Work
7.1. Introduction
With growing demand on the clinical pipeline, efficient manufacturing is emerging 
as a key issue in the biotech industry. The performance of manufacturing has a great 
influence on the timely delivery of drugs to the market and affects the financial 
health of a company. Global competition is driving the need to improve 
manufacturing efficiency through the need to achieve the following business and 
process objectives: accelerated time-to-market, improved process yields, maximised 
resource utilisation and reduced cost of goods. The need for computer-aided design 
tools to act in support of making the best business decisions relating to 
biomanufacture is becoming increasingly critical. Simulation tools can prove 
invaluable in the understanding of manufacturing systems, characterisation of unit 
operations and selection of process options; all of which contribute to better 
decision-making in the context of the business and process needs shaping the 
bioprocess sector. This final chapter summarises the contributions made in this 
thesis in exploring the possible development and deployment of a decision-support 
tool to aid the assessment of manufacturing alternatives from economic as well as 
process perspectives. It also recommends future work that can be carried out to 
address further issues in the biomanufacturing industry by the research.
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7.2. Overall Conclusions
An introductory background to the biopharmaceutical drug development and 
manufacturing pathway has been presented in Chapter 1. The recent surge in 
demand for antibodies has increased the need for large-scale efficient production of 
these biochemical entities. Early process development is necessary to enhance 
manufacturing operations in order to streamline timescales whilst containing costs. 
The application of computer-aided design tools is critical to aid process design and 
development of biochemical processes. The need for a bioprocess simulator that 
captures both the business and process perspectives of biopharmaceutical 
manufacturing is becoming increasingly important. However, process performance 
is affected by the need to comply with regulatory practices and to cope with 
randomness inherent in the system. Existing simulators often lack the capabilities to 
reflect regulatory conformation and incorporate uncertainties. These factors 
provided part of the impetus and motivation for this research, which examines the 
capacity of a bioprocess simulator to provide a business-process interface, model 
regulatory-compliance activities and incorporate risks in processes subject to 
uncertainty.
In Chapter 2, the industrial production of Mabs for large-scale applications is 
described as this provided the basis for the case studies in Chapters 5 and 6. There 
exist various expression techniques and cell culture methods for the commercial 
production of protein-derived products. A review of published literature indicated 
that mammalian cell culture is the most common technology for the expression of 
such recombinant proteins. The industry has converged on using stirred tank 
bioreactors as the standard technology for large-scale production of antibodies. Fed- 
batch and perfusion cultures are the two dominant modes of operation used for such 
mammalian-based processes. Typical industrial issues concerning the manufacture 
of antibodies, which provide the foundation for the case studies in this thesis, are 
highlighted. An investigation of the commercial production methods for Mabs 
enabled generic mammalian-based processes to be identified that were subsequently 
used as the basis for the unit operations included in the tool domain. Recent 
technologies used in the development of antibodies were discussed so as to assess 
future trends in antibody production.
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The development and implementation of a prototype tool, BioPharmKit, to model 
bioprocess operations in the manufacture of monoclonal antibodies is illustrated in 
Chapter 3. The main objective was to formulate a decision-support tool to compute 
cost measures, simulate resource handling, perform mass balance calculations and 
incorporate risks in order to facilitate the transparency and ease of decision-making 
in the biopharmaceutical industry. The conceptual framework seeks to integrate the 
technical, operational and economic aspects of biopharmaceutical manufacture. The 
hierarchical task-oriented approach employed in this work was adapted from 
previous work at University College London (UCL) and has been extended to 
include regulatory compliance activities. Such an approach enables the rapid 
modelling of information at different levels of details. The tool architecture also 
permits the explicit modelling of ancillary tasks such as equipment cleaning and 
regulatory activities, so as to estimate more accurately operative measures such as 
costs and resource utilisation. The graphical illustration and dynamic simulation of 
the process offers a comprehensive perspective of the modelling system. The 
economic feasibility and effectiveness of manufacturing options can be evaluated by 
examining key performance metrics such as the cost of goods, capital investment and 
net present value (NPV). Incorporating risk analysis permits the evaluation of 
potential risks associated with different manufacturing strategies and enhances the 
quality of decision-making within a company.
The usefulness of the simulation tool developed in this thesis is explored in Chapter
4. The tool can be employed to model a new plant during the early design stage. In 
addition, the tool can act as a platform to simulate optimal operating scenarios using 
existing plant capacity. It can also describe a range of case studies and help to 
address the typical problems facing the industry. Effective use of the simulation 
outcomes can contribute to improved process development, more efficient use of 
resources and result in worthwhile comparisons of manufacturing alternatives. The 
application of the prototype tool for accessing the impact of manufacturing 
alternatives on technical and financial performance metrics was demonstrated via 
industrial-related case studies in the subsequent chapters.
A typical issue in perfusion culture is how often to pool the fermentation broth in 
order to utilise fully resources while reducing operating costs. In the case study
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described in Chapter 5, which assessed the most appropriate pooling strategies in 
perfusion mode using mammalian cell culture, the modelling tool indicates how 
manufacturing options affect the demands on resources and manufacturing costs. A 
deterministic case was initially carried out and validated by industrial experts to 
ensure the outputs were computed correctly. A sensitivity analysis was then 
performed to determine the impact of individual variables on key output parameters. 
The effects of fluctuating titres, process yields and risk of contamination were 
analysed using the Monte Carlo simulation technique in order to reflect the inherent 
variability of process parameters during the operation of a biopharmaceutical plant. 
The stochastic simulation forecasts a range of possible outcomes, determines the 
likelihood that the key performance metrics could exceed a critical threshold, and 
computes the expected performance of the model in order to facilitate process 
analysis. Possible scenarios regarding the stability of product cell line and 
downstream purification scale were analysed to gain further insight into relevant 
events and enhance the decision-making.
Fed-batch and perfusion cultures are capable of achieving large-scale production of 
antibodies. Although the fed-batch culture has predominated, there has been 
increasing use of perfusion culture in recent years due to the high productivity 
achieved in such culture system. The use of the decision-support tool to compare the 
economic feasibility of both culture modes was investigated in Chapter 6. In the 
deterministic analysis, the values of the key economic and process output parameters 
were determined. To take into account the inherent variability of process variables, 
the key uncertainties in the system were identified and a sensitivity analysis was then 
performed to investigate the impact on output parameters. Another objective of this 
chapter was to compare risk analysis methods, such as the decision tree and Monte 
Carlo simulation techniques, to account for risk factors with known probabilistic 
characteristics. An illustration of how to determine the probabilistic cases and 
compute the expected output values using a decision tree was provided. The 
decision tree analysis provided a simple and efficient approach to select between 
manufacturing alternatives based on the expected values of performance metrics. 
The limitation of the decision tree analysis was found to be the inability to explicitly 
acknowledge the underlying uncertainty in the contributory estimates and to consider 
parallel events that could happen. A Monte Carlo analysis was then performed to
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provide a more accurate estimation of the overall uncertainty. Such a technique 
incorporates input parameters with probability distributions, generates frequency 
distributions for each designated output and computes various statistical summaries 
featuring the outputs. However, unlike decision trees, the Monte Carlo technique is 
more time-consuming in terms of computation and does not explicitly make a 
decision.
The work carried out in this thesis presents the design and implementation of a 
decision-support tool that links both the process and business aspects of 
biopharmaceutical manufacture. The tool, BioPharmkit, has customised built-in 
features specific for bioprocesses including costing functions to determine plant cost, 
operating costs and profitability of manufacturing options, mass balance models to 
calculate process data, risk parameters to carry out risk assessment and a graphical 
interface to build model flowsheets. In addition, the tool offers the ability to create 
newer unit operation models. Key disadvantages of the approach are that significant 
effort was required to customise existing unit operations models. This is because 
BioPharmkit does not have the availability of bioprocess models and sufficient data 
required to accommodate more rigorous and sophisticated models. Despite the 
limitations mentioned, the potential rewards of such a bioprocess simulation tool are 
significant. The benefits of the simulation tool for strategic decision-making have 
been demonstrated through application to industrial-related case studies. It is 
envisaged that such a tool might be used during the early stage of process 
development, which can lead to faster time-to-market, more efficient use of resources 
and enhanced the economic performance of a company.
7.3. Thesis Highlights
The novelty of this thesis is the development and implementation of a decision- 
support tool, BioPharmKit, with features specific to biomanufacture. The 
implementation of such a tool was based on the production of Mabs expressed in 
mammalian cells. Generic processes for the production of marketed Mabs have been 
used to provide the foundation for the unit operations included in the tool domain. 
The functionalities of the tool have been illustrated via application to two
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industrially-related case studies. The following section highlights the major 
contributions contained in this thesis.
• Integration o f business and process aspects o f biomanufature
The economic and process aspects of biomanufacturing are often quantitatively 
unconnected. The work in this thesis has linked both the business and process 
perspectives of the biopharmaceutical manufacturing industry in order to aid the 
decision-making process. The business aspects deal with the fixed capital 
investment, direct and indirect costs, cost of goods and NPV while the process 
aspects consider issues such as mass balance, resource utilisation profiles and annual 
output. The tool has included these features so as to model each of the business and 
process perspectives of biomanufacturing and to provide a more complete evaluation 
of manufacturing alternatives.
• Model the impact o f regulatory-compliance activities
The decision-making process is often complicated by the need to comply with 
regulatory issues. Traditional simulation tools often omit the modelling of such 
regulatory activities in the biomanufacturing environment. The addition of these 
activities with process flowsheet models is crucial to investigate the impact of such 
tasks on the process output parameters. The hierarchical, task-oriented tool 
implemented in this thesis provides the ability to model ancillary tasks explicitly. 
The regulatory-compliance tasks such as QC/QA and batch documentation have been 
implemented in the decision-support tool to enable the impact of such activities on 
the performance of the process to be investigated.
• Customised unit operation specific for perfusion culture
The operation of perfusion culture involves a continuous feed of media into the 
bioreactor while a continuous amount of spent culture is withdrawn. One complexity 
of the perfusion mode is the need for a retention device (e.g. spin filter) to retain the 
cells in the bioreactor. The tool is constructed in a modular way to provide the 
ability to extend and customise so as to include newer unit operations. Such 
implementation enables different culture modes to be evaluated based on profitability 
and process indices.
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• Provide a user-friendly interface
The decision-support tool developed in this thesis is user-friendly and allows the user 
to employ such a tool with great speed. The graphical user interface feature provides 
a clear visualisation of the simulation flowsheet. The dynamic animation of the tool 
enables the user to view the execution of tasks during the simulation process. The 
“drag” and “drop” feature of the decision-support tool simplifies the interaction 
between the user and the tool. Dialog boxes have been cloned from the Extend 
coding blocks to enable efficient communication.
• Incorporate risk analysis
Commercially available simulators often lack the capability to represent uncertainties 
in biomanufacture. Such randomness would have an impact on the decision-making 
process and hence the need to incorporate risk factors in simulation software is 
becoming increasingly important. The ability to carry out risk analysis would allow 
the risks associated with different manufacturing options to be evaluated and hence 
minimise the risk of incorrect conclusions as a result of the variability of the process 
parameters. The decision-support tool in this thesis has accomodated the 
randomness stemming from fluctuating fermentation titres, process yields, the 
possibilities of contamination and filter clogging. Such uncertainties are represented 
as Normal discrete distributions. Both the decision-tree and Monte Carlo simulation 
techniques, which are typical tools used for risk analysis, have been employed to 
evaluate the impact of uncertainties on key performance metrics.
7.4. Future Work
Biotechnology simulation is a rapidly advancing tool for biopharmaceutical 
manufacture. It allows the rapid assessment of a large number of options to be made 
when development goes beyond the level of initial laboratory studies. The decision- 
support tool developed in this thesis could evolve into a powerful tool for assisting 
decision-making. The framework established lays a strong foundation for exploring 
further work that can be used to address key issues in the industry. There are clearly 
many potential areas available for improving and extending the functionalities of the 
tool. The future work proposed in this section would be essential to enhance further
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the capabilities and robustness of the tool to aid the process of decision-making. 
Several examples are pointed out and discussed below.
• Improving coding efficiency o f the tool
As discussed in Chapter 6, the simulation of each Monte Carlo run required a 
substantial amount of time. The computational speed of the tool could be improved 
by to coding the mass balance calculations in Excel. This would greatly reduce the 
number of blocks required to configure each unit operation and less computational 
time would be needed to initialise and process these blocks during the simulation. In 
addition, simple calculations of the process yields for each unit operation would be 
sufficient instead of using the rigorous mass balance calculations adopted in this 
thesis.
• Customisation o f new unit operations
The construction of the tool in a modular and extensible manner has facilitated the 
development of applications and allowed the developer to extend new features with 
ease. Such customisation should enable the impact of new manufacturing 
technologies to be assessed based on running costs and manufacturing performance. 
The ability of the tool to build and customise new unit operations is demonstrated in 
a parallel study carried out at UCL (Mustafa et al., 2004). In this work, techniques 
such as expanded bed adsorption (EBA) chromatography are explored and developed 
in the software package. A case study is set up to compare the process and business 
benefits of a conventional process route employing packed chromatography beds and 
an alternative that uses EBA. The next phase of the study aims to investigate the 
potential feasibility of an EBA retrofit within a conventional packed-bed based 
process.
• Modelling o f explicit manufacturing tasks
In order to simplify the tool implementation process, material preparation steps were 
omitted from the modelling process. For instance, media and buffer are assumed to 
arrive pre-made in disposable bags. In future work, these activities could be 
modelled explicitly to achieve a more complete analysis. The incorporation of such 
preparation steps is essential to an examination of the impact on the resultant cost of 
goods and demand on resources, such as operator and materials. The modelling of
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these ancillary tasks could be achieved by communication with the finance and 
manufacturing departments of the companies so as to determine the relevant costs 
and typical raw materials demand.
• Integration with drug development pathway
In addition to the work presented in this thesis, parallel work (Rajapakse et al., 2004) 
has focused on simulating the activities for portfolio management during 
biopharmaceutical drug development from drug discovery to market launch. Linking 
such a framework with the model of biopharmaceutical manufacture, as described in 
this thesis, would allow the impact of manufacturing decisions to be evaluated based 
on development timescales and costs, as well as manufacturing performance such as 
resource utilisation and cost of goods.
• Linkage to a sophisticated database
The data for populating the model was obtained from an existing UCL database and 
verified through discussions with industrial experts and biopharmaceutical vendors. 
Microsoft Excel has been employed as the database providing a transparent interface 
to the Extend platform. A more sophisticated database (e.g. SQL, Oracle) could 
enhance the performance of the simulation tool. These databases offer more 
powerful capacities for organizing, managing and retrieving data. This needs to 
incorporate manufacturing data for different production processes for the various 
types of products.
The future work discussed in this section would be essential to capture pertinent 
features relating to biomanufacture and to enhance the capabilities the tool. In 
addition to improving the features of the decision-support tool, the tool could be used 
to investigate other industrially-related case studies. The case studies presented in 
this thesis have illustrated the application of the decision-support tool to assess the 
viability of manufacturing options in terms of process and economic aspects. The 
tool could be used to investigate novel manufacturing techniques so as to gain 
insights into real manufacturing situations. For instance, production of antibody- 
based proteins in transgenic goats, chickens and various plant varieties has been 
recently developed to achieve high yields at a potential lower cost of goods and
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capital investment. A detailed analysis of transgenic production is essential to 
provide a clear perception of these new process options.
Further simulation studies using the tool could be applied to the ultra scale-down 
project currently undertaken at UCL (Titchener-Hooker et al., 2001). The ultra 
scale-down mimics methodology allows the rapid prediction of the best way in 
which to produce complex biopharmaceuticals during the early stages of 
biopharmaceutical development pathway and where only small volumes of material 
are available for study. Such methods alone are inadequate to predict completely the 
production performance. The decision-support tool could be employed to 
supplement the scale-down and ultra scale-down strategies by allowing a capacity to 
ask “what i f ’ questions and to link the different scales of operation.
In conclusion, the tool developed in this thesis has generated new areas for further 
investigation. The development of more sophisticated simulation capabilities would 
increase the functionalities of the tool and enable more complex and rigorous 
modelling to be accomplished. The application of industrial-related case studies 
provides insights into real manufacturing situations and aids the evaluation of 
process scenarios. The simulation tool possesses great potential for growth as a 
computer-based decisional system to address strategic needs for the successful 
commercialisation of biopharmaceuticals. Such bioprocess simulators could become 
significant engineering tools for process design and development over the next 
decade.
- 1 9 4 -
References
Allen, D. H. Economic Evaluation o f Projects -  A Guide, 3rd edn.; Institute of 
Chemical Engineers; Hertford, England: Stephen Austin & Sons Ltd., 1991.
Andersen, D. C.; Krummen, L. Recombinant Protein Expression for Therapeutic 
Applications. Curr. Opin. Biotechnol., 2002,13, 117-123.
Aranha, H.; Forbes, S. Viral Clearance Strategies for Biopharmaceutical Safety. 
Pharm. Technol., 2001, Jun, 26-40.
Bailey, J. E.; Ollis, D. F. BioProcess Economics. In Biochemical Engineering 
Fundamentals, 2nd edn.; New York; London: McGraw-Hill, 1986; Chapter 12.
Baker, S. J. & Wheelwright, S. M. Financially Based Modelling of Recovery Process 
Alternatives. BioProcess Int., 2004, May, 42-54.
Banik, G. G.; Heath, C. A. Partial and Total Cell Retention in a Filtration-Based 
Homogeneous Perfusion Reactor. Biotechnol. Prog., 1995,11, 584-588.
Banks, J. Principles of Simulation. In Handbook o f Simulation: Principles, 
Methodology, Advances, Applications, and Practice', Banks, J. (Ed.); Wiley: Canada, 
1998; Chapter 1.
Bartley, A.; MacLeod, A. J. A Comparative Study of Monoclonal Antibody Yield 
using Batch, Continuous or Perfusion Suspension Culture Techniques. In Animal 
Cell Technology: Developments, Processes and Products', Spier, R. E., Griffiths, J. 
B., Macdonald, C. (Eds.); Butterworth-Heinemann: Oxford, UK, 1992; pp 376-378.
-  1 9 5 -
References
Bebbington, C. R.; Renner, G.; Thomson, S.; King, D.; Abrams, D.; Yarranton, G. T. 
High-Level Expression of a Recombinant Antibody from Myeloma Cells using a 
Glutamine Synthetase Gene as an Amplifiable Selectable Market, Bio/Technol., 
1992,10, 169-175.
Berthold, W. Cost Elements for Supply during Antibody Production Development. 
Presented at Production and Economics of Biopharmaceuticals -  Economics of 
Capacity Expansion and Creative Ways to Bridge the Capacity Crunch. San Diego, 
CA, IBC, Nov 18-23,2002.
Bibila, T. A.; Robinson, D. K. In Pursuit of the Optimal Fed-Batch Process for 
Monoclonal Antibody Production. Biotechnol. Prog., 1995,11, 1-13.
Birch, J. R. Suspension Culture, Animal Cells. In Encyclopaedia of Bioprocess 
Technology: Fermentation, Biocatalysis and Bioseparation’, Flickinger, M. C., Drew,
S. W. (Eds); Wiley: New York; Chichester, 1999; Vol 5.
Birch, J. R.; Froud, S. J. Mammalian Cell Culture Systems for Recombinant Protein 
Production. Biologicals, 1994, 22, 127-133.
Blau, G.; Mehta, B.; Bose, S.; Pekny, J.; Sinclair, G.; Keunker, K.; Bunch, P. Risk 
Management in the Development of New Products in Highly Regulated Industries. 
Comput. Chem. Eng., 2000, 24, 659-664.
Brastow, W. C.; Rice, C. W. Planning Pharmaceutical Manufacturing Strategies in an 
Uncertain World. BioProcess Int., 2003, Jun, 46-55.
Brown, M. E.; Renner, G.; Field, R. P.; Hassell, T. Process Development for the 
Production of Recombinant Antibodies using the Glutamine Synthetase (GS) 
System. Cytotechnol., 1992, 9, 231-236.
Byrom, D. Role and Timing of Process Development for Biopharmaceutical 
Manufacture. Pharm. Technol. Eur., 2000, Mar, 12(3), 52-56.
- 1 9 6 -
References
Chadd, H. E.; Chamow, S. M. Therapeutic Anitbody Expression Technology. Curr. 
Opin. Biotechnol., 2001,12, 188-194.
Chow, S.-C. Pharmaceutical Validation and Process Controls in Drug Developments. 
Drug Inf. J., 1997, 31, 1195-1201.
Chu, L.; Robinson, D. K. Industrial Choices for Protein Production by Large-Scale 
Cell Culture. Curr. Opin. Biotechnol., 2001,12, 180-187.
Clemento, A. New and Integrated Approaches to Successful Accelerated Drug 
Development. Drug Inf. J., 1999, 33, 699-710.
Coates, E. R.; Kuhl, M. E. Using Simulation Software to Solve Engineering 
Economy Problems. Comput. Ind. Eng., 2003, 45, 285-294.
Curling, J. The Cost of Chromatography. Presented at Production and Economics of 
Biopharmaceuticals. La Jolla, CA, IBC, Nov 13-15, 2000.
Dalm, C. Determining Viability in Perfusion Bioreactors. Genet. Eng. News, 2003, 
25(16), 60, 62.
Datar, R. V.; Cartwright, T.; Rosen, C.-G. Process Economics of Animal Cell and 
Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator. 
Bio/Technol., 1993,11, 349-356.
De Keyser, J.-L. High-Cell-Density Perfused Culture for Mabs. Genet. Eng. News, 
2002, 22(10), 52.
Deo, Y. M.; Mahadevan, M. D.; Fuchs, R. Practical Considerations in Operation and 
Scale-up of Spin-filter Based Bioreactors for Monoclonal Antibody Production. 
Biotechnol. Prog., 1996, 12, 57-64.
DePalma, A. Protein Products Push Large-Scale Cell Culture. Genet. Eng. News, 
2002, 22(7), 58, 61.
- 1 9 7 -
References
DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The Price of Innovation: New 
Estimates of Drug Development Costs. J. Health Econ., 2003, 22, 151-185.
Doblhoff-Dier, O.; Bliem, R. Quality Control and Assurance from the Development 
to the Production of Biopharmaceuticals. TIBTECH, 1999,77, 266-270.
Doctor, R. N.; Newton, D. P.; Pearson, A. Managing Uncertainty in Research and 
Development. Technovation, 2001, 21, 79-90.
Dove, A. Uncorking the Biomanufacturing Bottleneck. Nat. Biotechnol., 2002, 20, 
777-779.
Dynamic Chiropractic. Why Are U.S. Drug Prices So High?, 2003, 27(25). 
www.chrioweb.com (accessed 2004)
Evans, L. B.; Field, R. P. Bioprocess Simulation: A New Tool for Process 
Development. Chem. Eng. Aust., 1989, 74(4), 20-23.
Fahmer, R. L.; Blank, G. S.; Zapata, G. A. Expanded Bed Protein A Affinity 
Chromatography of a Recombinant Humanized Monoclonal Antibody: Process 
Development, Operation, and Comparison with a Packed Bed Method. J. 
Biotechnol, 1999, 75, 273-280.
Farid, S. A Decision-Support Tool for Simulating the Process and Business 
Perspectives of Biopharmaceutical Manufacture. PhD thesis; UCL; 2001.
Farid, S.; Novais, J. L.; Karri, S.; Washbrook, J.; Titchener-Hooker, N. J. A Tool for 
Modelling Strategic Decisions in Cell Culture Manufacturing. Biotechnol. Prog., 
2000a, 76(5), 829-836.
Farid, S.; Washbrook, J.; Birch, J.; Titchener-Hooker, N. J. A Hierarchical 
Framework for Modelling Biopharmaceutical Manufacture to Address Process and 
Business Needs. In Computer-Aided Chemical Engineering: ESCAPE-10', S. Pierucci 
(Ed); Elsevier Science B.V.: Amsterdam, 2000b; 8, pp. 673-678.
- 1 9 8 -
References
Farid, S.; Washbrook, J.; Titchener-Hooker, N. J. Decision-Support Tool for Risk 
Analysis in Biopharmaceutical Manufacture. In 8th International Conference on 
Computer Applications in Biotechnology (CAB8): Modelling and Control o f 
Biotechnological Processes', Dochain, D., Perrier, M. (Eds); IF AC, EFB, 2001; pp. 
167-171.
Fisher, M. P.; Pascucci, V. L. Regulatory Reflections Concerning the State of 
Biotechnology Progress, Drug In f J., 1996, 30, 41-46.
Focus on Catalysts. Global Biotechnology Market Expected to Post Ten-fold 
Growth. 2003(4), Apr, 2.
Foo, F.; Karri, S.; Davies, E.; Titchener-Hooker, N. J.; Dunhill, P. Biopharmaceutical 
Process Development: Part I, Information from the First Product Generation. 
BioPharm Eur., 2001, Jun, 58-64.
Furey, J. Scale-up of a Cell Culture Perfusion Process. Genet. Eng. News, 2002, 
22(7), 62.
Garber, K. Biotech Industry Faces New Bottleneck. Nat. Biotechnol.,2001, 19, 184- 
185.
Geigert, J. The Challenge of Managing Quality Control/Quality Assurance for 
Loosely Structured and Virtual Biopharmaceutical Companies. Drug Inf. J., 1997, 
31, 97-100.
Gerson, D. F.; Himes, V.; Hopfer, R.; Khandke, L.; Kohn, F.; Komotar, A.; Krumm, 
P.; Machulski, J.; Weisser, A.; Sciotto-Brown, S. Transfer of Processes from 
Development to Manufacturing. Drug Inf. J., 1998, 32, 19-26.
Ginsberg, P. L.; Bhatia, S.; McMinn, R. L. The Road Ahead for Biologies 
Manufacturing. US Bancorp Piper Jaffray Equity Research, 2002, 1-23.
- 1 9 9 -
References
Glaser, V. Biopharma Firms Must Mind Their QAs & QCs. Genet. Eng. News, 2002, 
22(8), 16, 18,65.
Gonzalez, Y.; Ibarra, N.; Gomez, H.; Gonzalez, M.; Dorta, L.; Padilla, S.; Valdes, R. 
Expanded Bed Adsorption Processing of Mammalian Cell Culture Fluid: 
Comparison with Packed Bed Affinity Chromatography. J. Chromatogr. B, 2003, 
784, 183-187.
Gosse, M. E.; Manocchia, M. The First Biopharmaceuticals Approved in the United 
States: 1980-1994. Drug Inf. J., 1996, 30, 991-1001.
Grimster, S. Biopharmaceutical Manufacturing: Past, Present and Future. Eur. 
Biopharm. Rev., 2003, 88-92.
Gura, T. Magic Bullets Hit the Target. Nat., 2002, 417, 584-586.
Happel, J.; Jordan, D. G. Chemical Process Economics, 2nd edn.; New York: Marcel 
Dekker, Inc., 1975; Chapter 3.
Hesse, F.; Wagner, R. Developments and Improvements in the Manufacturing of 
Human Therapeutics with Mammalian Cell Cultures. TIBTECH, 2000,18, 173-180.
Hjorth, R. Expanded-bed Adsorption in Industrial Bioprocessing: Recent
Developments. TIBTECH, 1997,15, 230-235.
Hodge, G. Economics of Disposable Process Components for the Manufacture of 
Monoclonal Antibodies. Presented at Production and Economics of 
Biopharmaceuticals -  Alternative Technologies for Speed to Market and Cost 
Reduction. San Diego, CA, IBC, Nov 18-23, 2002.
Holmer, A. F. New Biotechnology Medicines in Development, 2002, Pharmaceutical 
Research and Manufacturers of America (PHRMA), http://www.phrma.org. 
(accessed 2003)
- 2 0 0 -
References
Hood, E. E.; Woodard, S. L.; Horn, M. E. Monoclonal Antibody Manufacturing in 
Transgenic Plants -  Myths and Realities. Curr. Opin. Biotechnol., 2002,13, 630-635.
Hoorn, P. V. Continuous Perfusion vs Batch Fermentation. Presented at Production 
and Economics of Biopharmaceuticals -  Transcending the Limits of Manufacturing 
Medicines. La Jolla CA, IBC, Nov 13-15, 2000.
Houdebine, L.-M. Antibody Manufacture in Transgenic Animals and Comparisons 
with Other Systems. Curr. Opin. Biotechnol., 2002,13, 625-629.
Hu, W.-S.; Aunins, J. G. Large-scale Mammalian Cell Culture. Curr. Opin. 
Biotechnol., 1997, 8, 148-153.
Humphrey, A. Some Issues in Biotechnology Commercialisation. Technol. Soc., 
1996, 75(3), 321-332.
Iding, K.; Ltitkemeyer, D. Fraune, E.; Gerlach, K.; Lehmann, J. Influence of 
Alternations in Culture Condition and Changes in Perfusion Parameters on the 
Retention Performance of a 20pm Spin-filter during a Perfusion Cultivation of a 
Recombinant CHO Cell Line in Pilot Scale. Cytotechnol., 2000, 34, 141-150.
Imagine That, Inc. Extend User’s Guide V.5.0, 2000.
Jayme, D. W.; Smith, S. R. Media Formulation Options and Manufacturing Process 
Controls to Safeguard Against Introduction of Animal Origin Contaminants in 
Animal Cell Culture. Cytotechnol., 2000, 33, 27-36.
Kadouri, A.; Spier, R. E. Some Myths and Messages Concerning the Batch and 
Continuous Culture of Animal Cells. Cytotechnol., 1997, 24, 89-98.
Karri, S.; Davies, E.; Washbrook, J.; Titchener-Hooker, N. J. Biopharmaceutical 
Process Development: Part III, A Framework to Assist Decision Making. Biopharm 
Eur., 2001, Sep, 76-82.
- 2 0 1  -
References
Kelly, B. D. Biochemical Engineering Bioprocessing of Therapeutic Proteins. Curr. 
Opin. Biotechnol., 2001,12, 173-174.
King, D. J. Production of Monoclonal Antibodies. In Applications and Engineering 
of Monoclonal Antibodies', Taylor & Francis: Philadelphia, 1998; Chapter 5.
Lamble, N. Therapeutic Proteins: Strategic Market Analysis and Forecasts to 2010. 
Datamonitor pic., 2000. www.datamonitor.com (accessed 2002)
Lang, H. J. Simplified Approach to Preliminary Cost Estimates. Chem. Eng., 1948, 
55, 112-113.
Larrick, J. W.; Thomas, D. W. Producing Proteins in Transgenic Plants and Animals. 
Curr. Opin. Biotechnol., 2001,12, 411-418.
Law, A. M.; Kelton, W. D. Basic Simulation Modeling. In Simulation Modeling & 
Analysis, 2ndedn.; McGraw-Hill, 1991; Chapter 1.
Lawlis, B. A Worldwide Shortage of Biomanufacturing Capacity for Monoclonal 
Antibodies. Presented at Production and Economics of Biopharmaceuticals -  
Transcending the Limits of Manufacturing Medicines. La Jolla, CA, IBC, Nov 13- 
15, 2000.
Lias, R.; Fogerty, S. The Squeeze in Contract Biomanufacturing. Pharm. Technol. 
Eur., 2002, Jun, 31-34.
Macmillan, J. D.; Velez, D. Miller, L.; Reuveny, S. Monoclonal Antibody 
Production in Stirred Reactors. In Large Scale Cell Culture Technology, Lydersen, 
B. K., (Ed.); Hanser Publishers: Munich, 1987; pp. 22-58.
Mahadevan, M. D. Bioreactor Process Selection for Large-Scale Manufacture of 
Monoclonal Antibodies -  Tradeoffs and Recommendations. Bioprocessing J., 2003, 
25-31.
- 2 0 2 -
References
Marks, L.; Power, E. Using Technology to Address Recruitment Issues in the 
Clinical Trial Process. TIBTECH, 2002, 20(3), 105-109.
Martin, N.; Brennan, A.; Denome, L.; Shaevitz, J. High Productivity in Mammalian 
Cell Culture. Bio/Technol., 1989, 5, 838-840.
Matejtschuk, P.; Baker, R. M.; Chapman, G. E. Purification and Characterization of 
Monoclonal Antibodies. In Bioseparation and Bioprocessing Volume II: Processing, 
Quality and Characterization, Economics, Safety and Hygiene', Subramanian, G. 
(Ed); Wiley-VCH: Weinheim, 1998; Chapter 8.
McNamara, L. Where is the Blockbuster Market Heading? An Analysis of the 
Current and Future Blockbuster Market Until 2008. Industry Dynamics, 2002. 
www.samedanltd.com (accessed 2003)
Mercille, S.; Johnson, M.; Lanthier, S.; Kamen, A. A.; Massie, B. Understanding 
Factors that Limit the Productivity of Suspension-Based Perfusion Cultures Operated 
at High Medium Renewal Rates. Biotechnol. Bioeng., 2000, 67(4), 435-450.
Molowa, D. T.; Shenouda, M. S.; Meyers, A. P.; Tublin, P. W.; Fein, A. S. The State 
of Biologies Manufacturing: Part 2. JP Morgan Securities Inc., Equity Research, 
2002, 1-16.
Monge, M.; Hammarberg, B. Disposable Technology for Biomanufacturing: Scaling- 
up within a Modular Facility. Presented at Scaling Up of Biopharmaceutical 
Products. The Grand, Amsterdam, IBC, Jan 26-27, 2004.
Moran, E. B.; McGowan, S. T.; McGuire, J. M.; Frankland, J. E.; Oyebade, I. A.; 
Waller, W.; Archer, L. C.; Morris, L. O.; Pandya, J.; Nathan, S. R.; Smith, L.; 
Cadette, M. L.; Michalowski, J. T. A Systematic Approach to the Validation Process 
Control Parameters for Monoclonal Antibody Production in Fed-Batch Culture of a 
Murine Myeloma. Biotechnol. Bioeng., 2000, 69(3), 242-255.
- 2 0 3 -
References
Morrow, K. J. BioPharm Manufacturing Capacities. Genet. Eng News, 2001, 27(21), 
1,60,61,85.
Morrow, K. J. Industrial-Scale Antibody Production Strategies. Genet. Eng News, 
2002, 22(17), 8-71.
Mustafa, M. A., Washbrook, J., Lim, A. C., Zhou, Y., Titchener-Hooker, N. J., 
Morton, P.; Berezenko, S.; Farid, S. A Software Tool to Assist Business-Process 
Decision-Making in the Biopharmaceutical Industry. Biotechnol. Prog., 2004, 20(4), 
1096-1102.
Myers, S. C.; Howe, C. D. A Life-Cycle Financial Model of Pharmaceutical R&D. 
Program on the Pharmaceutical Industry, Massachusetts Institute of Technology,
1997.
Nichols, N. A. Scientific Management at Merck: An Interview with CFO Judy 
Lewent. Harvard Bus. Rev., 1994, 89-99.
Nicholson, I. J.; Latham, P. When to “Make or Buy” Means “Make or Break”. 
Bio/Technol., 1994,72, 473-477.
Norris, P. Seamless Process Development: Enhancing Speed to Market and Reducing 
Costs. Pharm. Visions. 2001, 36-39.
Novais, J. L.; Titchener-Hooker, N. J.; Hoare, M. Economic Comparison Between 
Conventional and Disposable-Based Technology for the Production of 
Biopharmaceuticals. Biotechnol. Bioeng., 2001, 75(2), 143-153.
Ohashi, R.; Singh, V.; Hamel, J.-F. P. Perfusion Culture in Disposable Bioreactors. 
Genet. Eng. News, 2001, 27(7), 40, 78.
Onigman, P. Transgenic Production Update. Presented at Production and Economics 
of Biopharmaceuticals -  Transcending the Limits of Manufacturing Medicines. La 
Jolla, CA, IBC, Nov 13-15, 2000.
- 2 0 4 -
References
Pandey, M. Investment Decisions in Pharmaceutical R&D Projects. Drug Discov 
Today, 2003, 8(21), 968-971.
Peter, M. S.; Timmerhaus, K. D. Plant Design and Economics for Chemical 
Engineers; McGraw-Hill: New York; London, 1991.
Petrides, D. P. BioPro Designer: An Advanced Computing Environment for 
Modelling and Design of Integrated Biochemical Processes. Comput. Chem. Eng., 
1994,18 S, S621-S625.
Petrides, D. P.; Cooney, C. L.; Evans, L. B.; Field, R. P.; Snoswell, M. Bioprocess 
Simulation: An Integrated Approach to Process Development. Comput. Chem. Eng., 
1989,18(4/5), 553-561.
Petrides, D. P.; Calandranis, J.; Cooney, C. Computer-Aided Design Techniques for 
Integrated Biochemical Processes. Genet. Eng. News, 1995a, 10, 28, 29, 35.
Petrides, D. P.; Sapidou, E.; Calandranis, J. Computer-Aided Process Analysis and 
Economic Evaluation for Biosynthetic Human Insulin Production -  A Case Study. 
Biotechnol. Bioeng., 1995b, 48(5), pp. 529-541.
Petrides, D. P.; Calandranis, J.; Cooney, C. Bioprocess Optimization via CAPD and 
Simulation for Product Commercialization. Genet. Eng. News, 1996, 24, 28, 40.
Pharmaceutical Industry Profile, Chapter 3, pp. 27-39, 1999.
Pisano, G. P.; Wheelwright, S. C. High-Tech R&D, The Logic of High-Tech R&D. 
Harvard Bus. Rev., 1995, 94-105.
Pollock, D. P.; Kutzko, J. P.; Birck-Wilson, E.; Williams, J. L.; Echelard, Y.; Meade,
H. M. Transgenic Milk as a Method for the Production of Recombinant Antibodies. 
J. Immunol. Methods, 1999, 231, 147-157.
- 2 0 5 -
References
Raiffa, H. Decision Analysis: Introductory Lectures on choices under Uncertainty, 
London: Addison-Wesley, 1968.
Rajapakse, A., Titchener-Hooker, N. J., Farid, S. Modelling of the 
Biopharmaceutical Drug Development Pathway and Portfolio Management. In 
Computer-Aided Chemical Engineering: ESCAPE-14’, Barbosa-Povoa, A., Matos, H. 
(Eds); Elsevier Science B.V.: Lisbon, 2004; 18.
Ramsay, B. Lean Compliance in Manufacturing. Pharm. Technol. Eur., 2001, Oct, 
62-68.
Reichert, J. M. New Biopharmaceuticals in the USA: Trends in Development and 
Marketing Approvals 1995-1999. TIBTECH, Sep 2000,18, 364-369.
Reichert, J. M. Monoclonal Antibodies in the Clinic. Nat. Biotechnol., 2001, Sep, 19, 
819-822.
Reichert, J. M. Trends in Development and Approval Times for New Therapeutics in 
the United States. Nat. Rev. Drug Discov., 2003, 2, 695-702.
Reichert, J.; Pavlou, A. From the Analyst’s Couch Monoclonal Antibodies Market. 
Nat. Rev. Drug. Discov., 2004, 3, 383-384.
Remer, D. S; Idrovo, J. H. Cost-Estimating Factors for Biopharmaceutical Process 
Equipment. Pharm. Technol. Int., 1991, Mar, 36-42.
Reuveny, S.; Velez, D.; Miller, L.; Macmillan, J. D. Comparison of Cell Propagation 
Methods for their Effect on Monoclonal Antibody Yield in Fermentors. J. Immunol. 
Methods, 1986, 86, 61-69.
Rouf, S. A.; Moo-Young, M.; Scharer, J. M.; Douglas, P. L. Single versus Multiple 
Bioreactor Scale-up: Economy for High-value Products. Biochem. Eng. J., 2000, 6, 
25-31.
- 2 0 6 -
References
Rouf, S. A.; Douglas, P. L.; Moo-Young, M.; Scharer, J. M. Computer Simulation 
for Large Scale Bioprocess Design. Biochem. Eng. J., 2001a, 8, 229-234.
Rouf, S. A.; Douglas, P. L., Moo-Young; M., Scharer, J. M. Economics of Fed-batch 
Operation: A Computer-aided Approach. Bioprocess and Biosystems Eng., 2001b, 
24, 65-71.
Rudolph, N. S. Biopharmaceutical Production in Transgenic Livestock. TIBTECH, 
1999,17, 367-374.
Savage, C. Scaleup and Bioproduction. Genet. Eng. News, 2000, 1, 65, 80.
Schenerman, M. A.; Hope, J. N.; Kletke, C.; Singh, J. K., Kimura, R.; Tsao, E. I.; 
Folena-Wasserman, G. Comparability Testing of a Humanized Monoclonal Antibody 
(Synagis®) to Support Cell Line Stability, Process Validation, and Scale-Up for 
Manufacturing. Biologicals, 1999, 27, 203-215.
Seaver, S. S. Lessons Learned from Working with Contract Manufacturers. 
BioPharm, 1995, 8(2), 20-25.
Shanklin, T.; Roper, K.; Yegneswaran, P. K; Marten, M. R. Selection of Bioprocess 
Simulation Software for Industrial Applications. Biotechnol. Bioeng., 2001, 72(4), 
483-489.
Sharpe, P.; Keelin, T. How SmithKline Beecham Makes Better Resource-Allocation 
Decisions. Harvard Bus. Rev., 1998, 45-57.
Sherman-Gold, R. Monoclonal Antibodies: The Evolution from ’80s Magic Bullets 
to Mature, Mainstream Applications as Clinical Therapeutics. Genet. Eng. News, 
1997, 4, 35.
Sherwood, D. Biopharmaceutical Contract Manufacturing: An Overview.
Bioprocessing J., 2003, 33-35.
- 2 0 7 -
References
Sinclair, A. Capacity Availability: Impact on Commercialisation Strategies. 
Screening 2-3, 2003, GIT VERLAG GmbH & Co. KG, Darmstadt, 36-38. 
www.gitverlag.com/go/screening (assessed 2003)
Singh, V. Disposable Bioreactor for Cell Culture using Wave-Induced Agitation. 
Cytotechnol., 1999, 30, 149-158.
Sinnott, R. K. In Coulson & Richardson’s chemical engineering (Chemical 
engineering design)', Pergamon Press: Oxford, 1993; Vol. 6.
Stewart, J. J.; Allison, P. N.; Johnson, R. S. Putting a Price on Biotechnology. Nat. 
Biotechnol., 2001,19, 813-817.
Taylor, B. W. Decision Analysis and Game Theory. In Introduction to Management 
Science', Prentice-Hall, Inc.: New Jersey; 1999.
Titchener-Hooker, N. J.; Zhou, Y.; Hoare, M.; Dunnill, P. Biopharmaceutical Process 
Development: Part II, Methods of Reducing Development Time. BioPharm Eur., 
2001, Sep, 68-74.
Tyler, J. E. Microencapsulation of Mammalian Cells. In Large-scale Mammalian 
Cell Culture Technology, Lubiniecki, A. S. (Ed.); Marcel Dekker, Inc.: New York, 
1990; pp. 343-361.
Voisard, D.; Meuwly, F.; Ruffieux, P.-A.; Baer, G.; Kadouri, A. Potential of Cell 
Retention Techniques for Large-Scale High-Density Perfusion Culture of Suspended 
Mammalian Cells. Biotechnol. Bioeng., 2003, 82(1), 751-765.
Walsh, G. Biopharmaceuticals: Biochemistry and Biotechnology, Wiley: Chichester,
1998.
Walsh, G. Biopharmaceutical Benchmarks. Nat. Biotechnol., 2000, Aug, 18, 831- 
833.
- 2 0 8 -
References
Walsh, G.; Murphy, B. Biopharmaceuticals, an Industrial Perspective’, Kluwer 
Academic Publishers, 2000; Chapter 1.
Walter, P. K. Cost and Capacity Comparison of Transgenics and Cell Culture 
Production Systems. Presented at Production and Economics of Biopharmaceuticals 
-  Transcending the Limits of Manufacturing Medicines. La Jolla, CA, IBC, Nov 13- 
15, 2000.
Wechsler, J. Drug Shortages Reveal GMP Concerns. Pharm. Technol. Eur., 2002, 
Jun, 17-20.
Werner, R. G. Potential and Efficiency in the Biotechnical Process. Pharm. Technol. 
Eur., 1994, May, 20-28.
Wheelwright, S. M. Protein Purification: Design and Scale up o f Downstream 
Processing. Hanser Publishers: Munich, Germany; 1991.
Woodside, S. M.; Bowen, B. D.; Piret, J. M. Mammalian Cell Retention Devices for 
Stirred Perfusion Bioreactors. Cytotechnol., 1998, 28, 163-175.
Xie, L.; Wang, D. I. C. High Cell Density and High Monoclonal Antibody 
Production through Medium Design and Rational Control in a Bioreactor. 
Biotechnol. Bioeng., 1996, 57(6), 725-729.
Yabannavar, V. M.; Singh, V.; Connelly, N. V. Mammalian Cell Retention in a 
SpinfiIter Perfusion Bioreactor. Biotechnol. Bioeng., 1992, 40{%), 925-933.
Yabannavar, V. M.; Singh, V.; Connelly, N. V. Scaleup of Spinfilter Perfusion 
Bioreactor for Mammalian Cell Retention. Biotechnol. Bioeng., 1994, 43(2), 159- 
164.
Young, M. W.; Okita, W. B.; Brown, E. M.; Curling, J. M. Production of 
Biopharmaceutical Proteins in the Milk of Transgenic Dairy Animals. BioPharm, 
1997, 10(6), 34-38.
- 2 0 9 -
References
Young, M. W.; Meade, H.; Curling, J. M.; Ziomek, C. A.; Harvey, M. Production of 
Recombinant Antibodies in the Milk of Transgenic Animals. Research in Immunol., 
1998a, 149(6), 609- 610.
Young, M. W.; Tiedemann, G.; Pepin, R. A.; Turner, J. D.; Okita, W. B.; Harvey, 
M.; Groet, S.; Curling, J. M. Transgenics Go Commercial. BioPharm, 1998b, Jul.
Zhou, W.; Chen, C.-C.; Buckland, B.; Aunins, J. Fed-Batch Culture of Recombinant 
NSO Myeloma Cells with High Monoclonal Antibody Production. Biotechnol. 
Bioeng., 1997, 55(5), 783-792.
- 2 1 0 -
APPENDIX A
List of Publications
Refereed Papers
Lim, A. C.; Zhou, Y.; Washbrook, J.; Titchener-Hooker, N. J; Farid, S. A Decision-Support Tool to 
Model the Impact o f Regulatory Compliance Activities in the Biomanufacturing Industry. Comput. 
Chem. Eng., 2004, 28(5), 727-735.
Mustafa, M. A., Washbrook, J., Lim, A. C., Zhou, Y ., Titchener-Hooker, N. J., Morton, P.; 
Berezenko, S.; Farid, S. A Software Tool to Assist Business-Process Decision-Making in the 
Biopharmaceutical Industry, Biotechnol. Prog., 2004, 20(4), 1096-1102.
Conference Paper
Lim, A. C.; Farid, S.; Washbrook, J.; Titchener-Hooker, N. J. A Tool for Modelling the Impact of  
Regulatory Compliance Activities on the Biomanufacturing Industry. In Computer-Aided Chemical 
Engineering: ESCAPE-13\ Kraslawski, A., Turunen, I. (Eds); Elsevier Science B. V.: Lappeenranta, 
2003; 14, pp. 1109-1114.
Oral Presentations
Lim, A. C.; Farid, S.; Washbrook, J.; Titchener-Hooker, N. J. A Structured Decisional-Support Tool 
for Rapid Bioprocess Modelling. American Chemical Society 225th National Meeting, New Orleans, 
Louisiana, USA, Presented on 26th Mar 2003.
Lim, A. C.; Farid, S.; Washbrook, J.; Titchener-Hooker, N. J. The Use o f a Modelling Tool to 
Quantify Risks and Uncertainty in the Biomanufacturing Industry. European Congress Biotechnology, 
Basel, Switzerland, Presented on 28th August 2003.
- 2 1 1  -
APPENDIX B
Newly Programmed Blocks
Table B.l. Newly programmed blocks in the tool.
Block Name Block Description
Convert j Convert |* Convert all time units to hours.
// Declare constants and static variables here, 
integer Units; 
real Duration;
// This message occurs for each step in the simulation, 
on simulate
{
// Determine the units used, 
if  (Minutes) Units = 1; 
i f  (Horns) Units = 2; 
i f  (Days) Units = 3; 
if  (Weeks) Units = 4;
/ /  Convert all units to hours, 
i f  (Units =  1) Duration = RawTaskProTime/60; 
i f  (Units == 2) Duration =  RawTaskProTime; 
i f  (Units —  3) Duration = RawTaskProTime*24; 
i f  (Units —  4) Duration =  RawTaskProTime*7*24; 
TaskProTime = Duration;
TaskProTimeOut =  Duration;
}
// If the dialog data is inconsistent for simulation, abort, 
on checkdata 
{
>
// Initialize any simulation variables, 
on initsim
{
>
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Block name Block Description
#
Attribute Table Attribute Table c _______________
ValueOut
3
a Store the attributes (i.e. mass and volume) o f process streams.
Valueln
//  Declare constants and static variables here, 
integer i; 
integer j;
// This m essage occurs for each step in the simulation, 
on simulate
{
// If the dialog data is inconsistent for simulation, abort, 
on checkdata
{
//  Initialize any simulation variables, 
on initsim
{
// Initialize all the rows o f  the table to 0 at start, 
for (i=0; i<32; i++)
{
ProcessStream[0][i] = 0;
}
}
// Store the attribute in their respective row.
On Attributeln
{
ProcessStream[0] [Resourceln] = Attributeln;
}
//  Output the value o f  the attribute when required. 
On Rowln
{
AttributeOut = ProcessStream[0] [Rowln];
}
//  Reset the attribute table.
On Resetln  
{
for (j= 0 ;j< 3 2 ;j+ + )
{
ProcessStream[0][j] =  0;
}
}
}
>
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Block name Block Description
Add Mass ,dd M ass
Add the mass o f each individual 
component in the process stream.
// Declare constants and static variables here, 
integer i; 
integerj;
// This message occurs for each step in the simulation, 
on simulate 
{
}
//  If the dialog data is inconsistent for simulation, abort, 
on checkdata 
{
}
/ /  Initialize any simulation variables, 
on initsim 
{
// Initialize all the rows o f  the table to 0 at start, 
for (i=0; i<32; i++)
{
ProcessStream[0][i] = 0;
}
}
// Add the mass o f each component in the process stream. 
On Massln
{
ProcessStream[0] [Resourceln] += Massln;
}
/ /  Output the mass o f  each component 
On Rowln
{
MassOut = ProcessStream[0] [Rowln];
}
//  Reset the table after use.
On Resetln
{
for (j=0; j<32; j++)
{
ProcessStream[0] [j] = 0;
}
}
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Block name Block Description
Utilisation
Jl. _EL!
C U t il is a t io n  B lo c k  a
Plot the peak demand of resource at 
run time.
// Declare constants and static variables here.
Real T ;
Real TotalUtilizn;
Real LastUtiliznValue;
Real CumulativeUtiliznValue;
Real TempResourceAvailable;
// This message occurs for each step in the simulation, 
on simulate
{
}
on DayElapseln
{
if  (TempResource Available == ResourceAvailableln) { 
OutputTotalUtiliznOut = 0;
}
else {
// Calculate the total utilizn in a day 
TotalUtilizn = U tiliznln - LastUtiliznValue; 
CumulativeUtilizn Value += TotalUtilizn; 
OutputTotalUtiliznOut = TotalUtilizn; 
LastUtiliznValue = CumulativeUtilizn Value;
}
}
// If the dialog data is inconsistent for simulation, abort, 
on checkdala 
{
}
// Initialize any simulation variables, 
on initsim 
{
T = 1;
LastUtiliznValue = 0;
CumulativeUtiliznValue = 0;
TempResource Available = Resource Availableln;
}
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Block name Block Description
Determine Task
Specify the type o f manufacturing 
process task.
D eterm ine Task a
// Declare constants and static variables here.
// This m essage occurs for each step in the simulation, 
on simulate 
{
if  (Fermentation = =  l)TaskOut = 0; 
if  (Centrifugation =  1) TaskOut = 1; 
if  (AffinityChromatography = = 1 )  TaskOut = 2; 
if  (IonExchange = = 1 )  TaskOut =  3; 
if  (GelChromatography == 1) TaskOut = 4; 
if  (Concentration =  1) TaskOut = 5; 
if  (Diafiltration —  1) TaskOut -  6; 
if  (ChemRetroVirus = 1 )  TaskOut = 7; 
i f  (VirusRednFiltration == 1) TaskOut = 8; 
if  (FinalFiltration =  1) TaskOut =  9; 
if  (CIP =  1) TaskOut = 10; 
if  (SIP == 1) TaskOut = 11; 
if  (Equilibration == 1) TaskOut = 1 2 ;  
if  (Regeneration = 1 )  TaskOut = 1 3 ;  
if  (ReEquilibralion == 1) TaskOut = 14; 
if  (PerfusionCulture == 1) TaskOut =1 5 ;
}
/ /  If the dialog data is inconsistent for simulation, abort, 
on checkdata
{
}
/ /  Initialize any simulation variables, 
on initsim
{
}
on CreateBlock 
{
Fermentation = TRUE;
}
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Block name Block Description
QC/QA ■ i Specify if  QC/QA is required.
//  Declare constants and static variables here.
//  This m essage occurs for each step in the simulation, 
on simulate
{
}
//  If the dialog data is inconsistent for simulation, abort, 
on checkdata 
{
}
//  Initialize any simulation variables, 
on initsim
{
if  (QCQA =  1) QCQAIn = 1; 
if  (NoQCQA == 1) QCQAIn = 0;
}
on createblock
{
NoQCQA = 1;
}
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The figure below illustrates the sequence of functions in a product-manufacture task 
(e.g. fermentation). The block coding within each function is complex and consists 
of multiple blocks connected to perform the desired procedure. Figure B.2 shows the 
detail of the “Check Equipment Status” function as an illustration of the coding 
within each function.
Return of Resources
Update Equipment Status
Check Equipment Status
M ass Balance Calculation
Cost Calculation
Delay of Manufacturing Task
Activation
Determine Availability of Resources
Batching of Resources
Figure B .l. Sequence of functions in a product-manufacture task.
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Get #  o f  R e s o u r c e s  A v a i l a b l e  in the resource pool: Decrement 
b v a n  am ount equal to the utilization of the resource
N um ofResAvail Num ofResAvail
#ofR esourcesA vail#1
Column#1
ResourcePool#1
TT3 (S3
■--------Column#1
I--------------ResourcePool#1
------------------- #ofR esourcesR em aining#1
Get E q u i p m e n t  S t a t u s  from 
the G lo b a l Array aga in ,
EqpStatus 
8=EqpStatus#1Column#1-R esourcePool#1
j p * '
'— EqpStatusReqd [ 1 ^ 1 1__
TEL
EqpCIPAfterTask
EqpStatus#1
EqpStatusReqd
Eqp-preparationStepsReqd?
Com pare the required and current equipm ent 
status. If the two equipm ent statuses do not 
match, equipm ent-preparation steps are required.
R esourcePool Column
Stop simulation if 
attribute U t i l i z a t i o n  =  0.
Utilizn
EqpStatus
EqpStatusReqd
EqpCIPAfterTask
No eqp-preparation s tep s  required
uuuuu
N o
E q p - p r e p a r a t i o n  
s t e p s  r e q u i r e d
ResourcePool#1 —  
Column#1 
UtiliznofEqp 
#of R esou  rcesAv ai I# 1 
UtiliznofEqp
Eqp-preparation s tep s  required
Eqp-preparationStepsReqd?
EqpCIPAfterTask
EqpStatusReqd
EqpStatus#1
#ofR esourcesR em aining#1
#ofR esourcesA vail#1
C h e c k  w h a t  
E q p - p r e p a r a t i o n  
s t e p s  r e q u i r e d
Figure B.2. Graphical diagram illustrating the blocks connected to set up the “Check Equipment Status” function within tht  fermentation task. 
The function compares the required and current equipment status before commencing the manufacturing process. If the two equipment 
statuses do not match, the relevant equipment-preparation tasks are activated.
APPENDIX C
Mass Balance Models
Table C .l. Simple mass balance models in B io P h a r m k i t*
Inputs Outputs Mass Balance Calculations
Fermentation
M ass-stoichiometry Outlet stream component
coefficient, a i mass, m i()Ut
m .M„, = Cr„
Feed stream component Extent o f reaction, x
2. x
mass, m iin
x  m '"~, t a lim
Reference component, m^  “ "f
r e f
3- n i„ „
Final concentration o f ref a i
m ,ou< = m nn “ "W*** —
component, Crej a lim
Total volume o f  feed
stream, Vm
Limiting substrate, lim
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Inputs Outputs Mass Balance Calculations
Centrifugation
Solids-carry-over- Solids removal fraction, 1. R
fraction, S R R =  \ -  S
Solid-volume-fraction in Supernatant and sediment 2. ni , ni•' .srd •' spp
sediment, v. solid component masses,
m  =  R * m
m s ,  m
• SUp srd
■ 'W  'i n
Total feed stream m K =  ni -  ni'sup in * srd
component masses, m tn Supernatant and sediment
liquid component masses,
3 - Plm
Total volume o f feed m u  , m,SUp sed
m i,n = m >nll„ ~ m sm
stream, V-^ tnt V  =  V  - VVL V  "l.o, K-',n 
m iSolid density, p s
* - = v :
* Assumption: Only 1
solid component 4. m ,l S fd
y  -
. ' W  p
V,
V  =
t o t  v d vv
V  = v  -  V
^ srd  tO t M d srd
m , = V ,  *  p ,
l srd  h r d  r  l \n
5. m u ,  m lt1 ' srd 1 Sup
m > ‘ ,„ *  m , , =  — —  *  m,
m ln
m n  ~ m n  ~ m n* *SUp 1 l in 1 *srd
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Inputs Outputs Mass Balance Calculations
Membrane filtration
Calculation mode: 
Membrane area per unit, 
A /  Processing time per 
cycle, t
Average flux, J  
Volum e o f feed stream,
V*
N o o f cycles, n 
Concentration factor,
CF
Rejection coefficient,
RC
Output mode:
Membrane area per unit, 
A /  Processing time per 
cycle, t
Total processing time, T
Permeate and retentate 
stream component
masses, mipenn, miret
1. A, t
V (T -C F ~ l)A  = .JnS-----^ ----- 1 or
J * n * t
t = VJ1-CF- ' )  
J *n* A
2. T 
T = n * t
3. V.
Ik
CF
Vs
ni
P,
5 ‘ = ° )  
v =v - Y  v™'rc- o ret i retHC, Q
Vy  -  un— * y
i retRC=0 y  retHC=0
ni =  y  *  n
I r^R V -0  I ret RC s0  ‘ i
6. mi perm
m — m — nil i perm l i in l i ret
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Inputs Outputs Mass Balance Calculations
Diafiltration
Calculation mode: Output mode: I. A , t
Membrane area per unit, 
A / Processing time per
Membrane area per unit, 
A / Processing time per
. D *V() D *V()A = --------2-  or t = -------- 2-
J * n * t J *n*  A
cycle, t cycle, t
2. T
Average flux, J Total processing time, T T = n * t
No of cycles, n Permeate and retentate 
stream component
3 Vret
Rejection coefficient, masses, miperm, mim
II
RC
4- m.
No of diafiltration
volumes, D
Volume of components in
,/ _ r" 
P i
tank, Vo
Component masses in
5. m.„,
P ‘m V b « ff
tank, mo v =v - Y vr e l /r „ m V buj j  ret 1 ret f r o m  vtl
v
y = ,buff * y
'  retJ ro m V buj f  T  T relJ ro m V buj j
b u ff
in = V * n1 ret f r , m V buy  l r e t P < m V bujj  1
6- m , r n
tfi — m + in1 re,  ' r e , ,... re t , .....w>i,/;
7-
m i p rrn , = m , i n - m , r r ,
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Inputs Outputs Mass Balance Calculations
Chromatography
Column height, H 
No o f column volumes,
c v
Linear flow rates, u
Column volume, Vrol
No o f cycles, n 
Yield fraction, y
Product-stream-column- 
volumes, CVpr(Hi
Processing time per cycle, 
t
Buffer volumes required,
V
Product and waste stream 
m asses, mipr(Hj, mtwaste
1. tr , r =  L ,W ,E
H *CVr
K  =
u r
2. Vr , r  =  L,W, E 
V , = C V , * V n l *n
3 ‘ V prod  =  C V prod  * K o l
" W , ™ ,  = m l L * y ,
y  _  m ‘ Pr<Xifron,L 
1 P ^ J r o m L  ~  p
v  - V  - Y v
pnxifram t: P "* ! L-l 1 P'**1 (ram L
v
V =  ,E * v
' Pr(Hl(ram E 17 P ^ fr o m  V
V E
m i p ro d  jrom f: ~  ^l p n x l  jr„mh * P i  
m i p rod  ~  m i p rod  Jrum i m i p rod  frtm h:
waste = m , L +  "h W  +  E  ~  »h prod
From gel filtration, the equations were 
similar except there were no terms related 
to the wash step.
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Inputs Outputs Mass Balance Calculations
Dead-end filtration
Calculation mode: 
Membrane area per unit, 
A / Processing time per 
cycle, t
Average flux, J  
Rejection factor, R F
Particle-volume fraction, 
v p ret
Output mode:
Membrane area per unit, 
A /  Processing time per 
cycle, t
Permeate and retentate 
stream component
m asses, m ipenn, m iret
L m i ret (0  <  RFj < 1 )  
" w , o = R F * m >„
Uliret1/ _ 1 reiRF* 0
iretRt* 0
2• m . r « „ J R F < = 0 )
y yT/ _ 1 re,Rht0
ret ~
Vpre,
v  = v  - Y vretKF=o ret t retRh M
Vv  =  un * v1 retRF = 0 W’ retRt = 0 
inRt = 0
m  = V  * o1 re,RF= 0 ' re,Rh = 0 1
3 - m ,perm
m , perm ret
4. A ,  t
V  = v .  - Vperm in ret
V  Va perm . permA  =  — —  or t  = ---------
J * t  J * A
Viral clearance
No o f virus units in inlet 
stream, vrm
Log clearance factor,
LCF
No o f virus units in outlet 
stream, vrmt
I. vr ,out
=  v n„ * 1 0 ^
* Adapted from Farid (2001)
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Nomenclature
S ym bols
a Mass-stoichiometry coefficient
A Membrane area
c Concentration
C Cost o f  equipment
Ce Equipment purchase cost
Cf Fixed capital investment
CF Concentration factor
CV Number o f  column volumes
D Number o f  diafiltration volumes
fL Lang factor
H Column height
J Average flux
LCF Log clearance factor
m Mass
n Number o f cycles
NCF Net cash flow
NPV Net present value
PV Present value
Q Capacity
r Discount rate
R Solid removal fraction
RC Rejection coefficient
RF Rejection fraction
S Solids carry-over fraction
t Processing time per cycle
T Total processing time
u Linear velocity
V Volume fraction
vr Virus units
V Volume
X Extent o f reaction
X Random variable
y Component yields
p Density
o Standard deviation
p Mean
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Subscripts
buff Buffer
col Column
E Elution
i Component
in Inlet stream
I Liquid phase
L Load
lim Limiting substrate
out Outlet stream
P Particle
perm Permeate
p ro d Product stream
re f Reference component
ret Retentate
s Solid
sed Sediment
sup Supernatant
tot Total
W Wash
waste Waste
